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Abstract 
 
Non-invasive evaluation of murine models for genetic muscle diseases 
 
 Novel therapeutic approaches are being introduced for genetic muscle diseases 
such as muscle dystrophies and congenital myopathies, all of them having remained 
without cure so far. These recent developments have motivated a renewed and 
augmented interest in non-invasive methods for muscle characterization and 
monitoring, particularly during and after therapeutic intervention. In this context, 
animal models are essential to better understand the disease mechanisms and to test 
new therapies. Recently, significant advances in the non-invasive evaluation of mouse 
models for genetic muscle diseases have been achieved. Nevertheless, there were still 
several mouse strains not characterized non-invasively, and it was necessary to 
develop sensitive methods to identify subtle alterations in the murine affected muscle. 
The purpose of this thesis was to apply non-invasive techniques in the study of 
murine models for genetic muscle diseases with variable phenotypes. Three mouse 
models for muscle dystrophy (mdx, Large
myd
, mdx/Large
myd
) and one mouse model for 
congenital myopathy (KI-Dnm2
R465W
) were studied with Nuclear Magnetic Resonance 
(NMR) methods. Two dystrophic strains (Large
myd
, mdx/Large
myd
) and normal mice 
after injury were studied through micro-Computed Tomography (micro-CT). On 
NMR, all affected mouse strains presented increased muscle T2, which could be 
related to variable features in the histological evaluation, including necrosis and 
inflammation, but also to clusters of fibers under regeneration or with altered 
cytoarchitecture. The combination of NMR and texture analyses allowed the 
unambiguous differential identification of all the dystrophic strains, although it was 
not feasible when comparing the muscle T2 measurements only. Mdx mice showed 
functional and morphological alterations of vascular network. In the KI-Dnm2
R465W
 
mice, a pilot study revealed tendencies of functional impairment. Finally, micro-CT 
images were unable to detect differences in muscle´s content in dystrophic mice. 
Altogether, these results not only increased the number of murine models for genetic 
muscle diseases non-invasively characterized, it also demonstrated some degree of 
 12 
 
specificity of the imaging anomalies, as revealed by texture analysis. It also showed 
that non-invasive NMR methods can be sensitive enough to identify subtle alterations 
in murine muscle phenotype, even in early stages. This thesis was developed under an 
international joint supervision between France and Brazil, and comprised an 
important transfer of technology, with the first non-invasive studies of murine 
muscles performed in Brazil.  
 
 13 
 
Resumo 
 
Avaliação não invasiva de modelos murinos para doenças musculares genéticas 
 
 Novas abordagens terapêuticas vêm sendo introduzidas para doenças 
musculares genéticas como distrofias musculares e miopatias congênitas, distúrbios 
que permanecem sem cura até o momento. Estes recentes avanços motivaram um 
interesse renovado e crescente por métodos não invasivos para a caracterização e 
monitoramento do músculo afetado, particularmente durante e após intervenções 
terapêuticas. Neste contexto, modelos animais são essenciais para uma melhor 
compreensão dos mecanismos das doenças e para testar novas terapias. 
Recentemente, avanços significativos na avaliação não invasiva de modelos murinos 
para doenças musculares genéticas foram alcançados. Entretanto, diversas linhagens 
de camundongos ainda não foram caracterizadas de maneira não invasiva, e ainda é 
necessário o desenvolvimento de métodos sensíveis para a identificação precoce de 
alterações sutis no músculo de camundongos afetados. A proposta desta tese é aplicar 
técnicas não invasivas inovadoras no estudo do músculo de modelos murinos para 
doenças musculares genéticas com fenótipos variados. Três modelos murinos para 
distrofias musculares (mdx, Large
myd
, mdx/Large
myd
) e um modelo murino para 
miopatia congênita (KI-Dnm2
R465W
) foram estudados com métodos de Ressonância 
Magnética Nuclear (RMN). Duas linhagens distróficas (Large
myd
, mdx/Large
myd
) e 
camundongos normais após injúria foram estudados através de micro-Tomografia 
Computadorizada (micro-CT). Em RMN, todas as linhagens de camundongos 
afetados apresentaram aumento de T2 muscular, o que foi relacionado a diversas 
anomalias na análise histológica, como necrose e inflamação, mas também a 
conjuntos de fibras em regeneração ou a fibras com citoarquitetura alterada. A 
combinação de RMN com análise de textura permitiu a identificação não ambígua de 
todas as linhagens distróficas, sendo que apenas a comparação dos valores de T2 
muscular não permitiu esta diferenciação. Camundongos mdx mostraram alterações 
funcionais e morfológicas na rede vascular do músculo. Estudo piloto em 
camundongos KI-Dnm2
R465W
 revelou tendências de comprometimento da função 
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muscular. Por fim, imagens de micro-CT não permitiram a detecção de diferenças na 
composição muscular em camundongos distróficos. Este conjunto de resultados não 
apenas enriquece o painel de modelos murinos para doenças musculares genéticas 
caracterizados de maneira não invasiva, mas também demonstra um certo grau de 
especificidade nas anomalias observadas nas imagens, como revelado pela análise de 
textura. Estes resultados também mostraram que métodos não invasivos de RMN 
podem ser suficientemente sensíveis para identificar alterações sutis no fenótipo 
muscular murino, mesmo em estágios precoces. Esta tese foi desenvolvida sob acordo 
de co-tutela internacional entre a França e o Brasil, e compreendeu uma importante 
transferência de conhecimento, com os primeiros estudos não invasivos de músculo 
murino realizados no Brasil. 
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Résumé 
 
Evaluation atraumatique de modèles murins de maladies musculaires génétiques  
 
 De nouvelles options thérapeutiques sont en cours d'introduction pour les 
maladies musculaires génétiques telles que les dystrophies musculaires et les 
myopathies congénitales, maladies jusque là sans traitement causal. Ces 
développements récents ont suscité un intérêt renouvelé et croissant pour les 
méthodes atraumatiques en vue de caractériser et de suivre les muscles atteints, en 
particulier pendant et après une intervention thérapeutique. Dans ce contexte, les 
modèles animaux sont essentiels pour mieux comprendre les mécanismes des 
maladies et pour tester des nouvelles thérapies. Récemment, il y a eu des avancées 
significatives dans l'évaluation atraumatique de modèles murins de maladies 
musculaires génétiques. Néanmoins, nombre de lignées de souris n'ont pas encore été 
caractérisées de façon atraumatique et il reste à mettre au point des méthodes plus 
sensibles pour identifier précocément des altérations subtiles dans le muscle des 
souris malades. L'objectif de cette thèse est d'appliquer des techniques atraumatiques 
innovantes à l'étude du muscle de modèles murins de maladies musculaires 
génétiques avec des phénotypes variés. Trois lignées de souris modèles de dystrophies 
musculaires (mdx, Large
myd
 et mdx/Large
myd
) et une lignée de souris modèle de la 
myopathie congénitale (KI-Dnm2
R465W
) ont été étudiées par des méthodes de 
Résonance Magnétique Nucléaire (RMN). Deux lignées dystrophiques (Large
myd
 et 
mdx/Large
myd
) plus des souris normaux après une blessure ont été étudiées par micro-
tomographie (micro-CT). En RMN, toutes les souches de souris affectées ont présenté 
un T2 musculaire augmenté, en relation avec une gamme d'anomalies histologiques, y 
comprises nécrose et inflammation, mais aussi des groupes de fibres en régeneration 
ou des fibres avec altérations de l'architecture. Avec la combinaison de la RMN et de 
l'analyse de la texture, il a été possible d'identifier sans ambiguïté toutes les lignées 
dystrophiques, alors que la seule mesure du T2 ne permettait pas de les différencier. 
Les souris mdx ont présenté des altérations fonctionnelles et morphologiques du 
reseau vasculaire musculaire. Pour les souris KI-Dnm2
R465W
, des études préliminaires 
ont révélé une tendance à développer des altérations fonctionnelles musculaires. 
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Finalement, les images de micro-CT n'ont pas pu détecter des différences du contenu 
musculaire dans les souris dystrophiques. L'ensemble des résultats non seulement 
enrichit le panel de modèles murins de maladies génétiques musculaires caractérisés 
de manière atraumatique, il révèle également un certain degré de spécificité des 
anomalies dans l'imagerie, comme l'a montré l'analyse de texture. Les résultats 
démontrent aussi que des méthodes de RMN non-invasives peuvent être assez 
sensibles pour identifier des altérations subtiles dans le phénotype musculaire murin, 
même à des stades précoces. Cette thèse a été développée dans le cadre d'une co-
tutelle internationale entre la France et le Brésil, et elle a comporté un important 
transfert de compétence, qui a permis de réaliser les premières explorations 
atraumatiques du muscle murin effectuées au Brésil.  
 17 
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General Introduction 
 
 Muscles are contractile organs essential for life, being responsible for 
functions such as breathing, locomotion (skeletal muscles), blood circulation 
(cardiac/smooth muscle) and food propulsion in the digestive system (smooth 
muscle). Only skeletal muscles are under voluntary control, and attached to bones 
they compose the locomotor system. 
 Muscle dysfunctions can be caused by influences like injury, cancer and 
infections, but can also be originated by genetic defects. Among the genetic disorders 
affecting primarily skeletal muscles, there are the muscle dystrophies and the 
congenital myopathies. Muscle dystrophies are caused by alterations in proteins 
present at the sarcolemma, the sarcoplasm, the basal lamina and even at the nucleus of 
muscle cells. Muscle dystrophy patients have progressive loss of muscle cells, with 
consequent weakness. The histopathological pattern includes variation in fiber size, 
necrosis, infiltration by inflammatory cells, and substitution by connective and 
adipose tissue (Emery, 2002). Congenital myopathies are caused by alterations in 
proteins from the contractile filaments, the sarcolemma or the sarcoplasm. Patients 
with congenital myopathies present weakness generally at birth, and disease progress 
is less accentuated than in muscle dystrophies. Histopathological analysis of 
myopathic muscles shows structural alterations such as the presence of rods, cores, or 
altered positioning of nucleus and other organelles (Nance et al., 2012). There is no 
cure for genetic muscle diseases, but several therapeutic protocols are in development, 
from pharmacological to cellular and genetic approaches. 
 Animal models for genetic muscle disorders play a crucial role in studies 
aiming to understand genetic, clinical and histopathological processes related to the 
disease, and are necessary also to test therapeutic protocols. Several animals with 
molecular, clinical or histological alterations similar to those observed in patients 
have been identified in nature or generated in laboratory. There are models for 
muscular diseases from different species, like dogs, cats, hamsters, fishes and pigs, 
but the murine models are the most commonly studied (Vainzof et al., 2008). 
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 Clinical evaluation, muscle proteins dosage in blood, electromyography, 
genetic studies and muscle biopsy are the most frequent procedures in diagnostic and 
follow up of muscle diseases. Imaging methods, including computed tomography 
(CT), ultrasound, radioisotopes based methods (scintigraphy, PET and SPECT) and 
nuclear magnetic resonance (NMR), are gaining space on the muscle diseases field. 
Among them, NMR has optimum qualities for soft tissue evaluation, allowing the tri-
dimensional visualization of deep structures without involving the use of ionizing 
radiation. CT images can also be used for the evaluation of patients with muscle 
diseases, but with less contrast for soft tissues than NMR, and with the use of ionizing 
radiation (Mercuri et al., 2007).  
 NMR allows image acquisition with different contrasts: T1, T2 and proton 
density weighted images can give different information about the same anatomical 
region. Apart of the morphological information, NMR allows metabolic and 
functional measurements. NMR spectroscopy gives information about the chemical 
composition of the tissue. 1H and 31P are the most common nuclei for in vivo 
spectroscopy studies, but different atomic nuclei can be evaluated (19P, 13C, 23Na, 
15N, etc). 31P spectroscopy allows the evaluation of tissue pH and of phosphate 
molecules, being particularly interesting to study the energetic metabolism. 1H 
spectroscopy can give information about metabolites such as lactate, creatine and 
lipids. Finally, functional NMR can give information about muscle blood perfusion 
and oxygen consumption, for example.  
 In the literature, NMR has been used to evaluate dystrophic patients' muscles 
(Finanger et al., 2012; Mercuri et al., 2007; Poliachik et al., 2012), heart (Verhaert et 
al., 2011) and brain (Rae et al., 1998; Razek et al., 2009), with morphological, 
functional and metabolic analysis. Patients with non dystrophic congenital myopathies 
have been also evaluated by NMR (Jungbluth et al., 2008; Quijano-Roy et al., 2011), 
in studies specially focused on morphological alterations such as muscle atrophy and 
fat replacement. The study of different genetic muscle diseases by CT and NMR 
images allowed the identification of unique patterns of muscle involvement 
depending on the primary mutation (Wattjes et al., 2010). 
 NMR studies from animal models for neuromuscular diseases face the 
challenge of reducing scale: it is necessary to increase the spatial resolution, 
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especially when considering mice, the most frequent animal for modeling genetic 
diseases. Despite of it, there is already a considerable amount of NMR data of animal 
models for neuromuscular disorders. The mdx mouse, model of the most frequent 
muscle dystrophy, Duchenne Muscular Dystrophy (DMD), has been exhaustively 
studied by NMR. Muscle morphology and metabolism were evaluated in mdx 
mouse by in vivo, ex vivo and in vitro MR imaging and spectroscopy (Amthor et al., 
2004; Dunn and Zaim-Wadghiri, 1999; Dunn et al., 1991; Griffin et al., 2001; Heier 
et al., 2014; Mathur et al., 2011; McIntosh et al., 1998a, 1998b; Pratt et al., 2013; 
Straub et al., 2000; Walter et al., 2005).  
 In a less extensive amount, different mouse models for muscle dystrophies 
were studied by NMR (Cole et al., 2002; Pacak et al., 2007; Schmidt et al., 2009; 
Tardif-de Géry et al., 2000; Walter et al., 2005), as the golden retriever muscular 
dystrophy dog (Claire et al., 2012; Fan et al., 2014; Thibaud et al., 2007, 2012; 
Yokota et al., 2009). In addition to the variable NMR methods capable to identify 
changes in the affected muscles, the use of mathematical tools for image texture 
analysis is gaining space, since it can identify subtle differences in the pattern of 
distribution of muscle lesions (Mahmoud-Ghoneim et al., 2006; Nketiah et al., 2014; 
Pratt et al., 2013; Škoch et al., 2004; Wang et al., 2013). A deeper bibliographic 
review of genetic muscle disorders and non-invasive muscle evaluation, for both 
human patients and animal models, is presented in Chapter 1. 
 Even with an increasing amount of noninvasive data showing differences 
between affected and normal mice, the use of NMR as an outcome measure depends 
on the reliability of the technique to track also subtle differences in the muscles. In 
this context, the Chapter 2 of this thesis aims to evaluate the potential of combining 
NMR and texture analysis in the comparison of dystrophic muscles under different 
gene mutations. Three mouse models for muscle dystrophies, covering a wide range 
of phenotypes, were evaluated by NMR T2 relaxometry: the mdx mouse, with a mild 
phenotype; the Large
myd
 mouse, model of the congenital muscular dystrophy 1D, with 
altered glycosylation of the protein alpha-dystroglycan; and the recently generated 
double mutant mdx/Large
myd
 mouse, with both mutations and a very severe phenotype 
(Martins et al., 2013). 
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 It is known that the dystrophic muscle presents microvascular alteration both 
in patients (Leinonen et al., 1979), dogs (Nguyen et al., 2005) and mice (Bagher et al., 
2011; Burch et al., 1981; Palladino et al., 2013). How these microvascular alterations 
affect the muscle metabolism and function in vivo is yet unexplored. The Chapter 3 
of this thesis aims to evaluate in vivo the possible functional and metabolic effects of 
the microvascular alterations in the mdx mouse muscle. A multimodal approach was 
used to allow simultaneous measures of muscle perfusion and 31P spectroscopy for 
the energetic metabolism inference after hypoxic stress. Hypothetical functional or 
metabolic alterations would take place before muscle degeneration and substitution by 
connective and adipose tissues, being possible early markers of the disease, and 
possibly helping to elucidate the mechanisms of the disease. 
 While dystrophic muscles are characterized by tissue alterations, including 
inflammation, necrosis, and infiltration by adipose and by connective tissue, 
congenital myopathies are characterized by structural and functional alterations inside 
the muscle fibers, which are followed by metabolic and/or functional impairment. The 
versatility of NMR measures can be helpful in the observation of the impact of these 
alterations in myopathic muscles. 
 Animal models for congenital myopathies have been identified in dogs (Beggs 
et al., 2010; Pelé et al., 2005) and engineered in mice (Buj-Bello et al., 2002; Durieux 
et al., 2010; Ottenheijm et al., 2013; Pierson et al., 2012; Ravenscroft et al., 2011). 
Gineste and collaborators published in 2013 three papers characterizing different 
murine models for nemaline myopathy with noninvasive methods, including NMR 
(Gineste et al., 2013a, 2013b, 2013c). To our knowledge, these are the only NMR 
descriptions of myopathic alterations in murine models of congenital myopathies. The 
Chapter 4 of this thesis aims to describe with in vivo NMR the KI-Dnm2
R465W
 mouse, 
model of autosomal dominant centronuclear myopathy. This murine model presents 
the most frequent mutation in the dynamin-2 gene in centronuclear myopathy patients. 
Its phenotype includes muscle weakness, atrophy, and the presence of histological 
features observed in patients, like the concentration of oxidative activity at the center 
of the muscle fibers (Durieux et al., 2010). Nevertheless, the high percentage of 
centronucleated fibers observed in patients is not present on the mouse model. In 
these mice, it is not observed infiltration by connective or adipose tissue in the 
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muscle, nor signals of inflammation or necrosis. In the search of additive information 
about the muscle commitment in this disease, in vivo morphological and relaxometry 
measures were acquired in this mouse model at two different ages, 3 and 6 months. 
Additionally, Chapter 5 describes pilot functional and metabolic studies with this 
mouse model, for the phenotypical characterization and for an initial evaluation of the 
regeneration process after acute injury. In vivo multiparametric functional NMR, with 
measurements of muscle blood perfusion, oxygen consumption and energetic 
metabolism, were carried out.  
 CT images from patients with muscle diseases can also reveal morphological 
alterations such as muscle atrophy and fat infiltration (Nakayama et al., 2013a). The 
muscular X-ray attenuation is reduced in patients with muscle dystrophies (Rickards 
et al., 1982; Swash et al., 1995), while it is not affected by bed rest (Rittweger et al., 
2013), indicating that alterations in the muscle content, like fibrotic or adipose 
infiltration, would affect its radiodensity. In the recent years, with the development of 
micro-CT equipments with micrometric resolution, the number of in vivo micro-CT 
studies with small animals has increased. Nevertheless, the great majority of them are 
focused on skeletal alterations (Gray et al., 2012; Manske et al., 2012), including 
studies on dystrophic mice bones (Novotny et al., 2011, 2012). In the literature, there 
are essays involving micro-ct studies of mouse heart (Detombe et al., 2012), lungs 
(Lederlin et al., 2012; Paik et al., 2014), and even muscles (Manske et al., 2010; 
Weber et al., 2012). Nevertheless, these micro-CT muscle studies are focused on 
muscle volume changes. The possible radiodensity alterations on dystrophic muscle 
from mouse models are still unknown. In this context, the major objective of Chapter 
6 of this thesis is the evaluation of the potential use of X-ray micro tomography in the 
study of dystrophic muscle. The severe dystrophic mouse model mdx/Large
myd
 and the 
parental lineage Large
myd
 were selected for this essay due to the progressive muscle 
degeneration and the intense infiltration of the muscle by connective tissue. 
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Chapter 1. Bibliographic Review: Non-invasive study of 
genetic muscle disorders 
 
Muscular Dystrophies  
 
 Muscular dystrophies are an extensive group of progressive genetic diseases 
where skeletal muscles are primarily affected. Mutations in genes coding for 
sarcomeric, sarcolemmal, sarcoplasmatic/cytosolic, nuclear or extracellular matrix 
proteins can cause muscular dystrophies. The absence or altered function of one of 
these proteins is responsible for a cascade of events that ends in muscle fibers 
degeneration and necrosis, with substitution of muscle by connective and adipose 
tissue. Histological analysis of dystrophic muscle reveals fibrosis, muscle fiber size 
variation, internalization of the nuclei, infiltration by inflammatory and adipose cells, 
necrosis and muscle fiber degeneration (Dubowitz et al., 2013; Shieh, 2013). Patients 
present progressive weakness, starting at different ages depending on the disease. 
More than 30 different forms of muscular dystrophy have been described, being 
divided in three major groups: dystrophinopathies; limb girdle muscular dystrophy 
(LGMD) and congenital muscular dystrophies (CMD) (Dalkilic and Kunkel, 2003).   
 Dystrophinopathies are characterized by mutations in the dystrophin gene, 
located at Xp21 (Hoffman et al., 1987). There are two forms of dystrophinopathies, 
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). DMD 
is the most common muscular dystrophy by incidence, affecting up to 1:3000 boys at 
birth. In DMD, the gene mutation leads to the absence of the protein dystrophin in 
muscle and to a severe phenotype. In BMD, the dystrophin protein is present but in 
less quantity and with abnormal function, leading to a milder phenotype (Emery, 
2002). In dystrophinopathies, the skeletal muscle is the major impacted tissue, but 
additional alterations can be present: cardiomyopathy is observed in DMD patients 
and heterozygous females (Mirabella et al., 1993; Nigro et al., 1990), slower gastric 
and intestinal flow are present in DMD patients (Borrelli et al., 2005), and more than 
30% of DMD patients have cognitive impairment in a variable degree (Bresolin et al., 
1994).  
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 Dystrophin is normally expressed not only in skeletal muscle cells, but also in 
cardiac muscle, central nervous system and smooth muscle cells (Love et al., 1993). 
In skeletal muscle, the protein dystrophin is located under the sarcolemma, in 
association with glycosylated proteins, composing the dystrophin-glycoprotein 
complex (DGC) (Ervasti and Campbell, 1991, 1993). The DGC is responsible for the 
link between the actin cytoskeleton and the extracellular matrix, acting also on 
cellular and membrane signaling pathways (Rando, 2001a) and on calcium 
homeostasis regulation (Gumerson and Michele, 2011). Apart of dystrophin, DGC is 
composed by the dystroglycan and sarcoglycan complexes, dystrobrevin, syntrophins 
and sarcospan, which interact with other intra and extracellular proteins (Figure 1.1). 
Dystrophin interacts by its N-terminal portion with actin filaments in the cytoplasm, 
while the C-terminal portion interacts with syntrobrevin in the cytoplasm and β-
dystroglycan (β-DG) in the sarcolemma. β-DG by its turn is linked to the peripheral 
membrane protein α-dystroglycan (α-DG), which is responsible for the connection of 
the DGC with the extracellular matrix protein α-2 laminin. This link occurs through 
sugar chains in the glycosylated extension of α-DG, with high affinity to Laminin G 
(LG)-like domains present in various extracellular matrix proteins, such as laminins, 
perlecan and agrin in muscle, and neurexin in brain (Barresi and Campbell, 2006; 
Ervasti and Campbell, 1993; Straub and Campbell, 1997). 
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Figure 1.1: Schematic representation of the dystrophin-glycoprotein complex (DGC), 
showing its components: dystrophin, dystroglycan complex, sarcoglycan complex, α-
dystrobrevin, syntrophins and sarcospan. The extracellular (EC) matrix protein 
laminin-2 binds to the complex through α-dystroglycan, while F-actin, syncoilin and 
filamin-2 are intracellular (IC) ligands. Calmodulin, Grb2 and nNOS are also 
associated to the DGC as signaling molecules. The post-traductional modifications 
are shown: glycosylation in dystroglycans and sarcoglycans, and phosphorylation sites 
(P) in dystrophin, α-dystrobrevin, β-dystroglycan, syntrophins, α- and γ-sarcoglycans 
(Rando, 2001a). 
 
 Mutations in genes coding for DGC proteins or proteins involved in 
posttranslational modifications of the DGC components can lead to different forms of 
muscular dystrophies. Among these, mutations in genes coding for the sarcoglycans 
are related to LGMD, while alterations in the glycosylation of the protein α-DG are 
related to LGMD and CMD (Dalkilic and Kunkel, 2003).  
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 LGMDs are the more heterogeneous subgroup of muscular dystrophies, 
including more than 20 different forms. In LGMD, muscles from pelvic and shoulder 
girdle are those initially affected. The phenotype is highly variable, from severe forms 
with early onset and rapid progression, to milder presentations, with first symptoms 
appearing after the 4th decade of life and with slow progression. LGMDs are 
classified according to the pattern of inheritance (autosomal dominant or recessive) 
and the causative genes. Mutations in genes related to LGMD can also cause different 
diseases, such as myofibrilar myopathy, Miyoshi myopathy and CMD (Mitsuhashi 
and Kang, 2012).  
 Patients affected by the third subgroup of muscle dystrophies, CMD, present 
weakness and hypotonia at birth or in the first months of life. Progressive dystrophic 
alterations are observed in histological analysis, and patients often show involvement 
in the brain and other organs. The list of genes associated with CMDs is still 
expanding, but the great majority of them are related to the interaction of the DCG 
with the extracellular matrix (Emery, 2002; Mercuri and Muntoni, 2012). This 
interaction is mediated by the α-DG linkage to the extracellular matrix protein 
laminin. Posttranslational modifications in these two proteins, specifically 
glycosylation, are essential to maintain and regulate this link. Mutations in the gene 
coding for dystroglycans are very rare, but alterations in genes coding for proteins that 
participate in the glycosylation of α-DG, such as POMT1, POMGnT1, FKTN, FKRP 
and LARGE, are related to different forms of LGMD and CMD (Moore and Winder, 
2012; Muntoni et al., 2008).  
 
 
Vascular alterations in Duchenne muscle dystrophy 
 
 DMD is the most studied muscle dystrophy, due to the high incidence and 
severity. The current hypothesis for the pathophysiology of DMD is that the absence 
of dystrophin fragilizes the sarcoplasm, which would suffer from micro-lesions due to 
mechanically induced damage from muscle contractions. Sarcoplasm rupture alters 
calcium homeostasis, which would result in cell death. Satellite cells would try to 
regenerate the muscle, but after several rounds of degeneration and regeneration, the 
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satellite cells pool would be exhausted and muscle degeneration would predominate. 
Processes such as inflammation, fibrosis and impaired vascular adaptation would take 
place secondarily, even worsening the disease manifestation (Deconinck and Dan, 
2007).  
 Recently, the so-called ―two-hit‖ hypothesis for the disease mechanism in 
DMD has gained space. According to this hypothesis, dystrophin absence cause not 
only increased susceptibility to mechanical stress, but also vascular and metabolic 
alterations that when combined lead to the dystrophic phenotype (Ennen et al., 2013; 
Rando, 2001b).  
 Despite of the general lack of dystrophin in the muscle of DMD patients, in 
initial stages of the disease muscle lesions present in small and random clusters of 
degenerating fibers, usually surrounded by normal muscle fibers (Engel, 1967; Miike, 
1983). This pattern of focal lesions is observed also in healthy muscle when submitted 
to infarction (Hathaway et al., 1970; Mendell et al., 1971). The hypothesis that muscle 
vascular insufficiency could be related to the disease manifestation has prompted 
several studies. In the 70 and 80 decades, optical and electronical microscopy of 
muscle blood vessels of DMD patients identified only very few nonspecific 
anomalies. DMD muscle was described as presenting replication of the capillaries’ 
basement membrane, degenerating and regenerating capillary cells, and platelet 
aggregation in small blood vessels (Fidziańska et al., 1986; Koehler, 1977; Miike et 
al., 1987). Nevertheless, no alterations in muscle blood flow at rest could be observed 
in DMD patients (Bradley et al., 1975; Gudrun et al., 1975; Leinonen et al., 1979).  
 Even if the recent studies are notably focused on muscle fibers and satellite 
cells as the major players in muscular dystrophies, it is accepted that alterations in the 
vascular system may play an important role in the disease manifestation. Skeletal 
muscle is highly vascularized, and endothelial cells are essential to muscle 
regeneration. Dystrophin is expressed also in smooth muscle cells, including 
endothelial cells, but it is absent in DMD patients and mdx mice (Miyatake et al., 
1989). The dystrophin absence in endothelial cells reduces its ability to react to shear 
stress due to blood flow (Loufrani et al., 2001). Since this is a mechanical stimulus for 
angiogenesis (Ichioka et al., 1997), the dystrophin absence could impair the formation 
of new vessels in dystrophic muscle (Ennen et al., 2013).  
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 Apart of morphological alterations in the vascular network, dystrophin 
absence may impact on the vascular function as well. Dystrophin protein links to 
neuronal NO-synthase (n-NOS) in the sarcolemma of normal muscle cells. The 
enzyme n-NOS is responsible for the muscular production of the local vasodilator 
nitric oxide (NO), which acts on relaxing smooth muscle in response to increased 
metabolic demands (Ennen et al., 2013; Kobzik et al., 1994). Apart from vasodilation 
function, NO has been related to myofiber differentiation, modulation of the 
contractile force and regulation of exercise-induced glucose uptake in health muscles 
(Lee et al., 1994; Roberts et al., 1997). In the absence of dystrophin, n-NOS is present 
in a reduced amount and is not properly anchored to the sarcolemma (Brenman et al., 
1995; Crosbie et al., 2002). The reduced and misplaced n-NOS in the dystrophin 
absent muscle is considered to increase the damage in the disease (Deconinck and 
Dan, 2007; Rando, 2001b; Wehling et al., 2001). Indeed, DMD and BMD patients 
have altered vasoconstriction regulation under exercise, which results in functional 
ischemia (Sander et al., 2000; Thomas, 2013).  
 The fibrosis intensely present in muscles from DMD patients has also been 
related to alterations in blood vessels, due to increased myofiber-capillary distances, 
which can affect muscle function and gas exchanges (Desguerre et al., 2009). It is 
known that endothelial cells secrete several soluble factors, which act on the muscle 
regeneration process, and that satellite cells are preferentially present around vessels. 
An increased distance between capillaries and myofibers may have an impact on 
muscle regeneration (Arsic et al., 2004; Christov et al., 2007).  
 In the recent years, studies aiming to develop new therapeutic approaches for 
DMD with focus on the vascular network have gained space. It is believed that the 
attenuation of  abnormal microcirculation would reduce muscle damage, increase 
tissue perfusion and reduce the cardiac workload (Ennen et al., 2013). Increasing the 
NO available in dystrophic muscle has been efficient to ameliorate the dystrophic 
phenotype in mdx mice, by reducing the post-contraction damage, reducing 
inflammation, and preserving the number and function of satellite cells (Asai et al., 
2007; Brunelli et al., 2007; Voisin et al., 2005). Modulation of vascular endothelial 
growth factor (VEGF) and its receptor (VEGFR) have also shown benefits in mdx 
mice (Messina et al., 2007). These results indicate that increasing the microvascular 
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network in muscle could  improve the microvascular control and lead to clinical 
benefits in the dystrophic muscle (Ennen et al., 2013; Shimizu-Motohashi and 
Asakura, 2014). 
 
 
Congenital myopathies 
 
 Congenital myopathies are a group of genetic muscle diseases with non-
dystrophic characteristics in the histological analysis. Nevertheless, clinical 
presentation in congenital myopathies can be very similar to what is observed in 
muscular dystrophy patients. Generally, congenital myopathies are characterized by 
the presence of morphological alterations in the muscle fiber, such as the presence of 
regions with protein accumulation (rods), regions with altered organelles’ distribution 
(cores), and altered positioning of the nucleus. Despite of these observations in 
histological analysis, dystrophic characteristics such as inflammation, degeneration, 
necrosis, extensive fibrosis and regeneration are not observed in general. Creatine 
kinase level in blood serum is normal or slightly increased in congenital myopathies, 
while it is highly increased in muscular dystrophies. Additionally, congenital 
myopathies are not progressive or have very slow progression, in opposition to the 
progressive pattern of  muscle dystrophies (Sewry et al., 2008; Tubridy et al., 2001). 
 The three major categories of congenital myopathies are nemaline myopathies, 
core myopathies and centronuclear myopathies. Nemaline myopathies are 
characterized by the presence of sarcoplasmic or intranuclear rod structures formed by 
Z-disk derived material. Mutations in the genes alpha-actin (ACTA1), nebulin (NEB), 
alpha and beta tropomyosin (TPM3 and TPM2 respectively), troponin T1 (TNNT1), 
cofilin (CLF2), and a protein of the BTB/Kelch family (KBTBD13) can be related to 
nemaline myopathies. Patients show proximal weakness, respiratory insufficiency and 
facial weakness. The symptoms can be present at birth or have childhood- and even 
adult-onset. In general, patients with intranuclear rods have a more severe phenotype 
than those with sarcoplasmatic rods (Jungbluth et al., 2008; Nance et al., 2012; 
Romero and Clarke, 2012).  
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 Core myopathies are characterized by the presence of areas without any 
oxidative or glycolytic enzimatic activity, reflecting the absence of mitochondria in 
that region. One or more core structures can be present in the muscle fiber, with 
variable size and distributions. Cores can be characterized as central cores or 
minicores. Central cores run over all length of muscle fibers, while minicores are 
smaller areas of disorganized myofibrilar material that are wider than longer in 
longitudinal histological sections. Based on the histological characteristics, patients 
are classified as having central core disease or multiminicore disease. Mutations in 
the ryanodine receptor I (RYR1) or in the selenoprotein N1 (SEPN1) genes can be 
related to core myopathies. Patients present with proximal muscle weakness, 
congenital or with early onset, possibly affecting facial muscles. Even if clinical 
symptoms are present at early age, histological features may not be present, which 
brings difficulties to the diagnosis (Jungbluth et al., 2008; Nance et al., 2012).  
 Centronuclear myopathies are characterized by the presence of muscle fibres 
with internalized or centralized nuclei, in opposition to the peripheral positioning 
observed in normal muscle fibers. Histopathological characteristics can include 
abnormal NADH-TR staining, but do not involve extensive muscle degeneration and 
regeneration. Centronuclear myopathies can be related to mutations in the gene 
coding for the protein myotubularin (MTM1), which leads to the X-linked recessive 
myotubular myopathy; mutations in the gene coding for amphiphysin 2 (BIN1), 
leading to autosomal recessive centronuclear myopathy; mutations in the gene coding 
for dyanmin-2 (DNM2), with autosomal dominant heritage; or to mutations in the 
RYR1, hJUMPY and MTMR14 genes in sporadic cases (Bitoun et al., 2005, 2007; 
Jungbluth et al., 2008; Tosch et al., 2006; Wilmshurst et al., 2010). A mutation in the 
PTPLA gene was related to centronuclear myopathy in labrador dogs, but until now, 
there is no report of mutations in this gene causing centronuclear myopathy in humans 
(Pelé et al., 2005). Clinically, centronuclear myopathies are highly variably regarding 
the age of onset and pattern of weakness, ranging from severe congenital forms to 
adult-onset forms with slow progression and mild phenotype (Nance et al., 2012). 
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Animal Models for Genetic Muscle Diseases 
 
 There is no established cure for muscular dystrophies and congenital 
myopathies, which prompted the search for innovative therapeutic protocols, 
including cellular and genetic therapies. In this context, animal models for these 
genetic muscle diseases have an essential role in the elucidation of disease 
pathomechanisms and in the development of new therapeutic strategies. Several 
animal models for genetic muscle diseases have been described in the literature, 
including natural and genetically engineered models. These animals mimic the 
genetic, molecular and/or clinical aspects of the disease, providing information about 
the pathogenesis of these disorders and allowing tests for therapeutic strategies 
(Vainzof et al., 2008). 
 
 
Animal models for Muscular Dystrophies   
  
 The Dmd
mdx
 mouse (hereafter called simply mdx) is the most frequently 
studied mouse model for DMD. This mouse has a stop codon in exon 23 of the 
murine dystrophin gene, which leads to total absence of this protein in muscle, as 
observed in DMD patients (Bulfield et al., 1984; Sicinski et al., 1989). The absence of 
the protein dystrophin leads to an associated reduction of  other DGC proteins 
(Ohlendieck and Campbell, 1991), with consequent progressive muscle deterioration 
and weakness (Pastoret and Sebille, 1995). Histological analysis shows dystrophic 
changes such as variation in the caliber of muscle fibers, presence of muscle fibers 
with centralized nuclei, clusters of degenerating and regenerating fibers, infiltration 
by inflammatory cells and by connective tissue (Bulfield et al., 1984). As observed in 
human patients, different skeletal muscles are not identically affected. Diaphragm 
presents accentuated and earlier dystrophic characteristics, while masseter muscle is 
partially spared and limb muscles like gastrocnemius have an intermediary phenotype 
(Muller et al., 2001; Stedman et al., 1991). Nevertheless, differently from human 
patients, the mdx mouse can continuously regenerate its muscles and has a mild 
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phenotype, which makes the analysis of functional benefits  in therapeutic protocols 
very difficult (Dangain and Vrbova, 1984; Dubowitz, 2004; Tanabe et al., 1986). 
 Dog models for dystrophinopathies in general have the phenotype closer to 
that observed in human patients. Spontaneous mutations in the dystrophin gene were 
observed in Golden Retriever (Valentine et al., 1992), Rotweiller (Winand et al., 
1994) and German Shorthaired Pointer dogs (Schatzberg et al., 1999). The Golden 
Retriever Muscular Dystrophy dog (GRMD) is the more frequently studied canine 
model to DMD. GRMD dogs have a mutation in the dystrophin gene, leading to 
absence of the protein in muscle. Histopathological evaluation shows progressive 
dystrophic alterations in skeletal and cardiac muscles, and the phenotype is very 
severe. GRMD dogs mimic the molecular, histopathological and phenotypical aspects 
of DMD, being frequently used in the last step of therapeutic trials before tests in 
human patients (Shelton and Engvall, 2005). Recently, the GRMD mutation has been 
transferred to Beagle dogs, a smaller canine strain widely used in research (Shimatsu 
et al., 2003). 
 The animal models for LGMD include mutations in the respective genes, with 
special attention to the sarcoglycans genes. Absence of -sarcoglycan was observed as 
the primary molecular defect in BIO14.6 hamsters. This hamster has a spontaneous 
mutation in the gene coding for the protein -sarcoglycan, leading to its absence in 
muscle (Straub et al., 1998). Mouse models have been generated with null mutation in 
each of the four sarcoglycans genes (Araishi et al., 1999; Duclos et al., 1998; Hack et 
al., 1998). Animal models of sarcoglycanopathies present progressive muscular 
dystrophy with variable degree of severity, in some cases including cardiomyopathy. 
In all these models, there is a secondary reduction in the expression of the other 
components of the sarcoglycans/sarcospan complex, and loss of membrane integrity 
(Allamand and Campbell, 2000). 
 There are interesting mouse models of congenital muscular dystrophies, with 
alterations in the link between the DGC complex and the extracellular matrix. Among 
them, dy/dy and dy
2J
/dy
2J
 mice were identified in Jackson Laboratories 
(http://www.jax.org/), presenting total and partial deficiency of the protein α-2 
laminin, muscular dystrophy and dysmyelination of the peripheral nervous system. 
These mouse lineages model merosin-deficient congenital muscular dystrophy 
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(CMD1A), but dy
2J
/dy
2J
 mice have a milder phenotype than the dy/dy lineage 
(Vainzof et al., 2008). Two α-2 laminin knock-out strains have been generated, with 
complete absence of this protein: dy3K and dyW. These mouse strains show severe 
phenotype, similar to that observed in the dy/dy mouse (Kuang et al., 1998; Miyagoe 
et al., 1997). 
  The Large
myd
 mouse is the murine model for CMD-1D. It has a mutation in 
the Large gene, which codes for the glycosyltransferase LARGE protein. The 
mutation leads to a reduced glycosylation of α-DG, and a consequent reduction in its 
binding to α-2 laminin in the extracellular matrix (Moore and Winder, 2012). Patients 
with CMD-1D have a very severe phenotype, with muscular and cognitive 
impairment (Muntoni et al., 2008). Large
myd
 mice have also a severe phenotype, with 
accentuated muscle degeneration and substitution by connective tissue. Mice have a 
shortened lifespan, reduced size and neurological impairment (Grewal and Hewitt, 
2002). 
 Double mutant mice with the mdx background have been created in the 
attempt to approach the severe phenotype observed in DMD patients, such as the 
double knockout mdx:utrn-/-, with absence of both dystrophin and utrophin. It has 
been proposed that the protein utrophin, a homolog of dystrophin, could partially 
compensate for the absence of this protein in the mdx mice, being responsible for its 
mild phenotype. Double mutant mice with both utrophin and dystrophin absence have 
a much more severe muscular and cardiac phenotype than mdx mice, closer to that 
observed in DMD patients (Deconinck et al., 1997; Grady et al., 1997).  
 Recently, the double mutant Dmd
mdx
/Large
myd
 mouse (hereafter-called 
mdx/Large
myd
) has been generated in our laboratory by crossbreeding of mdx and 
Large
myd
 lineages. Homozygous mice for both mutations present a very severe 
phenotype, worse than both parental lineages. Lifespan is reduced and the degree of 
muscle degeneration and infiltration by connective tissue is increased when compared 
to the parental lineages. These mice have a partial deficiency of the enzyme LARGE, 
and a complete absence of the protein dystrophin. It has special interest in testing 
cellular or genetic therapeutic protocols, since it allows the evaluation of the 
dystrophin expression as a marker of therapeutic success (Martins et al., 2013). 
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Animal models for congenital myopathies 
 
 There are several mouse models for nemaline myopathy, including mouse 
models with mutation in the α-actin gene Acta1 (Ravenscroft et al., 2011), the  
nebulin gene (Ottenheijm et al., 2013; Yamamoto et al., 2013), the muscular troponin 
T gene (Wei et al., 2014) and the cofilin2 gene (Gurniak et al., 2014). All these mouse 
models have phenotype very similar to what is observed in human patients. Mouse 
models for core myopathies include the Sepn1 knockout mouse, which do not present 
weakness and histopathological features as observed in humans (Rederstorff et al., 
2011), and the knock-in models with mutation in Ryr1, which model the clinical and 
histological alterations observed in patients (Boncompagni et al., 2009; Zvaritch et 
al., 2009). 
 The myotubular myopathy murine models include  the  Mtm1 knock-out (Buj-
Bello et al., 2002) and the Mtm1 p.R69C knock-in mice (Pierson et al., 2012), which 
model the myotubular myopathy with similar clinical and histological features as 
observed in patients. Fugier and collaborators have developed a mouse with altered 
splicing in the Bin1 gene and muscle weakness, possibly modeling the autosomal 
recessive form of centronuclear myopathy (Fugier et al., 2011). Finally, the most 
frequent mutation in patients with centronuclear myopathy related to dynamin-2 has 
been inserted in the knock-in KI-Dnm2
R465W
 mouse. Heterozygous mice have only a 
small proportion of centronucleated fibers, in opposition to what is observed in 
humans. Muscle atrophy and force reduction are progressive and start at 2 months of 
age (Durieux et al., 2010).  
 Dog models for congenital myopathies include the Labrador retriever with 
mutation in the PTPLA gene (Pelé et al., 2005), the Labrador retriever with mutation 
in the MTM1 gene (Beggs et al., 2010) and dogs with canine Inherited Myopathy of 
Great Danes (IMGD), with mutation in the BIN1 gene (Böhm et al., 2013). Similar to 
the dog models for muscular dystrophies, canine models for congenital myopathies 
have phenotype similar as the observed in human patients. Mutations in the RYR1 
gene have been described in pigs (Fujii et al., 1991), dogs (Roberts et al., 2001) and 
horses (Aleman et al., 2004), but the major clinical manifestation observed in these 
animals is the malignant hypertermia phenotype instead of core myopathy. These 
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animal models have spontaneous mutations, in opposition to the engineered mouse 
models. 
 Recently, Childers and collaborators could correct the muscle pathology and 
prolong the lifespan in murine and canine models for myotubular myopathy with 
mutation in the MTM1 gene. Treatment was efficient when used both in initial and 
late stages of the disease, raising hope to patients and researchers in this field 
(Childers et al., 2014). Noninvasive methods to follow the possible benefits of these 
new therapeutic strategies in clinical trials are highly desirable. In this context, NMR 
studies in patients and animal models for muscle diseases have been developed, in a 
first moment to better describe the muscle involvement in these disorders, but with 
potential use as an outcome measure in clinical trials.   
 
 
Non-invasive evaluation of genetic muscle diseases 
 
 The diagnostic of genetic muscle diseases is based on clinical evaluation, 
quantification of muscle proteins in serum, electromyography, muscle biopsy and 
molecular analysis. Due to the large spectrum of genes related to muscle disorders, 
genetic testing can be a difficult task, especially while next generation sequencing is 
not widely used. In this way, imaging methods such as Computed Tomography (CT) 
and Magnetic Resonance Imaging (MRI) can allow the identification of the pattern of 
muscle involvement, orienting the genetic testing and helping in the differential 
diagnosis. Muscle MRI and CT from patients with genetic muscle disorders allowed 
the identification of the pattern of muscle involvement in these diseases, with strong 
correlation with genotype. The pattern of affected and spared skeletal muscles varies 
among muscular dystrophies, congenital myopathies and also between other muscle 
pathologies, such as inflammatory myopathies (Lamminen, 1990; Mercuri et al., 
2007; Quijano-Roy et al., 2011, 2012; Wattjes et al., 2010). Early and correct 
diagnosis can affect the management of muscular dystrophy and congenital myopathy 
patients, since some of these diseases may involve cardiac and pulmonary 
complications that require early intervention (Shieh, 2013). 
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 Besides of its importance in helping diagnosis, nuclear magnetic resonance 
(NMR) imaging (MRI), spectroscopy (MRS) and functional analysis (fMRI) have 
been used to study muscle morphology, metabolism and function in genetic muscle 
diseases. The non-invasive character of NMR, the use of non-ionizing radiation, the 
good contrast between fat and muscle tissue, and the possibility of studying muscle 
metabolism and function makes NMR a very interesting tool in the follow up of the 
natural history and of the effects of therapeutic trials in muscle disorders.  
 It has been shown that muscle MRI correlates with clinical evaluation in DMD 
patients (Liu et al., 1993), but  it allows additionally the identification of muscle 
impairment before the evidence of clinical signs, like in mild BMD patients and DMD 
female carriers (Tasca et al., 2012a, 2012b). MRI methods that can identify fat 
infiltration in muscles, presence of edema related to inflammation or necrosis, and 
that quantify fat and water content in muscles have been extensively applied in the 
study of DMD patients (Fischmann et al., 2012, 2013; Gaeta et al., 2012; Leroy-
Willig et al., 1997; Marden et al., 2005; Pichiecchio et al., 2002; Wren et al., 2008). 
Quantitative NMR (T1 and T2 measurements) also correlates with clinical parameters 
and with qualitative evaluation of the fat content in muscle MRI from DMD patients, 
raising the interest on its use in disease and therapy monitoring (Arpan et al., 2013; 
Huang et al., 1994; Kim et al., 2010; Mavrogeni et al., 2009; Willcocks et al., 2014).  
 When applied to different muscle dystrophies, NMR still gives interesting 
results. It has been shown that muscle and brain NMR correlate with clinical and 
genetics in myotonic dystrophy (Bachmann et al., 1996) and dysferlinopathies 
(Paradas et al., 2010). Oculopharyngeal muscular dystrophy patients, who present a 
very mild phenotype with slow progression, present MRI alterations that correlate 
with the disease progression, and that can be detected in a more sensitive way with 
MRI than with clinical evaluation (Fischmann et al., 2012). 
  Metabolic and functional NMR evaluation of dystrophic muscle have shown 
impaired metabolism in DMD patients, with changes in pH and altered metabolite 
ratios in 31P (Newman et al., 1982; Torriani et al., 2012) and 1H MRS (Hsieh et al., 
2009). DMD patients also showed higher intracellular Na
+
 levels in 23Na MRS 
(Weber et al., 2011). 31P MRS alterations were also observed in milder dystrophies at 
rest or in exercise protocols, such as in BMD (Lodi et al., 1999; Tosetti et al., 2011) 
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and LGMD (Lodi et al., 1997). MRI has been additionally used to track cell injected 
in DMD patients (Odintsov et al., 2013). 
 
 
NMR in the study of animal models for genetic muscle diseases 
 
 When applied to small animals, NMR faces the challenge of reducing 
dimensions and increasing resolution. Additionally, while in human patients with 
muscle disorders the muscle degeneration is followed by fat infiltration, mouse 
models for muscle diseases present low to zero fat infiltration in muscles (Carnwath 
and Shotton, 1987; McIntosh et al., 1998b). MRI analysis of intramuscular fat 
infiltration is therefore not as informative in mice as it is in patients, which raises the 
interest in other NMR approaches to non-invasively evaluate murine models, such as 
quantitative T1 and T2 measurements, in vivo spectroscopy and functional NMR.   
 It has been shown that mdx mice have increased muscle T2 values, at rest and 
after exercise (Mathur et al., 2011). Muscle heterogeneity in T2-weighted MRI also 
changes in mdx mice with the disease evolution (Pratt et al., 2013), indicating that not 
only T2 values but also quantitative measures of the distribution of muscle alterations 
can correlate with the phenotype in dystrophic mice. Muscle T2 has already been used 
to follow dystrophic muscle after gene therapy in a murine model for LGMD-2D 
(Pacak et al., 2007).  
 While all these studies compared dystrophic murine models to wild-type or 
control mice with the same background, Tardif-de-Géry and collaborators have 
compared muscle T2 values from two mouse models with deficiency in the protein 
laminin, the very severely affected dy/dy mouse and the dystrophic, but less severely 
affected, dy
2J
/dy
2J
 mouse. Both models have increased T2 when compared to wild-
type mice at least in one stage of the disease, but no difference was observed between 
the two dystrophic mouse strains (Tardif-de Géry et al., 2000).  
 MRI can also be informative in the evaluation of sarcoplasmatic membrane 
integrity in murine models for muscle dystrophies. Mutations in the DGC components 
can lead to alterations in the sarcoplasmic membrane, increasing its permeability. This 
can be accessed by injection of contrast agents that will be internalized in muscle 
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fibers in a different manner if there are membrane alterations. In addition, this 
approach can reveal which muscles have more membrane damage. In this way, it was 
possible to reveal muscle membrane alterations in vivo in mdx (Amthor et al., 2004; 
Straub et al., 2000), scga-null (Straub et al., 2000) and dysferlin-deficient mice 
(Schmidt et al., 2009). 
 Metabolic alterations have also been accessed in vivo by 1H and 31P MRS in 
mdx:utrn-/- mice (Cole et al., 2002) and in vitro by 1H MRS in different tissues of 
mdx mice (Griffin et al., 2001; McIntosh et al., 1998a). Finally, alterations in muscle 
MRI have been tracked after gene therapy in the murine model for LGMD-2D (Pacak 
et al., 2007), highlighting the value of NMR in the non-invasive tracking of 
therapeutic benefices in mouse models for muscle dystrophies.  
 There are still very few NMR studies with animal models for congenital 
myopathy. Gineste and collaborators have developed a series of NMR studies in three 
different mouse models for nemaline myopathy. The heterozygous nebulin knock-out 
mouse was studied by 31P NMR and MRI, combined with force measures, protein 
and gene expression analysis. Force reduction and altered proteomic profile were 
observed (Gineste et al., 2013c). The H40Y mouse, with mutation in the actin α-1 
gene, showed reduced force but no changes in subcutaneous or intermuscular fat, 
neither in 31P spectroscopy. The similar energetic consumption with a decreased 
muscle force indicated that the energetic metabolism is altered in H40Y mice, with 
increased energetic cost for muscle contraction (Gineste et al., 2013a). Finally, the 
transgenic Tg(ACTA1)Asp286Gly mouse, also with mutation in actin α-1, was 
evaluated with NMR and force measures. These mice showed muscle atrophy, force 
reduction and increased muscle T2, without fat infiltration and no differences in the 
31P MRS, indicating higher energetic cost for the muscular activity (Gineste et al., 
2013b). 
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muscle involvement in three mouse 
models of muscle dystrophy: mdx, 
Large
myd
 and mdx/Large
myd
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Abstract 
 
 Quantitative nuclear magnetic resonance imaging (MRI) has been considered 
a promising non-invasive tool for monitoring therapeutic essays in small size mouse 
models of muscular dystrophies. Here, we combined MRI (anatomical images and 
transverse relaxation time constant - T2 - measurements) to texture analyses in the 
study of four mouse strains covering a wide range of dystrophic phenotypes. Two still 
unexplored mouse models of muscular dystrophies were analyzed:  the severely 
affected Large
myd 
mouse and the recently generated and worst double mutant 
mdx/Large
myd
 mouse, as compared to the mildly affected mdx and normal mice. The 
results were compared to histopathological findings. MRI showed increased 
intermuscular fat and  higher muscle T2 in the three dystrophic mouse models when 
compared to the wild-type mice (T2: mdx/Large
myd
: 37.6±2.8 ms; mdx: 35.2±4.5 ms; 
Large
myd
: 36.6±4.0 ms; wild-type: 29.1±1.8 ms, p<0.05), in addition to higher muscle 
T2 in the mdx/Large
myd
 mice when compared to mdx (p<0.05). The areas with 
increased muscle T2 in the MRI correlated spatially with the identified 
histopathological alterations such as necrosis, inflammation, degeneration and 
regeneration foci. Nevertheless, muscle T2 values were not correlated with the 
severity of the phenotype in the 3 dystrophic mouse strains, since the severely affected 
Large
myd
 showed similar values than both the mild mdx and worst mdx/Large
myd
 
lineages. On the other hand, all studied mouse strains could be 
unambiguously identified with texture analysis, which reflected the observed 
differences in the distribution of signals in muscle MRI. Thus, combined T2 intensity 
maps and texture analysis is a powerful approach for the characterization and 
differentiation of dystrophic muscles with diverse genotypes and phenotypes.  These 
new findings provide important noninvasive tools in the evaluation of the efficacy of 
new therapies, and most importantly, can be directly applied in human translational 
research. 
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Introduction 
 
 The muscular dystrophies are an extensive group of genetic diseases where the 
major characteristic is the progressive muscle degeneration, caused by mutations in 
genes coding for sarcolemmal, sarcomeric, cytosolic, nuclear or extracellular matrix 
proteins. The absence or altered function of one of these proteins is responsible for a 
cascade of events, which ends in the muscle fibers degeneration and substitution by 
connective and adipose tissue. The patients present progressive weakness, starting at 
different ages depending on the mutation. Up to now, there is no effective cure for this 
group of diseases, and several therapeutic protocols are in development (Buckland 
and Gaspar, 2014; Emery, 2002). 
 The most frequent form of muscular dystrophy is Duchenne Muscular 
Dystrophy (DMD), caused by mutations in the dystrophin gene and with an incidence 
of 1 in 3300 live male births (Deconinck and Dan, 2007; Hoffman et al., 1987). The 
dystrophin protein is part of the dystrophin-glycoprotein complex (DCG), which links 
the cytoskeleton from muscle fibers to the extracellular matrix. This connection is 
mediated by the dystroglycan complex, composed by the sarcolemmal beta-
dystroglycan (β-DG) subunit and the peripheral membrane alpha-dystroglycan (α-
DG). While β-DG links to the subsarcolemmal protein dystrophin, α-DG is 
responsible for the connection with the extracellular matrix protein α-2 laminin. This 
link occurs via the sugar chains in the glycosylated extension of α-DG, which have 
high affinity to Laminin G (LG)-like domains present in various extracellular matrix 
proteins, such as laminins, perlecan and agrin in muscle, and neurexin in brain 
(Barresi and Campbell, 2006; Ervasti and Campbell, 1993; Straub and Campbell, 
1997). Mutations in the gene coding for dystroglycans are very rare, but alterations in 
α-DG glycosylation are related to several forms of myopathy, such as limb girdle 
muscular dystrophies and congenital muscular dystrophies (Muntoni et al., 2008). 
 The study of animal models for neuromuscular disorders has an essential role 
in understanding the pathogenetic mechanisms of the muscular diseases and in the 
development of therapeutic strategies. There are several natural or created animal 
models for the different forms of muscle dystrophy, which can model the genetic, 
molecular and/or clinical aspects of the disease. The Dmd
mdx
 mouse (hereafter called 
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simply mdx) is the most frequently used mouse model for DMD. This mouse has a 
stop codon in exon 23 of the murine dystrophin gene, which leads to the total absence 
of this protein in the muscle, as observed in DMD patients (Bulfield et al., 1984; 
Hoffman et al., 1987; Sicinski et al., 1989). Nevertheless, differently from the human 
patients, the mdx mouse can continuously regenerate its muscles and has a mild 
phenotype, which  makes the analysis of functional benefices in therapeutic protocols 
very difficult (Dangain and Vrbova, 1984; Dubowitz, 2004). 
 Double mutant mice with the mdx background have been created in the 
attempt to approach the severe phenotype observed in DMD patients, such as the 
double knockout mdx:utrn
-/-
, with absence of both dystrophin and utrophin 
(Deconinck et al., 1997; Grady et al., 1997); the mdx/mTR mouse, with impaired 
telomerase activity (Sacco et al., 2010); and the Dmd
mdx
-Large
myd
 mouse (hereafter 
called mdx/Large
myd
), recently generated  in our laboratory by crossing mdx and 
Large
myd
 murine lineages (Martins et al., 2013). The Large
myd
 myodystrophy mouse 
has a mutation in the glycosyltransferase Large gene, which leads to reduced 
glycosylation of α-DG and a severe and progressive myodystrophy. Mutations in the 
human gene LARGE are related to congenital muscular dystrophy 1D (CMD1D), with 
severe muscle and central nervous system involvement. The double mutant 
mdx/Large
myd
 mouse presents deficiency of both dystrophin and LARGE proteins, and 
a very severe phenotype, worse than both parental lineages. The lifespan is reduced 
and the degree of muscle degeneration and infiltration by connective tissue is 
increased when compared to the parental lineages. The mdx/Large
myd
 mouse gives 
clues of the interplay between α-DG glycosylation and dystrophin deficiency and is 
useful for testing therapies due to the functional, genetic and protein alterations 
(Martins et al., 2013). 
 Different therapeutic strategies for muscular dystrophies are in development, 
including genetic and cellular approaches. The gold standard to evaluate the 
dystrophic muscle is still the histological analysis, but non-invasive methods are 
highly desirable. Nuclear magnetic resonance (NMR), and more specifically magnetic 
resonance imaging (MRI), have a great potential in the study of skeletal muscle due to 
its flexibility in generating images from soft tissues with different contrasts, 
additionally enabling metabolic and functional studies. MRI studies in dystrophic 
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patients have revealed different patterns of muscle involvement depending on the 
mutation, which can be used to orient the molecular testing in the differential 
diagnosis (Quijano-Roy et al., 2012; Wattjes et al., 2010). Human DMD clinical 
evolution and muscle metabolism alterations can be non-invasively tracked by NMR, 
with a good correlation between quantitative NMR parameters and the clinical 
evaluation (Arpan et al., 2013; Fischmann et al., 2013; Gaeta et al., 2012; Hsieh et al., 
2009; Torriani et al., 2012; Tosetti et al., 2011; Willcocks et al., 2014; Wren et al., 
2008). 
 When applied to small animals, MRI faces the challenge of reducing 
dimensions and increasing resolution. Additionally, differently from human patients, 
mouse models of muscular dystrophies present low to zero fat infiltration in the 
muscle (Carnwath and Shotton, 1987; McIntosh et al., 1998b). The MRI analysis of 
intra-muscular fat infiltration is therefore not as informative in mice as it is in 
patients, which prompted the search for other MRI approaches to non-invasively 
evaluate mouse models, such as transverse relaxation time constant (T2) 
measurements and muscle texture analysis.  
 T2 is an NMR value intrinsic for each type of tissue, reflecting the motility of 
its water protons. When the examined tissue presents pathologic processes such as 
necrosis, inflammation or edema, this dynamic is altered, which results in changes in 
the tissue T2. Previous studies have reported abnormal muscle T2 in some dystrophic 
models, such as mdx (McIntosh et al., 1998; Walter et al., 2005; Mathur et al., 2011), 
γ-sarcoglycan knock-out γsg-/- (Walter et al., 2005), α-sarcoglycan knock-out sgca-/- 
(Pacak et al., 2007), and α-2 laminin deficient  dy/dy and dy2J/dy2J mouse models 
(Tardif-de Géry et al., 2000), as compared to normal controls. Texture analysis is an 
emerging approach that includes several techniques to quantify variations in the 
image intensity or patterns. When applied to muscle MRI, texture analysis has 
demonstrated to be a potential tool to evaluate subtle differences in the pattern of 
distribution of muscle lesions (Mahmoud-Ghoneim et al., 2006; Nketiah et al., 2014; 
Škoch et al., 2004). In the mdx mouse (Pratt et al., 2013) and the GRMD dystrophic 
dog (Fan et al., 2014), longitudinal studies were able to correlate texture parameters 
with age and progression of the disease. 
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 Considering this, we hypothesized that T2 measurements combined to muscle 
MRI texture analysis would be sensitive enough to characterize and differentiate 
dystrophic muscle phenotypes caused by different gene mutations. Here, we used this 
approach to evaluate two still unexplored mouse models of muscular dystrophies, the 
recently generated mdx/Large
myd
 mouse and the Large
myd 
parental lineage, in addition 
to mdx and C57Bl mice. These mouse strains cover a wide range of dystrophic 
phenotypes, with variable degrees of muscle necrosis and inflammation, and could be 
unambiguously identified with quantitative muscle T2 and texture analysis. The new 
findings will have important applications to noninvasive follow of potential 
therapeutic protocols. 
 
 
Materials and Methods 
 
Ethics Statement 
 
 All the experiments were approved by the Research Ethics Committee of the 
Biosciences Institute, University of São Paulo, protocol 176/2013. 
 
 
Animals 
 
 Four mouse strains were evaluated: the dystrophic mdx, Large
myd
 and 
mdx/Large
myd
, in addition to C57Bl/6 mice as normal controls (wild-type). 47 mice, 
aged between 2 and 4 months (8-19 weeks), both male and female, were studied: 9 
double mutants mdx/Large
myd
, 13 mdx, 12 Large
myd
 and 13 wild-type. As the two 
models with a weaker phenotype, in particular mdx/Large
myd
 mice, are difficult to 
obtain (25% of affected sibling and high degree of perinatal death, (Martins et al., 
2013)), a more flexible range of ages was adopted. To homogenize the groups, the 
accepted age range was allowed to vary between 8 and 18 weeks for all mouse strains. 
At this stage, muscle dystrophy is patent in all mouse strains. This age range is 
posterior to the critical period in mdx mice, when a peak of myofiber necrosis, muscle 
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weakness and regeneration is observed between the 2
nd
 and the 5
th
 weeks of life 
(Muntoni et al., 1993). All the animals were from the Human Genome Research 
Center animal house, Bioscience Institute (Sao Paulo). The mice were kept in 
controlled environment, with water and food at libidum.  
 
 
Magnetic Resonance Imaging acquisition and analysis 
 
 The mice were anesthetized with intraperitoneal injection of 
ketamine:xylazine (2:1, 1.5-2.5 µl/g according to the lineage) and symmetrically 
positioned for the MRI acquisitions. The images were acquired in a 2 tesla/30 cm bore 
superconducting magnet (Oxford Instruments 85310HR, Abingdon, United 
Kingdom), interfaced to a Bruker Avance AVIII console (Bruker-Biospin, Inc., 
Billerica, MA, U.S.A.) running PARAVISION 5.0. A crossed-saddle radiofrequency 
coil projected for small animals (Papoti, 2006) was used to image the mice's posterior 
limbs.  
 Four scans were performed in each mouse, with the same geometry (4 slices, 
1.5 mm slice thickness, 4 mm inter-slice distance and spatial resolution 0.176X0.176 
mm
2
/pixel): two scans for anatomical images with the same parameters (repetition 
time - TR=1800 ms, echo time - TE=52.5 ms), with and without fat suppression for 
qualitative evaluation of possible fat infiltration in the muscles (with fat 
suppression:16 averages; without fat suppression: 4 averages); and two scans for the 
calculation of the T2 maps, each one using a different echo time  (to avoid the 
contribution of stimulated echoes): TE1=12.1 ms and TE2=40 ms (TR=1500 ms, 1 
average when TE1=12.1 ms, 4 averages when TE2=40 ms, spatial resolution: 
0.176X0.176 mm
2
/pixel). The T2 value for each pixel was calculated using the Bloch 
equation for the spin-spin relaxation time (Supporting Information S2.1), and T2 
maps were generated using a routine developed in the MATLAB software (The 
MathWorks, Inc., Natick, Massachusetts, USA). The total acquisition time was 51 
minutes. The examination time never exceeded 1 hour and 30 minutes. 
  In the T2 maps, two slices were selected for analysis: one positioned at the 
lower leg and one at the thigh. One slice was considered representative of thigh and 
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leg muscles since injured fibers would present anomalies along all its length. 
Nevertheless, this limits the analysis to the muscles observed in a defined anatomical 
position. 
  Four Regions of Interest (ROI) were evaluated: two in the lower leg T2 map, 
at the posterior and anterior compartment muscles, and two in the thigh T2 maps, 
covering the medial and lateral muscles. The ROIs were drawn to exclude any non-
muscle tissue. For each ROI, the mean T2 value and the standard deviation were 
analyzed.  
 The muscle texture in MRI was evaluated with the softwares MaZda 4.6 and 
B11 3.3 (Strzelecki et al., 2013; Szczypinski et al., 2007; Szczypiński et al., 2009), 
using the T2-weighted images acquired with TE=40 ms and TR=1500 ms. The lower 
leg image was selected and one ROI was drawn in the left lower leg of each mouse, 
including all muscle groups but excluding subcutaneous fat, bones and skin. All the 
371 texture features offered by the Mazda software were calculated. The co-
occurrence matrices parameters contrast and entropy were selected due to their 
significance for the identification of our studied groups, and resulted in the reduction 
of the 371 features to 40. Among them, Mazda software automatically selected 30 
features, by combining the maximization of the Fischer coefficients, the maximization 
of the mutual information between two selected features, the minimization of the 
classification error probability and minimization of the average correlation 
coefficients (F+PA+MI). The 30 selected features (listed in Supporting Information 
S2.2) were then used as input to Linear Discriminant Analysis (LDA) in the software 
B11.  
 
 
Histological analysis 
 
 Two days after the NMR session, the mice were euthanized in a CO2 chamber. 
The whole left leg was collected and preserved in formaldehyde solution (4% in 
Phosphate Buffer Saline - PBS). The right leg was dissected and the lower leg 
posterior compartment (gastrocnemius and soleus) was imbedded in Tissue-tek OCT 
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freezing medium (Optimal Cutting Temperature, Sakura Finetek USA, Torrance, CA, 
USA) and frozen in liquid nitrogen. 
 The histological qualitative evaluation was performed on at least 2 mice for 
each lineage. The formaldehyde-preserved samples were decalcified and embedded in 
plastic resin according to the manufacturer procedure (HistoResin, Leica, Wetzlar, 
Germany). Resin embedded samples were cut in 5 µm slices and frozen samples were 
cut in 8 µm slices. Both frozen and resin embedded histological sections were stained 
with Hematoxilin and Eosin (H&E). Additional Gomori trichrome and sirius red 
staining were done in the frozen sections. 
 
 
Statistic analysis 
 
 The T2 mean values for each ROI were analyzed with a three-factors 
ANOVA, followed by the Bonferroni muticomparison test when ANOVA detected 
differences (p<0.05). The three considered factors were: presence of the mutation in 
the dystrophin gene (Dmd
+/+
=no mutation/Dmd
-/-
=with mutation); presence of the 
mutation in the gene Large (Large
+/+
=no mutation/Large
-/-
=with mutation); and 
muscle group (1: lower leg posterior, 2: lower leg anterior, 3: thigh lateral, 4: thigh 
medial). The lineage was split in two factors to evaluate a possible cumulative effect 
of both mutations in the double mutant mdx/Large
myd
 mouse, and the muscle groups 
were studied separately to evaluate a possible different pattern of muscle involvement 
in the dystrophic mouse strains. The differences were considered significant when 
p<0.05. This level of significance was achieved in ANOVA when F(1,164)>3.90 for 
the comparison of mice from different genetic background and when F(3,164)>2.66 
for the comparison of different muscle groups. Analyses were performed with NCSS 
2001 software (Kaysville, Utah, USA). 
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Results 
 
 The three dystrophic mouse strains showed increased amount of fat between 
the muscles when compared to the wild-type mice (Figure 2.1). However, no intra-
muscular fat could be detected in any of the mouse strains with MRI: the muscle 
hyperintensities present in the images without fat suppression (Figure 2.1,  NFS) were 
identically observed in the images with fat suppression (Figure 2.1, FS), indicating 
that these areas were not related to fat infiltration.  
 
 
Figure 2.1: Intermuscular fat in dystrophic mice. MRI of the four mouse strains 
(lower leg), showing intermuscular fat but no visible fat infiltration in the muscles in 
the three dystrophic strains. The arrows indicate the presence of fat between the 
muscles, as bright areas in the non fat-supressed images (NFS) and dark areas in the 
images with fat suppression (FS). The arrowheads indicate hyperintense areas present 
in the images with and without FS, which are therefore not related to fat infiltration. 
TE=52.5 ms, TR=1800 ms.  
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Muscle T2 
 
 In the individual comparison between muscle groups for each lineage, only the 
wild-type mice showed differences: thigh medial muscles have higher muscle T2 than 
the lower leg muscles (p<0.01). In the three dystrophic strains no differences were 
observed between the muscle groups. Therefore, all muscles were grouped in one 
unique T2 value for each animal for the comparison between the mouse strains (Table 
2.1).  
 
 
Table 2.1. T2 per muscle group in milliseconds for the four mouse strains studied. 
  mdx/Large
myd
 mdx Large
myd
 wild-type 
N 9 13 12 13 
Lower leg - 
posterior 36.96 ± 2.84 34.95 ± 3.70 35.48 ± 2.15 28.34 ± 1.71 
Lower leg - 
anterior 37.15 ± 3.77 33.43 ± 2.85 33.95 ± 3.59 28.05 ± 1.28 
Thigh - lateral 37.70 ± 3.07 36.41 ± 7.20 37.79 ± 5.38 29.69 ± 1.36 
Thigh - medial 38.34 ± 1.66 36.31 ± 3.00 38.48 ± 2.54 30.36 ± 1.93 
Comparison 
between muscles p=0.76 p=0.32 p=0.025 p<0.01 
All muscles 37.56 ± 2.82 35.23 ± 4.53 36.58 ± 4.00 29.11 ± 1.82 
 
No differences were observed between the muscle groups in the three dystrophic 
mouse strains. p-values are for the comparisons between muscle groups for each 
mouse strain. Since four individual comparisons were done, the Bonferroni correction 
was applied and the differences were considered significant if p<0.0125. 
  
 
 Considering the mouse strains individually, muscle T2 was markedly 
increased in the three dystrophic mouse models when compared to the wild-type mice 
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(p<0.05). Additionally, mdx/Large
myd
 mice had significantly higher muscle T2 than 
mdx mice (p<0.05, Table 2.1, Figure 2.2). 
 
 
  
Figure 2.2: Muscle T2 for mdx/Large
myd
, Large
myd
, mdx and wild-type mice. 
Muscle T2 in milliseconds for the four mouse strains evaluated. *: Muscle T2 
different from wild-type mice; #: muscle T2 different from mdx mice.  
 
 
  When considering the effect of each gene mutation separately in muscle T2 
values, ANOVA showed that there was a significant interaction between the absence 
of dystrophin and the defective glycosylation of α-DG (p<0.001). The presence of 
both mutations lead to an increase in muscle T2 when compared to the mdx mice, but 
this increase was lower than the simple sum of the effects of each mutation (Figure 
2.3). 
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Figure 2.3: Effect of each mutation on muscle T2. Both the dystrophin absence and 
the α-DG glycosylation defect increase muscle T2, but the combination of both does 
not produce an additive effect. 
 
 
Muscle texture analysis 
 
 Despite similar values of T2, it was possible to observe differences in the 
distribution of hyperintense regions in muscle MRI: while mdx mice presented focal 
areas with hyperintense signal randomly distributed in the muscles (patchy), Large
myd
 
mice presented a global increase in muscle signal, distributed homogeneously in all 
muscles (waxy). The double mutant mdx/Large
myd
 presented a waxy aspect in muscle 
images, with a few focal hyperintense areas, as a mixture of the patterns observed in 
the parental strains. The differences in global appearance observed visually in the 
muscle images from the dystrophic mice were then quantified using texture analysis 
algorithms. The four groups were properly distinguished with the constructed model, 
and all the individuals were correctly classified by it. The linear separability was 0.91 
and 3 dimensions could model 97% of the original data. Plotting the data over the 
three dimensions of the model nicely visualized the clustering of the mice into four 
groups according to the mutation (Figure 2.4). 
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Figure 2.4: Texture analysis differentiates the four mouse strains. Two views of 
the same plot showing the clustering of mice groups after texture analysis from lower 
leg MRI. 1: wild-type, 2: mdx/Large
myd
, 3: Large
myd
, 4: mdx mice. MDF: Most 
Discriminant Features. 
 
 
Histological analysis 
 
 The histological analysis was based on qualitative comparison of dystrophic 
pathologic features, such as the presence of degenerating and regenerating cells foci, 
necrosis, and infiltration by connective and adipose tissues. Homogeneous and pale 
eosinophilic sarcoplasm was related to degenerating and necrotic fiber, while 
basophilic sarcoplasm and central nuclei were related to regenerating fibers (Figure 
2.5) (Dubowitz et al., 2013; Salimena et al., 2000).  
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Figure 2.5: Identification of dystrophic pathological structures. Histological 
sections of a 3 month-old mdx/Large
myd
 mouse (frozen sample), approximately at the 
same position, stained with (A) Hematoxilin-Eosin, (B) Sirius Red, and (C) Gomori 
trichrome, magnification X 100. The arrows indicate thick areas of connective tissue. 
 
 
 Histological sections from the resin embedded samples, which preserved the 
anatomical organization of the muscle groups, where chosen to represent the MRI 
slices (Figure 2.6). 
 The mdx mice showed a patchy pattern in the MRI (Figure  2.6 C), and the 
hyper-signal areas in MRI corresponded spatially to foci of dystrophic alterations, 
such as clusters of degenerating and regenerating cells, infiltration by inflammatory 
cells and spots of adipose tissue in the periphery of the muscles (Figure 2.6 G, K). It 
was also possible to observe variation in the fibers caliber, high proportion of 
centronucleated muscle fibers and increased amount of connective tissue in all the 
lower leg muscles, but these alterations did not necessarily correlate with hyperintense 
areas in the MRI.  
 The Large
myd
 mice presented dystrophic histological characteristics distributed 
in a more diffuse pattern through the muscles, in accordance with the waxy pattern 
observed in the MRI (Figure 2.6 B, F). The histological analysis revealed the presence 
of degenerating and regenerating muscle cells, inflammatory infiltrates and fibrosis in 
a diffuse distribution, with occasional small clusters of degenerating and regenerating 
fibers. The muscles were generally more compromised than in the mdx mice (Figure 
2.6 J).  
 The mdx/Large
myd
 mice showed infiltration by inflammatory cells, fibrosis and 
degenerating fibers diffusely distributed across the muscles, such as the Large
myd
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mice, especially in the posterior compartment muscles of the leg. Additionally, there 
were few big clusters of degenerating and regenerating fibers, which co-localized with 
hyper-signal areas in the MRI, but in a less accentuated proportion than in the mdx 
mice (Figure 2.6 A, E). In general, the mdx/Large
myd
 mice presented a more severe 
degree of dystrophic lesions in the histological analysis than both parental mouse 
strains (Figure 2.6 I). 
 The wild-type mice showed polygonal fibers with regular size and peripheral 
nuclei. There was no fat accumulation inside the muscles, and between the muscles 
the amount of fat was reduced in comparison to the three dystrophic mouse strains. 
The endomysial and perimysial connective tissue were thinner than in the three 
dystrophic mouse strain (Figure 2.6 H, L). The normal histological pattern was 
compatible with the homogeneous and low intensity signal in muscle MRI (Figure 2.6 
D). 
 
 
Figure 2.6: MRI versus histological analysis. MRI (A-D; TE=40 ms, TR=1500 ms) 
and histological images (H&E, magnification X6: E-H; magnification X200: I-L) of 
the left lower leg from mdx/Large
myd
 (A, E, I), Large
myd
 (B, F, J), mdx (C, G, K) and 
wild-type mice (D, H, L). The regions highlighted in the MRI (first row) and in the 
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whole lower leg histological image (second row) are presented in a higher 
magnification in the third row. Different histological processes could be related to the 
hyperintensities regions in the MRI, such as clusters of degenerating cells (I), 
regenerating and adipose cells cells (K), and regions with mixed dystrophic 
characteristics (J).   
 
 
Discussion 
 
 Noninvasive tools for muscle evaluation have an immediate application in 
therapeutic protocols, to follow possible benefits in longitudinal studies with minimal 
impact on the subjects. For this purpose, it is essential that the selected tool could not 
only detect differences between dystrophic and normal muscle, but that it could also 
detect more subtle differences between various degrees of muscle involvement, both 
in patients and in animal models. In this MRI study, we have evaluated for the first 
time the muscle MRI pattern in the Large
myd
 and the double mutant mdx/Large
myd
 
mouse models of muscular dystrophy, as compared to mdx and C57Bl/wild-type mice. 
These mouse strains cover a wide range of dystrophic phenotypes, from the mildly 
affected mdx mouse to the severely compromised mdx/Large
myd
 mouse. Using a 
combined approach including qualitative MRI evaluation, muscle T2 relaxometry and 
texture analysis, in comparison to the standard histological analysis, we have shown 
that noninvasive MRI can successfully discriminate muscles from these four mouse 
strains. 
 MRI acquired with and without fat saturation revealed no identifiable fat 
infiltration in the muscles of any of the mouse strains, but an increased fat 
accumulation between the muscles in the MRI could be observed in the dystrophic 
mice when compared to the wild-type. This observation was confirmed by the 
histological analysis, where it was possible to identify bigger fat deposits between the 
muscles in the dystrophic mouse strains. Our results extend to the more severely 
dystrophic Large
myd
 and mdx/Large
myd
 models the previously described MRI findings 
in the mdx mouse, of no fat infiltration in skeletal muscles visible with MRI 
(McIntosh et al., 1998b; Pratt et al., 2013; Walter et al., 2005). 
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 In addition to the increased intermuscular fat, the histological analysis 
revealed sporadic adipose cells in the muscles of the three dystrophic mouse strains, 
notably in the mdx mice, where small clusters of adipose cells were present especially 
along the fascia. This is in accordance with previous MRI observation in DMD 
patients, where increased fat signal along the fascia in young DMD boys was present 
even when the intramuscular fat replacement was minimal (Marden et al., 2005). 
Although no fat infiltration could be observed in the mice MRI, we believe that the 
presence of only sporadic and isolated adipose cells in the muscle would not be 
visually detected in the MRI in the resolution used in this study. It is possible though 
that this punctual presence of fat in the muscle can lead to changes in the muscle T1 
and T2 measurements, in addition to alterations in the MRI muscle texture.  
 The quantitative evaluation of the mean muscles T2 showed increased values 
for the three dystrophic mouse strains when compared to the wild-type mice. An 
increased but not cumulative effect of the dystrophin absence and the α-DG 
glycosylation defect was observed in the double mutant mdx/Large
myd
 mouse: its 
muscle T2 was higher than the value observed in the mdx mouse, but it was not 
different from the Large
myd
 mouse. The increased muscle T2 in the dystrophic mice is 
in accordance with previous studies showing  higher muscle T2 in the mdx mouse 
(Mathur et al., 2011; Walter et al., 2005), and in other mouse models of muscular 
dystrophies such as laminin-deficient mice (Tardif-de Géry et al., 2000) and the γ-
sarcoglycan-null mice (Walter et al., 2005). Our NMR study in Large
myd
 and 
mdx/Large
myd
 mice extend the number of dystrophic mouse models where increased 
muscle T2 is observed, corroborating the hypothesis that even if no significant fat 
infiltration is observed in the MRI of murine models of muscle dystrophy, increased 
muscle T2 would be a common feature of the dystrophic muscle, both in patients and 
animal models with variable phenotype.  
 Muscle water T2 reflects the mobility of water molecules in the tissue. The 
loss of muscle proteins, the presence of infiltrated adipose and inflammatory cells, 
and the edema originated by inflammation and necrosis in the dystrophic muscle lead 
to alterations in the mobility of water molecules, and consequently can contribute to 
the T2 alterations (Kim et al., 2010). The absence of the dystrophin protein 
destabilizes the DGC and leads to increased membrane damage in the mdx mouse. 
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Sarcolemma disruption and increased cell permeability cause edema and 
extravasation of the sarcoplasmatic content (Straub et al., 1997), with consequent 
altered mobility of water molecules and increased T2. Even if the mdx mouse has a 
mild phenotype, the membrane disruptions are present in higher proportion when 
compared to the more severely affected α-2 laminin-deficient mice, dy/dy and 
dy
2J
/dy
2J 
(Straub et al., 1997). The same pathological disruption of the sarcolemma is 
observed in cardiac muscle cells from Large
myd
 mice (Kabaeva et al., 2011), and is 
possibly present also in the skeletal muscles from Large
myd
 and the double mutant 
mdx/Large
myd
 mice. Thus, sarcolemma disruption, in addition to the consequent 
necrosis and inflammatory infiltrates observed in areas with hyperintense signal in the 
MRI, could be more related to the increased muscle T2 in the three dystrophic mouse 
strains, than the overall phenotype.  
 The T2 determination based on two echoes at two different TEs has long been 
dismissed as inadequate and imprecise. This needs to be revised and our data bring 
more evidence pointing into that direction. When image signal-to-noise ratio is high, 
two-point determination is accurate, often more than CPMG echo trains. In practice, 
scanner imperfections but also RF propagation through tissues create B1 field 
deviations that are responsible for the generation of stimulated echoes that bias the T2 
decay. Most often, the measured mono-exponential T2 with this sequence is longer 
than the true T2. The single echo collection as was performed here prevents the 
introduction of stimulated echos. While obsolete at first glance, the method used here 
is in reality as valid as and probably more accurate than more popular methods.  
 We are here dealing with mono-exponential T2, which is classically used to 
characterize global water T2 dynamics in a given tissue. Muscle T2 decay is in reality 
multi-exponential and can be exploited to determine tissue water compartments and 
exchanges, as shown by the work by Saab (Saab et al., 1999) and more recently by 
Araujo (Araujo et al., 2014). It requires different and very demanding experimental 
approaches, which are seldom used in practice. In that respect, standard multi-echo 
sequences do not allow better than the 2 echoes method to tackle this multi-
compartment organization of tissue. 
 In the comparison between MRI and the histological analysis, appropriate co-
localization of the distribution of alterations was observed in the three dystrophic 
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mouse strains, which is essential to validate the use of MRI as an outcome measure. 
In humans, a correlation between the degree of muscle involvement in MRI and the 
progression of dystrophic alterations in histological analysis was observed in DMD 
patients, but with MRI and muscle biopsy done in different muscles (Kinali et al., 
2011). In the mdx mouse, our data comparing the histological analysis with the MRI 
in the same muscles showed that high intensity areas in muscle MRI were co-
localized with variable dystrophic characteristics in the histological analysis, in 
accordance with the previous studies in this model (McIntosh et al., 1998b). 
Additionally, we extended for the first time this characterization for Large
myd
 and 
mdx/Large
myd
 dystrophic murine models, which showed a similar co-localization of 
alterations in the MRI versus the histological analysis. In all these dystrophic models 
the areas with increased muscle T2 in the MRI correlated spatially with several 
different histopathological alterations such as necrosis, inflammation, degeneration or 
regeneration foci. Thus, even if the increased muscle T2 could not differentiate 
individually each one of these pathological findings, the T2 maps reveal a disease 
process at a tissue level. Apart of the non-invasive nature, this MRI approach allows 
the evaluation of the dystrophic process along several muscles in the same exam, 
which is methodologically difficult considering the use of standard histological 
techniques. 
 Muscle T2 values were not correlated with the severity of the phenotype in the 
3 dystrophic mouse strains, since the severely affected Large
myd
 mice showed similar 
values than both the mild mdx and severe mdx/Large
myd
 lineages. Notably, the major 
histological difference between these strains is fibrosis, which was not detectable with 
the MRI sequences used in this study. Connective tissue presents very short T2 
values, being visualized only with appropriated pulse sequences such as Ultra Short 
Echo-time sequences (UTE) (Gatehouse and Bydder, 2003), which could not be used 
due to technical limitations. On the other hand, the MRI images showed clear 
different patterns of muscle signals. The muscle MRI was patchy in mdx mice, with 
delimited regions of increased MR signal distributed through the posterior limb 
muscles, both in the lower leg and in the calf images. The Large
myd
 mice, by its turn, 
showed a waxy pattern in the muscle MRI, with a general increase in the MR signal 
distributed homogeneously through the lower leg and thigh muscles. Finally, the 
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mdx/Large
myd
 mice showed generally a diffuse increase in the MR signal, like the 
Large
myd
 mice, but there were also hyperintense regions in the lower leg muscles, 
similar to what was observed in the mdx mice. After refining the muscle texture 
analysis with the evaluation of the co-occurrence matrix parameters entropy and 
contrast, it was possible to cluster the mice from different groups.  
 Changes in the muscle texture in small animals have already been reported in 
rats when comparing atrophic, regenerating and normal muscles (Mahmoud-Ghoneim 
et al., 2006). In the mdx model, a heterogeneous muscle signal was also observed in a 
variable degree according mouse’s age, with a peak between the age of 5 and 17 
weeks (Pratt et al., 2013). Additionally, texture parameters have been considered 
reliable biomarkers of disease progression in the GRMD dystrophic dog (Fan et al., 
2014; Wang et al., 2013). Here we show the possibility of classifying murine models 
of muscle dystrophies with different phenotypes using quantitative NMR and texture 
analysis with prior knowledge. It is possible that the differences observed with our 
texture analysis were more evident due to the mice’s age, since  it was close to the 
described  peak  of  muscle heterogeneity in the  mdx model (Pratt et al., 2013). Even 
though, these results indicate that MRI when combined to texture analysis can provide 
a refined noninvasive identification of muscle alterations, not only between drastically 
different conditions but also when more subtle differences are present. This approach 
can be potentially transferred to human applications. In this case, a preliminary step 
would be to select the most discriminant combination of texture indices in muscle 
MRI from patients with known diagnosis. Then, the model could be validated by 
investigating in which category new patients would be classified in confront with 
genetic analysis. 
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Conclusions 
 
 While muscle mean T2 values were abnormal in all dystrophic muscle, and 
reflected the spatial distribution of different histopathological changes, they did not 
clearly distinguish the three different genotypes, nor were correlated to severity of the 
phenotype. On the other hand, texture analysis algorithms unambiguously separated 
muscles from mdx, Large
myd
 and mdx/Large
myd
 mice, reflecting the waxy versus 
patchy distribution of lesions in the different strains. Combined T2 maps and texture 
analysis provide a powerful non-invasive characterization of dystrophic muscles, even 
when performed at 2 tesla and derived from two single TEs measurements. Our 
findings have important implications to validate the use of MRI as an outcome 
measure in therapeutic protocols applied to mouse models of muscle dystrophies, with 
the possibility of direct applications in human translational research. 
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Supporting Information  
 
S2.1. T2 calculation from two images at different echo times 
 
 The Bloch Equation for the spin-spin relaxation time (Equation 2.1) express 
the exponential decay of the sample magnetization as a function of the initial 
magnetization (M0), the echo time (TE), and the spin-spin relaxation time of the 
sample (T2): 
(2.1)  
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MM        
 
 If two images are collected at different echo times, TE1 and TE2, the ratio 
M1/M2 is given by: 
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 The signal to noise ratio (SNR), corrected by the number of excitations used to 
compose the image (NEX), is proportional to the sample magnetization: 
(2.3)  
NEXNoise
Signal
M         
 
 Combining The Equations 2.2 and 2.3, the T2 value can be estimated by (2.4): 
(2.4)  
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 The equation (2.4) was the basis of the MatLab routine designed to calculate 
the T2 maps. The noise was estimated by measuring the mean signal in a region of 
interest (ROI) placed in an empty area from the images. 
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S2.2. Features selected for Texture Analysis 
 
 Two parameters related to the co-occurrance matrix, contrast and entropy, 
were manually selected. The co-occurrence matrix is the second order histogram of 
the image, with the estimate of the joint probability pdT(i,j) of two pixels, at distance 
d along a direction T, to have particular values i and j. MaZda calculates the co-
occurrence matrix for up to 5 pixels of distance, and considering 4 directions (0º, 45º, 
90º and 135º). The co-occurence matrix parameters are therefore computed for (d,0), 
(0,d), (d,d) and (d,-d), where d points to the distance between two pixels, which can 
take integer values from 1 to 5.  
 In the sequence (Table 2.2), 30 features were automatically selected by 
combining the maximization of the Fischer coefficients, the maximization of the 
mutual information between two selected features, the minimization of the 
classification error probability and minimization of the average correlation 
coefficients (F+PA+MI). The selected features are listed below, and they were used as 
input to Linear Discriminant Analysis (LDA). 
 
Table 2.2. Features selected for texture analysis (F+PA+MI). 
 Feature  Feature  Feature 
1 S(0,4)Contrast 11 S(5,-5)Contrast 21 S(0,3)Entropy 
2 S(4,0)Contrast 12 S(4,4)Entropy 22 S(2,2)Entropy 
3 S(2,0)Entropy 13 S(4,4)Contrast 23 S(0,2)Entropy 
4 S(2,-2)Entropy 14 S(5,0)Entropy 24 S(3,3)Entropy 
5 S(5,-5)Entropy 15 S(0,5)Entropy 25 S(1,-1)Entropy 
6 S(3,-3)Entropy 16 S(1,0)Contrast 26 S(1,1)Entropy 
7 S(4,-4)Entropy 17 S(5,0)Contrast 27 S(0,1)Entropy 
8 S(3,0)Entropy 18 S(5,5)Entropy 28 S(1,0)Entropy 
9 S(0,3)Contrast 19 S(5,5)Contrast 29 S(0,2)Contrast 
10 S(4,0)Entropy 20 S(0,4)Entropy 30 S(2,-2)Contrast 
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Complements to the manuscript 
 
 In addition to the measurements described in the manuscript, two verification 
steps were done to ensure the reliability of the results: (i) the validation of the 2-points 
T2 measurement by the comparison with results acquired with a standard multiecho 
sequence for T2 measurement; and (ii) the evaluation of post-mortem alterations on 
muscle T2. 
 
 
Validation of the 2 points T2 measurements with a multiecho sequence    
 
 While usually the T2 values are estimated using multi-echo sequences, here, to 
avoid the influence of stimulated echoes, we proposed the estimation of muscle T2 
with only 2 echo times. To validate this methodology, the muscle T2 values from 2 
C57Black/6 (wild-type) and 3 mdx/Large
myd
 mice were measured using a multiecho 
sequence, and the results were compared with the T2 values estimated with 2 echo-
times.  
 The mice were scanned in a 3.0T MRI system (Intera Achieva, Philips 
Healthcare, Best, The Netherlands), with a 1H quadrature mouse volume coil (RAPID 
Biomedical GmbH, Germany), at LIM44, Faculty of Medicine, University of Sao 
Paulo. The sequence parameters were: TR= 1000 ms, 20 echo times, from 7.8 ms to 
156 ms (TE = 7.8*n ms, n=1, …, 20). The geometry parameters were: slice thickness 
2 mm; resolution 0.2 x 0.2 mm/pixel; 4 slices; interslice space: 3 mm. The acquisition 
time was 24 minutes, and the total exam never exceeded 1 hour. 
 ROIs were designed in the gastrocnemius (Gastr) and tibialis anterior (TA) 
muscles in the slice corresponding to the lower leg. The T2 values were estimated 
fitting the exponential decay of the signal with the increase of the echo time. The first 
image (TE = 7.8 ms) was excluded from the fitting since it is not affected by 
stimulated echoes as the consecutive images. The last five echo times were excluded 
from the fitting, due to low signal to noise ratio observed for muscle. 
 The T2 values obtained were similar to those measured from the 2 echo-times 
T2 calculation, as shown in Table 2.3. 
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Table 2.3: Comparison of multiecho and 2 points T2 measurements in wild-type and 
dystrophic mdx/Large
myd
 mice. 
Multi Echo T2 measurement (14 TEs) 2 points T2 measurement (2 TEs) 
wild-type 
N=2 
TA 29.27 ± 1.33 
wild-type 
N=13 
TA 28.14 ± 1.28 
 Gastr 30.63 ± 2.13  Gastr 28.43 ± 1.71 
mdx/Large
myd
 
N=3 
TA 37.24 ± 1.87 
mdx/Large
myd
 
N=9 
TA 37.26 ± 3.77 
 Gastr 40.62 ± 1.98  Gastr 37.09 ± 2.84 
 
  
 The values obtained with the two methods were similar, indicating that the 
estimative of the T2 values from two images acquired at different echo times is a 
reliable measurement in living mice. 
 
 
Post-mortem changes in the T2 values 
 
 The double mutant mdx/Large
myd
 mice were very sensitive to the anesthetic: 
from 16 mdx/Large
myd
 mice analyzed, 6 died during the measurements due to the 
anesthesia. 2 Large
myd
, 1 mdx and 1 C57Bl/6 (wild-type) mice also died during the 
measurements, under anesthesia. The T2 values obtained from the mice that died 
during the experiments tended to be higher than the values obtained from living mice 
from the same lineage. To evaluate the muscle T2 changes after death, 2 mdx and 1 
wild-type mice were imaged under anesthesia. Immediately after the end of the 
acquisition, mice were killed by cervical dislocation and MRI was repeated. Table 2.4 
shows the results of these measurements. 
 The post-mortem T2 values were increased for the three mice and all muscle 
groups, with T2 values increasing from 6 to 31%. The T2 standard deviation was 
increased for the three mice for the calf muscles, from 7 to 60%. Nevertheless, for the 
thigh muscles, the T2 standard deviation was increased in the wild-type and in one 
mdx (Mdx#71) mouse, from 6 to 37 %, while it decreased around 10% for one mdx 
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mouse (Mdx#70). The high variability observed in the post-mortem T2 measurements 
could be related to osmotic changes due to the stopped activity of ionic pumps. Thus, 
the exams from mice that died during the image acquisition were discarded from 
muscle T2 and texture analyses in the manuscript. 
 
 
Table 2.4: Post-mortem muscle T2 changes values from 1 C57Bl/6-WT and 2 mdx 
mice.  
Mouse  Lower Leg Thigh 
  Posterior Anterior Lateral Medial 
wild-
type 
Alive 29.91 ±5.86 30.03 ±6.90 30.97 ±5.28 31.84 ±6.34 
Dead 34.89 ±7.18 34.80 ±7.78 34.12 ±6.87 33.85 ±6.74 
Dead/Alive 1.17 ±1.23 1.16 ±1.28 1.10 ±1.30 1.06 ±1.06 
Mdx 
#70 
Alive 33.36 ±7.97 31.05 ±8.86 43.05 ±17.88 35.27 ±8.27 
Dead 36.71 ±8.75 37.96 ±9.47 46.91 ±15.83 38.16 ±7.43 
Dead/Alive 1.10 ±1.10 1.22 ±1.07 1.09 ±0.89 1.08 ±0.90 
Mdx 
#71 
Alive 31.24 ±7.39 30.51 ±6.02 30.75 ±5.98 31.57 ±5.73 
Dead 37.36 ±8.19 39.93 ±9.63 37.07 ±7.40 39.03 ±7.82 
Dead/Alive 1.20 ±1.11 1.31 ±1.60 1.21 ±1.24 1.24 ±1.37 
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Structural and functional alterations of 
skeletal muscle microvascular network in 
dystrophin-deficient mdx mice 
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Chapter 3. Structural and functional alterations of 
skeletal muscle microvascular network in dystrophin-
deficient mdx mice 
  
 
 This NMR study is shared with the PhD thesis of Claire Latroche, under the 
supervision of Gregory Jouvion, Fabrice Chrétien (Institut Pasteur, Human 
histopathology and animal models, Infection and epidemiology Department, Paris, 
France) and Bénedict Chazaud (INSERM U1016, Institut Cochin, Paris, France). 
NMR study was done at the NMR Laboratory of the Myology Institute, Paris, France, 
and is shared between this thesis and Claire Latroche's thesis. All the additional 
analyses presented here were done by Claire Latroche, and are presented to support 
the discussion of the NMR results. 
 This chapter has been submitted for publication in the American Journal of 
Pathology in November 2014, and accepted for publication after revision in May 
2015.  
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ADP: Adenosine diphosphate, ASL: Arterial spin labelling, ATP: Adenosine 
triphosphate, CFPE: capillary to fiber perimeter exchange, DMD: Duchenne muscular 
dystrophy, GFP: green fluorescent protein, HE: haematoxylin and eosin, NMR: 
nuclear magnetic resonance, NOS: nitric oxide synthase, PCr: Phosphocreatine, Pi: 
phosphate inorganic, SATIR: SATuration-Inversion Recovery, VEGF/R: vascular 
endothelial growth factor/Receptor 
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Abstract 
 
 Duchenne Muscular Dystrophy (DMD) is a progressive neuromuscular 
disease, caused by an absence of dystrophin, inevitably leading to death. Although 
muscle lesions are well characterised, blood vessel alterations that would have major 
impact on muscle regeneration remain poorly understood. Our aim was to elucidate 
alterations of the vascular network organisation, taking advantage of Flk1
GFP/+
 crossed 
with mdx mice (model for human DMD where all blood vessels express GFP), and 
functional repercussions using in vivo nuclear magnetic resonance (NMR), combining 
arterial spin labelling imaging of perfusion, and 
31
P-spectroscopy of phosphocreatine 
kinetics. For the first time, our study focused on old (12 month-old) mdx mice, 
displaying marked chronic muscle lesions, very similar to the lesions observed in 
human DMD, in comparison to young-adult (3 month-old) mdx mice displaying only 
mild muscle lesions with no fibrosis. Using an original approach combining specific 
animal model, state of the art histology/morphometry techniques, and functional 
NMR, we demonstrated (i) that the microvascular system is normal in young-adult in 
contrast to old mdx mice, displaying marked capillary alterations, and (ii) functional 
repercussions on muscle perfusion and bioenergetics after a hypoxic stress, that vary 
depending on stage of pathology. This original approach clarifies disease evolution 
and paves the way for setting up new diagnostic markers or therapeutic strategies. 
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Introduction 
 
 Duchenne muscular dystrophy (DMD) is the most frequent genetic 
neuromuscular disorder affecting 1:3500 school-age boys worldwide. This X-linked 
muscle disease is characterised by progressive skeletal muscle weakness and 
cardiomyopathy, leading to premature death generally because of respiratory and/or 
cardiac failure. The cause of DMD is the absence of dystrophin, a key component of 
the dystrophin-associated protein complex involved in the linkage between myofiber 
cytoskeleton and extracellular matrix. When linkage is disrupted, muscle fibers 
develop normally but are more susceptible to damage due to mechanical stretch. 
Despite presence of satellite cells and successive regeneration attempts, myofibers 
undergo necrosis and are eventually replaced by connective and adipose tissue (De 
Paepe and De Bleecker, 2013). 
 Muscle lesions in DMD have been widely investigated, with studies focussing 
principally on myofibers and/or satellite cells. Although (i) skeletal muscle is one of 
the most vascularised tissues, (ii) endothelial cells are essential in muscle regeneration 
process, and (iii) dystrophin is expressed in endothelial/smooth muscle cells, disease 
impact on blood vessels and effect of blood vessel alteration in disease expression 
remain poorly understood. In recent years, interest in DMD vascular network has 
increased with primary focus on vasculature-related therapeutic strategies (Ennen et 
al., 2013) such as methods to increase vasculature by modulating VEGF/VEGFR 
pathways (Shimizu-Motohashi and Asakura, 2014). These strategies were initially 
based on: (i) observation of ―grouped necrosis‖ in muscles of DMD patients, i.e. 
simultaneous necrosis of contiguous myofibers, suggesting local failure in capillary 
blood supply and muscle ischemic necrosis (Engel and Hawley, 1977), and (ii) 
membrane-associated nitric oxide synthase (NOS) deficiency in dystrophin-deficient 
muscle (Rando, 2001b). The hypothesis of an ischemic process has been strongly 
discussed, as other studies could not detect any vascular bed abnormality in DMD 
either morphologically using electron microscopy (Koehler, 1977) or physiologically 
by studying muscle blood flow (Bradley et al., 1975; Gudrun et al., 1975; Leinonen et 
al., 1979). More recent studies carried out in DMD patients confronted blood vessel 
alteration with tissue fibrosis. They suggested that endomysial fibrosis plays an 
 75 
 
essential role, causing an increase in capillary-to-myofiber distances, which impairs 
both muscle fiber mechanical function and gas exchanges (Desguerre et al., 2009). 
Moreover, increased distances between capillaries and myofibers could potentially 
impede their reciprocal stimulation by soluble factors secreted during muscle repair 
(Christov et al., 2007). 
 Rare studies addressed the relevance of muscle vascular network in 
dystrophinopathy pathophysiology in animal models, focusing on muscle vascular 
density and characterisation of a possible hypoxic condition in dystrophic muscle. 
Part of these studies pointed to a decreased vascular density and an impaired 
angiogenesis in 6 week- to 6 month-old mdx mice (Landisch et al., 2008; Loufrani et 
al., 2004; Matsakas et al., 2013), the dystrophin-deficient murine model of human 
DMD. However, contradictory results were also published in mdx mice, showing a 
higher hindlimb perfusion one week after femoral artery dissection and significant 
increase in arteriole length density in 2 month-old animals (Straino et al., 2004). 
These discrepancies could be related in part to the effect of aging in disease 
progression; age appears to be an important parameter to consider when studying 
vascular changes (Shimizu-Motohashi and Asakura, 2014). Thus, involvement of 
blood vessels in the pathogenesis of dystrophy is still not completely understood.  
 In the present study, we investigated both structural organisation and in vivo 
function of vascular system in young-adult (3 month-old) mdx mice, displaying only 
moderate subacute muscle lesions with no fibrosis, and old (12 month-old) mdx mice, 
displaying marked muscle lesions with persistent inflammation and fibrosis (Grounds 
et al., 2008), more relevant for the study of DMD pathophysiology in human. We 
used complementary morphological approaches based on genetically-modified mice 
that allowed for the first time to reconstruct the 3-dimensional microvascular network 
in mdx mouse. These were confronted to innovative histological techniques and 
dynamic and non-invasive multiparametric and functional nuclear magnetic resonance 
(NMR). 
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Materials and Methods 
 
Mice 
  
 C57Bl/6J control mice were obtained from Charles River Laboratory 
(l’Arbresle, France), mdx-4Cv mice, model for human DMD, were kindly provided by 
Pr. Gherardi (Hôpital Henri Mondor, France), Flk-1
GFP/+
 mice, in which green 
fluorescent protein (GFP) is targeted in vascular endothelial growth factor (VEGF) 
receptor-2 gene locus, exhibiting a bright GFP signal in all endothelial cells, were 
kindly provided by A. Medvinsky (Institute for Stem Cell Research, University of 
Edinburgh, UK), and mdx-4Cv::Flk-1
GFP/+
 mice were obtained by crossing mdx-4Cv 
with Flk-1
GFP/+ 
mice. Male animals were used: young-adult (3 month-old) or old (12 
month-old).  
 Animals were housed in animal facilities of the Institut Pasteur licensed by the 
French Ministry of Agriculture and complying with European Union regulations. 
Protocols were approved by the Institut Pasteur Animal Experimentation Ethics 
Committee (01332.01). 
 
 
Microvascular network organisation in three dimensions 
 
 Young and old Flk-1
GFP/+
 and mdx-4Cv:Flk-1
GFP/+
 mice were anesthetised with 
isoflurane inhalation (Forene, Abbott, Rungis, France) and killed by cervical 
dislocation. Gastrocnemius muscles were removed and imaging of vascular network 
was carried out in two conditions: thick cryo-sections or whole muscle. 
Gastrocnemius muscle was snap frozen in liquid nitrogen-cooled isopentane before 
cryosectionning (100μm-thick sections). Confocal acquisitions were performed using 
a spinning disk microscope (Leica, Wetzlar, Germany), laser femto-second was used: 
Chameleon Ultra, 20×/0.7 and 40x/0.75 objectives and a CoolSnap HQ2 camera. 
Optical slices were taken every 0.5 or 0.3µm interval along the z-axis (80µm). For 
whole muscle conditions, images of Gastrocnemius blood vessels were obtained from 
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the entire muscle using multi-photon scanner resonant confocal Leica TCS-SP5 with 
20x/0.95 objective. Optical slices were taken every 0.5µm along the z-axis. 
 
 
Histology 
 
 Gastrocnemius muscles were collected from mice after NMR experiments, 
snap frozen in liquid nitrogen-cooled isopentane and kept at –80°C. Six different 
levels of 7µm-thick sections were cut and stained with hematoxylin-eosin (HE) to 
describe histopathological modifications of muscle tissue, and Sirius red for 
visualisation of collagen. For immunohistochemistry analyses, muscle cryosections 
were incubated with anti-CD31 (Pharmingen) and anti-laminin (Sigma) antibodies, 
overnight at 4°C, revealed by cy3- or TRITC-labeled secondary antibodies (Jackson 
ImmunoResearch Laboratories). 
 
 
Morphometric analysis 
 
 Two-dimension analysis was performed to evaluate distribution of muscle 
fiber diameter, percentage of centro- or peri-nucleated fibers, capillary count and 
distribution around each myofiber using ImageJ (NIH, Bethesda, USA) and NIS-
Element (Nikon) softwares. At least 200 fibers were considered for each muscle. 
 Three-dimensional analysis was performed to evaluate organisation of 
vascular network. For each muscle, 10z-stack image reconstructions were achieved on 
80 to 150µm-thick frozen sections. Analysis was carried out using IMARIS 
(ImarisBitplane, Zurich, Switzerland) software (quantification of vessel density, 
tortuosity, volume, anastomose count and distance between capillaries). 
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Nuclear Magnetic Resonance analysis 
 
 NMR experiments were performed on: 3 month-old mdx-4Cv (n=6) and 
control C57Bl/6J (n=9) and on 12 month-old mdx-4Cv (n=5) and control C57Bl/6J 
(n=7). 
 
Hyperaemic response paradigm  
 To highlight differences between normal and altered muscles we classically 
applied a stress to increase the global need for perfusion. Ischemia-reperfusion stress 
was applied to the mouse left hindlimb which provokes maximal vasodilatation and 
limited resistance of arteries/arterioles (Bertoldi et al., 2008) just after tourniquet 
release. 
 In practice, anaesthesia was induced with 4% isoflurane delivered in 1.5L/min 
air and maintained with 1.75% isoflurane. During experiments, a water heating pad 
ensured a constant temperature of 37°C and breathing was monitored. After a 24min 
NMR acquisition at rest (baseline), ischemia of the leg was induced by occlusion of 
femoral artery by two surgical threads placed around the thigh and pulled tight by 
application of a weight (Bertoldi et al., 2008). After 30min of ischemia, the weight 
was instantly removed, inducing a hyperaemic response, which was monitored over 
the next 30min. During whole protocol, dynamic acquisitions of NMR scans of 
interleaved perfusion imaging and 
31
P-spectroscopy (
31
P-NMRS) were collected. 
 
Multiparametric functional NMR (mpf-NMR) acquisitions  
 In vivo NMR experiments were conducted in a 4Tesla Biospec system 
equipped with a 20cm diameter 200mT.m
-1
 gradient insert (BrukerBioSpin MRI 
GmbH, Ettlingen, Germany). Mice were placed supine in a 6cm diameter, 12cm 
length volume transmitter 
1
H coil for whole-body signal excitation. An actively 
decoupled 2cm diameter surface 
1
H coil, positioned below the left calf, was used for 
image signal reception. Muscle metabolites were probed by a 10mm 
31
P saddle-
shaped coil placed around the left leg. 
 As described in detail elsewhere (Baligand et al., 2009; Bertoldi et al., 2008), 
Arterial Spin Labelling (ASL)-NMR imaging and 
31
P-NMRS acquisitions were 
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interleaved using the dedicated Bruker MultiScanControl software (BrukerBioSpin 
GmbH) in order to follow simultaneously and non-invasively: (i) muscle perfusion 
signal by SATuration-Inversion Recovery (SATIR) (time resolution: 10sec), and (ii) 
mitochondrial activity by dynamic 
31
P-NMRS (time resolution: 2.5sec). In brief, ASL 
imaging is based on non-invasive alternate magnetic tagging of blood water spins to 
provide endogenous markers of muscle perfusion, measured in regions of interest 
(ROI) drawn in posterior compartment of the leg. Muscle bioenergetics and pH were 
assessed from ratios of energetic phosphates measurable by 
31
P-NMRS at rest, in vivo 
mitochondrial oxidative capacity was directly assessed from the rate of creatine 
rephosphorylation at the end of ischemia, and intramuscular pH was calculated from 
chemical shift between phosphocreatine (PCr) and inorganic phosphate (Pi). A 
minimum of 50% PCr depletion at the end of ischemia was necessary to reliably 
measure dynamics for PCr recovery, and examinations which did not reach this 
threshold were rejected. 
 
 
Statistics 
 
 Perfusion data were analysed by two-way ANOVA and repeated 
measurements ANOVA, followed by Bonferroni comparison of means when 
necessary. Analyses were performed with NCSS-2007 software (Kaysville, USA). 
Group comparisons for phosphorus spectroscopy analysis were performed using 
Mann-Whitney test. 
 Statistical analysis of histological data was performed with GraphPad-Prism 
software (La Jolla, USA). Fiber diameter repartition was evaluated by a chi-square 
test followed by a multi-t-test corrected for multiple comparisons using Holm-Sidak 
method. Same multi-t-test was used to evaluate capillary count/fiber repartition. 
 Statistical significance was taken at p<0.05 and p-values indicated on figures 
are *p<0.05, **p <0.01, and ***p<0.001. Numerical NMR and histological data are 
reported as mean±SD. 
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Results 
 
 
Normal microvascular network organisation in young-adult Flk1
GFP/+
::mdx mouse. 
 
 Polyphasic subacute lesions, characterised by small inflammatory infiltrates 
and centrally nucleated fibers, were observed in Gastrocnemius muscle (Figure 3.1 A-
B). Surprisingly, these lesions had no impact on blood microvascular network 
organisation; in both Flk1
GFP/+
 and Flk1
GFP/+
:mdx mice, microvascular network was 
well organised with straight capillaries located along myofibers, parallel to each other 
with few anastomoses oriented perpendicularly to capillaries (Figure 3.1 C-F). 
Capillary diameter, measured using diameter of endothelial cell fluorescence, was 
similar in both groups (13-14µm), as well as anastomose count (1,200-1,650 
anastomoses/mm
3
) (Figure 3.1 G-H). 
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Figure 3.1. Normal microvascular network organisation in 3 month-old mdx 
mice. In contrast to wild-type mice (A), mdx mice (B) display subacute lesions in 
Gastrocnemius muscle, characterised by small inflammatory infiltrates (star) 
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associated with regenerated myofibers displaying central nuclei (arrows) (HE 
staining). Microvessel 3D organisation of Flk1
GFP/+
 (C, E) and Flk1
GFP/+
::mdx (D, F) 
mice: normal blood capillary organisation, with capillaries regularly scattered along 
myofibers (C-F) (Scale bars: 50µm). Morphometric analyses revealed similar 
diameter (G) and anastomose count/mm
3
 (H) between capillaries from wild-type and 
mdx mice. 
 
 
 Immunofluorescence analyses did not detect any significant difference 
between young-adult wild-type and mdx mice (Figure 3.2). Both muscles displayed 
the same myofiber cross-section diameter, fiber size distribution, and 
―capillarization‖, quantified by capillary count per fiber. Collectively, these results 
highlighted a normal capillary organisation in muscles of both groups. 
 Capillary-to-fiber perimeter exchange index (CFPE) has been used to calculate 
the contact surface area between capillaries and myofibers. It provides an indirect 
quantitative criterion to evaluate movement of oxygen from capillaries to muscle 
fibers (Hepple, 1997). CFPE index was not affected in young-adult mdx mice (Figure 
3.2 F). 
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Figure 3.2. Capillary morphometry in 3 month-old mice. Young-adult wild-type 
(n=5) and mdx (n=3) mice display similar: capillary distribution in Gastrocnemius 
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muscle (A, B) (laminin-FITC and CD31-TRITC immunohistochemistry to label basal 
lamina (green) and blood vessels (red); Scale bar: 50 µm), fiber size repartition (C), 
capillary count per fiber (D), capillary diameter (E), and capillary to fiber perimeter 
exchange index (CFPE). 
 
 
Muscle blood perfusion is modified in young-adult mdx mice. 
 
 Despite similar microvascular organisation, profiles of reactive hyperaemia 
were significantly different in mdx (n=6) and wild-type (wt) (n=9) mice (Figure 3.3 A, 
p<10
-6
 with ANOVA). The release of ischemia provoked an instantaneous increase of 
perfusion, which was lower in wt mice (mdx: 78.7±27.1 ml/min/100g; wt: 41.3±32.3 
ml/min/100g, 20s post-release). In wt mice, this first perfusion peak was followed by 
a drop to reach a plateau around a value of 26.6±9.2 ml/min/100g peaking at 270s 
post-ischemia. In contrast, mdx muscle perfusion slightly increased to a mean 
perfusion value of 84.8±24.8 ml/min/100g at 300s post-ischemia and reduced to 
26.3±25.9 ml/min/100g only 850s after stress release (Figure 3.3 A). Moreover, the 
global volume repaid after ischemia was significantly higher in mdx mice (wt: 
474.3±216.3 ml/100g; mdx: 1017±369.2 ml/100g, p<0.05). The response to ischemic 
stress was therefore different and enhanced in young-adult mdx mice while no 
morphological modification of microvessels was detected.  
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Figure 3.3. Muscle blood perfusion during ischemia-reperfusion. After release of 
ischemia, a rapid and important increase in perfusion is detected. (A) Different 
profiles of perfusion were obtained in young-adult mice: total perfusion was higher in 
mdx mice and a first ―peak‖ of perfusion followed by a rapid decrease in muscle 
perfusion was only detected in wild-type mice. (B) A first ―peak‖, similar to what was 
observed in young-adult wild-type mice, was also observed in 12 month-old control 
animals. This first ―peak‖ was not present in mdx mice, which also displayed a 
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reduced perfusion, with a maximum perfusion equivalent to half the value observed in 
wild-type mice during the hyperaemia phase. As the release of ischemia induced 
movements of the leg, images affected by these movement artefacts were removed 
from analysis of muscle perfusion. 
 
 
Muscle bioenergetics in young-adult mice (Table 3.1) 
 
 At rest, mdx mice displayed a slightly higher Pi/PCr ratio compared to wt, 
which reflects an increase in ADP concentration in dystrophic mice. In addition, a 
lower PCr/γATP ratio was observed in mdx mice, reflecting a decrease in 
metabolically functional muscle tissue.  
 The 30min ischemic stress induced a higher Pi/PCr ratio in mdx mice while 
PCr depletion tended to be accelerated compared to wt (mdx: ΔPCr = 65±9 %; wt: 
ΔPCr = 58±6 %; p=0.09). 
 At reactive hyperaemia, release revealed a significant acceleration of PCr 
resynthesis rate in mdx mice compared to wt, reflecting higher mitochondrial ATP 
production in the mdx. 
  
Table 3.1. Energetic metabolism analysis from 
31
P-spectroscopy in young-adult mice. 
  wt (n=9) mdx (n=6) 
ΔPCr (%) 58 ± 6 65 ± 9 
τPCr (s) 118 ± 34 76 ± 34* 
   pH at rest (pHrest) 7.20 ± 0.04 7.17 ± 0.03 
pH end ischemia (pHend) 7.00 ± 0.08 6.98 ± 0.03 
   Pi/PCr at rest (Pi/PCrrest) 0.08 ± 0.03 0.10 ± 0.01* 
Pi/PCr end ischemia (Pi/PCrend) 0.93 ± 0.25 1.71 ± 0.52* 
PCr/ATPγ at rest (PCr/ATPγrest) 3.39 ± 0.25 3.01 ± 0.27* 
PCr/ATP γ end ischemia (PCr/ATPγend) 1.80 ± 0.62 1.39 ± 0.51 
 
Ischemia stress was sufficient as the mean depletion of phosphocreatine (PCr) for wt 
and mdx mice was above 50%. Pi/PCr at rest and after ischemia were higher in mdx 
compared to wt mice while PCr/ATPγ at rest was lower (*p<0.05). 
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 However, contrarily to wt, combined 
31
P-NMRS and perfusion results showed 
a very tight correlation between time of rephosphorylation τPCr and various 
parameters reflecting perfusion: maximum perfusion (R
2
= 0.66, p<0.05), time-
perfusion integrals (R
2
> 0.98, p<0.001 until 50s; R
2
>0.93, p<0.01 until 150s) (Figure 
3.4). In wt, none of the correlations between τPCr and perfusion were significant. 
 
 
 
Figure 3.4. Correlation between perfusion and time of creatine 
rephosphorylation (τPCr) in 3 month-old mice. Correlation between τPCr and 
maximal perfusion (A) or time-perfusion integrals until 50s (B) is significant in mdx 
mice (p<0.05 and p<0.0001, respectively). In wt, none of the correlations were 
significant. 
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 In summary, phosphate metabolism was accelerated during ischemia in 3 
month-old mdx mice. At recovery, mitochondrial oxidative rephosphorylation was 
unexpectedly faster and perfusion was increased in comparison to age-matched 
control mice. Moreover, perfusion in mdx was directly related to mitochondrial ATP 
production. This is unlike normal healthy case where a luxury perfusion is observed 
and is neither limiting nor correlated to τPCr. 
 
 
Alteration of microvascular network organisation in old Flk1
GFP/+
::mdx mouse  
 
 Old mdx mice displayed marked histological lesions; some already observed in 
young-adult as anisocytosis or centrally nucleated myofibers, others included 
persistence of chronic inflammation, and presence of endomysial/perimysial fibrosis 
(Figure 3.5 A-D). The microvascular network was as well organised in old Flk1
GFP/+
 
as in young-adult mice (Figure 3.5 E, G). In contrast, Flk1
GFP/+
::mdx mice displayed 
significant alterations, characterised by a marked increase in tortuosity and irregular 
scattering of capillaries (Figure 3.5 F, H). Capillary diameter was similar in both 
groups (12 µm, Figure 3.5 I), but we identified a higher anastomose count, from more 
than 50,000 anastomoses/mm
3
 for Flk1
GFP/+
::mdx mice to less than 1,000 
anastomoses/mm
3
 for control Flk1
GFP/+
 (p<0.01) (Figure 3.5 J). Collectively, these 
results pointed to an anarchic blood vessel organisation in this context of 
dystrophinopathy. 
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Figure 3.5. Alteration of microvascular network in 12 month-old mdx mice. 
Twelve month-old wild-type mice display histologically normal muscles (A), with no 
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fibrosis (C), and regularly scattered capillaries along myofibers, with few 
anastomoses (E, G, J). In contrast, 12 month-old mdx mice display chronic 
histological lesions (B), characterised by multifocal inflammatory infiltrates (mostly 
macrophages), included in endomysial collagen tissue (fibrosis; stars), associated with 
a marked variation in myofiber size (anisocytosis) and the presence of atrophic and 
regenerating myofibers displaying centrally-located nuclei (arrows). Sirius red 
staining and fluorescence microscopy reveal a moderate to marked endomysial 
fibrosis (D) and microvascular network alterations (F,H), characterised by irregularly 
scattered tortuous capillaries (Scale bars: 50µm). Even if capillary diameter is similar 
between mdx and wild-type mice (I), a clear increase in anastomose count/mm
3
 is 
detected for old mdx mice (J). A, B: HE staining. C, D: Sirius red staining (specific 
for collagen staining). **p<0.01. 
 
 
 Immunofluorescence analyses showed that (i) myofiber cross-section mean 
diameter was smaller in mdx mice (mdx: 47.4±4.2 µm; wt: 61.2±3.9 µm; p<0.001) 
(Figure 3.6 C), (ii) the smaller myofibers (<50µm) were clearly under-vascularised 
(Figure 3.6 E), (iii) perinucleated (Figure 3.6 G), and (iv) represented almost 60% of 
total muscle fibers in mdx mice in contrast to 35% in controls (Figure 3.6 D). These 
data suggested either a progressive degradation of tissue with no maintenance of 
microvascular network with time or a defect of neo-angiogenesis. The CFPE was not 
affected in old mice (Figure 3.6 F). Collectively, these results pointed to severe 
alterations of microvessel organisation, especially around small/atrophic myofibers, 
suggesting chronic alteration of endothelial-myogenic cell interface. 
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Figure 3.6. Twelve month-old mdx mice display atrophic myofibers with low 
capillarisation. Anisocytosis is more pronounced in old mdx mice, with the presence 
of small atrophic myofibers (A-C) (Laminin-FITC and CD31-TRITC 
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immunohistochemistry; Scale bars: 50µm). Capillary count per fiber highlights that 
small myofibers with a diameter up to 60µm display less capillaries at their periphery 
(E). These atrophic myofibers represent more than 60% of the total myofibers in mdx 
mice (D). The distance between capillaries and myofibers, calculated using the 
capillary to fiber perimeter exchange index (CFPE) is similar in both groups (F). 
Small myofibers with low capillarisation are mostly perinucleated myofibers (G) 
(*p<0.05, **p<0.01, ***p<0.001). 
 
 
Alteration of muscle perfusion in old mdx mice 
 
 Despite severe alterations in mdx muscle microvascular network organization, 
no difference in muscle perfusion was observed between mdx and wt mice at rest 
(mdx: 12.09±5.90 ml/min/100g; wt: 8.19±2.19 ml/min/100g). After tourniquet 
release, rapid increase of perfusion was detected in muscles of the posterior hindlimb 
compartment; this increase was significantly lower in old mdx mice (mdx perfusion 
maximal value at 380s post-ischemia: 60.5±39.3 ml/min/100g; wt perfusion maximal 
value at 400s post-ischemia: 106.1±38.1 ml/min/100g, p<0.05), in contrast to what 
was seen in young mice. 
 Analysis of variance of perfusion time-courses demonstrated differing profiles 
between WT and mdx (p<10
-4
), with specific differences in the early phase of 
reperfusion. A similar initial peak of perfusion, as the one observed in young-adult wt 
mice, was detected in the old wt group, 20s post-ischemia, but was absent in mdx 
mice (Figure 3.3 B). 
 Thus at 12 months, both mdx and wt showed different profiles from young-
adult animals (ANOVA, p<10
-6
), and in contrast to wt and young-adult mdx, old mdx 
mice displayed a decrease in muscle perfusion and a modified perfusion profile after 
an ischemic stress. 
 
 
 93 
 
Muscle bioenergetics in 12 month-old mice (Table 3.2) 
 
 At rest, no difference in pH was observed between wt (n=7) and mdx (n=5) 
mice but hypoxic stress induced a significant acidosis in both groups (p<0.005), more 
pronounced in mdx (wt: ΔpH = 0.22±0.06; mdx: ΔpH = 0.30±0.04; p<0.05). Ischemia 
was associated with a significant increase in PCr depletion in old dystrophic mice 
compared to wt, though the difference in Pi/PCr ratio between the two groups was not 
significant. Unlike in young mice, the rephosphorylation rate was comparable in both 
groups. Indeed  τPCr was shorter in the old compared to the young wt mice (p<0.01), 
but it was unchanged with age in the mdx mice.Thus, no alteration of oxidative 
capacities was observed in old mdx mice in response to hypoxic stress compared to 
age-matched control mice, despite reduced perfusion. In older mice (wt and mdx), no 
correlation was found between τPCr and perfusion variables. 
 
Table 3.2. Energetic metabolism analysis from 
31
P-spectroscopy in old mice. 
  wt (n=7) mdx (n=5) 
ΔPCr (%) 54 ± 4 63 ± 2** 
τ PCr (s) 66 ± 25 80 ± 20 
   pH at rest (pHrest) 7.16 ± 0.07 7.18 ± 0.04 
pH end ischemia (pHend) 6.94 ± 0.04 6.87 ± 0.04* 
   Pi/PCr at rest (Pi/PCrrest) 0.08 ± 0.04 0.10 ± 0.01 
Pi/PCr end ischemia (Pi/PCrend) 1.24 ± 0.40 1.34 ± 0.20 
PCr/ATPγ at rest (PCr/ATPγrest) 2.98 ± 0.35 3.05 ± 0.16 
PCr/ATPγ end ischemia (PCr/ATPγend) 1.20 ± 0.35 1.36 ± 0.30 
 
Ischemia stress was sufficient as the mean depletion of phosphocreatine (PCr) for wt 
and mdx mice was above 50%. ΔPCr is higher in mdx mice; pH decreased for both wt 
and mdx mice after ischemia, but mdx mice suffered a more severe acidosis. Others 
energetic parameters did not change in our experimental conditions (*p<0.05, 
**p<0.01). 
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Discussion 
 
 Our study deciphers lesions of muscle microvascular network, in a model of 
chronic myopathy, using combination of state of the art histology/morphometry 
techniques and totally non-invasive functional approach. This experimental paradigm, 
combining histopathology and mpf-NMR, clearly relevant for clinical diagnosis and 
research, allowed us to associate for the first time the fine 3D-alterations of muscle 
microvascular network with functional repercussions on muscle. 
 Concerning the animal model, previous studies used 6 week to 6 month-old 
mdx mice (Loufrani et al., 2004; Matsakas et al., 2013; Palladino et al., 2013), which 
display very few chronic lesions with no fibrosis, in contrast to what happens in 
human (Grounds et al., 2008). We therefore worked on 12 month-old mdx mice, 
displaying persistence of endomysial inflammation and fibrosis, more representative 
of human DMD and thus more relevant for chronic myopathy and DMD 
pathophysiology study, in contrast to young-adult mdx mice displaying no chronic 
lesions. We demonstrated (i) strong alterations of microvascular network structure 
associated with reduced muscle perfusion in old mdx mice, (ii) functional increase in 
muscle perfusion and mitochondrial oxidative phosphorylation with normal 
microvascular network organisation in young-adult mdx mice, and (iii) a different 
impact of age on wild-type and mdx mouse muscles. 
 In young-adult and old wild-type mice, no difference could be detected in 
muscle histology or microvascular network organisation. Perfusion is primarily 
regulated by smooth muscles that control blood flow distribution and capillary 
recruitment (Clifford and Hellsten, 2004). Capillary resistance, at rest, plays only a 
minor role in perfusion regulation. Using ischemia-reperfusion, we provoked 
maximal arteriolar dilatation in order to limit arteriolar resistance, and thus capillary 
network becomes predominant in control of muscle perfusion (Baligand et al., 2012). 
Analysis of perfusion profiles revealed the existence of a ―peak‖ of perfusion in the 
first seconds after ischemia release, for young-adult and old wild-type mice. This 
initial ―peak‖ suggests specific regulation of perfusion in early phase after ischemia 
release, probably coordinated by perivascular smooth muscles and/or pericytes 
(Yemisci et al., 2009). 
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 Surprisingly and in contrast to previous studies describing decreased vascular 
density (Loufrani et al., 2004; Matsakas et al., 2013), we did not detect any alteration 
in vascular network 3D-organisation in young-adult mdx mice. However, muscle post-
ischemic perfusion was higher than in age-matched control mice. Moreover, time 
resolution of mpf-NMR allowed to demonstrate the absence of the initial ―peak‖ of 
perfusion, probably because of an alteration of perivascular smooth muscles and/or 
pericytes. In smooth muscle, loss of dystrophin indeed results in decreased capacity of 
vasculature to respond to shear stress induced endothelium-dependant dilatation, 
probably related to NO production alteration (Loufrani et al., 2001). Absence of 
dystrophin also provokes defects in mechanotransduction, secondarily responsible for 
down-regulation of new blood vessel formation (Ando and Kamiya, 1992; Davies and 
Nowak, 2006; Ichioka et al., 1997). One of the main mechanisms considered in the 
literature to explain variations of perfusion in dystrophinopathies is a defect in 
neuronal NO (nNOS) synthase activity. In DMD pathogenesis, absence of dystrophin 
leads to an impairment of nNOS localisation to the sarcolemma resulting in muscle 
vasoconstriction and abnormal blood flow during muscle contraction (Brenman et al., 
1995; Loufrani et al., 2001; Sander et al., 2000). Concerning pericytes, Yemisci 
demonstrated in the brain, after a 2h ischemic stress, that pericytes remain contracted 
despite successful re-opening of blood flow, impairing microcirculatory reflow 
(Yemisci et al., 2009). These experiments were carried out ex vivo, and no functional 
in vivo validation was done. Our data obtained in mpf-NMR seem therefore to 
highlight functional alterations of smooth muscles and/or pericytes after ischemic 
stress. This alteration is severe enough to significantly impact perfusion profiles 
between control and mdx mice, and we are currently carrying out new experiments to 
better understand the effect of an absence of dystrophin in perivascular cells and their 
involvement in dystrophinopathy pathophysiology. Interestingly, a longitudinal PET 
study in dystrophic mice evidenced that normalised resting blood flow and blood 
volume, in addition to FDG uptake, were higher in 8 week old dystrophic mice than in 
wt, and  progressively decreased to below wt values at 22 weeks of age, and this age-
dependent effect graded with severity of dystrophy (Ahmad et al., 2011). 
 Old Flk1
GFP/+
::mdx model allowed us to highlight disorganisation of 
microvascular network. A marked increase in capillary tortuosity, an irregular 
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scattering, and an increase in anastomose count were observed. Existence of these 
highly abundant anastomoses, suggests that ―radial‖ as well as ―longitudinal‖ (parallel 
to myofibers) blood flow is important, and in turn, that ―longitudinal‖ flow is 
abnormally heterogeneous, capillary longitudinal resistance being likely to vary a lot 
from capillary to capillary which would be the driven force for collateral flow. 
 Considering the close association between capillaries and myofibers, we 
demonstrated in old mdx mice that more than 60% of myofibres were atrophic with 
peripheral nuclei and displayed less capillaries at their periphery, resulting in a global 
undercapillarisation. In parallel, NMR analysis revealed a two-fold decrease in 
perfusion after ischemia release. The significant decrease of capillary density around 
small myofibers is likely responsible for these functional alterations. Under maximal 
arteriolar dilatation, capillary resistance, which is inversely proportional to capillary 
density, becomes indeed predominant in controlling peripheral resistance. Our data 
are thus in agreement with other studies demonstrating the effect of age on 
dystrophinopathy pathophysiology (Palladino et al., 2013; Straino et al., 2004). Our 
hypothesis is that interaction between angiogenesis and myogenesis could be affected 
in old mdx mice; the increasingly scarce capillaries would provoke an alteration of 
myofiber regeneration that in turn could lead to impairment of remaining 
microvascular network support, maintaining a vicious circle. Christov et al. already 
introduced the idea that angiogenesis and myogenesis are coupled during muscle 
regeneration, these processes involving several growth factors, such as vascular 
endothelial growth factor - VEGF (Christov et al., 2007). Treatment with VEGF 
strongly ameliorates mdx phenotype, with improvement of functional parameters, 
increase in capillary density, improved muscle regeneration, and decrease in 
interstitial fibrosis (Deasy et al., 2009; Messina et al., 2007). Fibrosis is by the way a 
key parameter influencing perfusion, and is increased in DMD (Desguerre et al., 
2009). However, fibrosis might not be the most limiting factor to perfusion, as it only 
represents 10% of old mdx mice muscle tissue in our study. Moreover, distance 
between capillaries and myofibers, generally modified with endomysial fibrosis 
(Hepple, 1997), is similar between young-adult and old wild-type and mdx mice. 
 The reproducibly observed in vivo increase of post-ischemic muscle perfusion 
with old age in wt animals was found to be reproducible with age in this and other 
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mouse strains, but no explanation is currently put forward, while effect of aging on 
perfusion is still debated even in humans (Rudroff et al., 2014; Trinity et al., 2014). 
 In parallel to perfusion analysis, acquisition of 
31
P-spectroscopy revealed 
moderate energetic metabolism alterations, in agreement with previous literature, and 
contrarily to what might be expected from alterations of enzymatic activities or 
defects of mitochondrial localization in vitro. Compensatory mechanisms must thus 
exist in dystrophic muscle (Cole et al., 2002; Dunn et al., 1991; Heerschap et al., 
1988). 
 As for perfusion, anomalies in phosphorus metabolites in wild-type animals 
depended on age, as already evoked in early studies of mdx metabolism (Dunn et al., 
1991, 1993). Anomalies at rest were more marked in younger mdx: Pi/PCr reflecting 
resting ADP production was increased while PCr/ATP proportional to functional 
muscle was reduced (-11%), coherently with other reports (Cole et al., 2002; Dunn et 
al., 1991; Heerschap et al., 1988) (-50% or more in DMD children (Kemp et al., 
1993)). 
 Unlike a recent study in 3 month-old mdx mice (Percival et al., 2013), where 
10min ischemia was used as stress protocol, we found greater depletion after 30min 
ischemia in both young-adult and old mdx. During prolonged ischemia, two energetic 
pathways are activated to supply ATP demand: ATP-PCr system and glycolytic 
pathway. Production of ATP directly from PCr consumption is very small; it is 
therefore unlikely that PCr would be consumed to compensate for defective glycolytic 
pathway. The higher depletion observed in both young-adult and old mdx could more 
likely reflect a higher ATP demand to maintain ionic homeostasis. 
 Confrontation between perfusion and metabolic data obtained simultaneously 
by NMR revealed that despite strongly reduced perfusion in old mdx mice, oxidative 
metabolism was preserved, suggesting existence of a ―luxury perfusion‖, i.e. reserve 
of perfusion that can be eliminated without impact on muscle physiology, as 
previously evidenced in a model of peripheral artery disease (Vidal et al., 2002). It 
generally explains the absent – or very loose – correlation between perfusion and PCr 
recovery rates in wild-type animals and in old mdx. This contrasts with the tight 
correlation between initial perfusion and τPCr of young mdx mice, which display 
faster τPCr recovery and stronger perfusion than controls. Using optical spectroscopy 
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to analyse myoglobin and haemoglobin oxygen desaturation in parallel to 
31
P-NMRS, 
Percival observed strong uncoupling between ATP synthesis and O2 consumption in 4 
month-old mdx, dystrophic muscle producing 39% ATP less per O2 consumed than 
controls (Percival et al., 2013). We might thus hypothesize that at this young age, 
increased perfusion might be a means to compensate for mitochondrial inefficiency. 
 
Conclusion 
 
 In conclusion, we demonstrated strong structural and functional alterations in 
muscle microvascular network of dystrophin-deficient mdx mice, with an increasing 
severity in parallel to aging. Our approach combining 3D-morphological analyses 
with non-invasive functional evaluation, allowed to better characterise the impact of 
histological lesions on tissue function. Collectively, our data pointed out that vascular 
network has a key role in dystrophinopathy pathophysiology and would be very 
important target for the set-up of new innovative therapeutic strategies. 
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Supplementary Information  
 
S3.1. Nuclear Magnetic Resonance analysis 
 
Multiparametric functional NMR (mpf-NMR) acquisitions.  
 Ischemia of the left leg was induced by occlusion of the femoral artery by two 
surgical threads placed around the thigh. During the experiment, both perfusion 
through arterial spin labelling (ASL) NMR imaging and energetic metabolism through 
31
P-NMR spectroscopy were followed.  
 
NMR perfusion analysis.  
 Arterial spin labelling (ASL) is based on the non-invasive magnetic tagging of 
blood water spins. Images were acquire after positive or negative labelling alternately 
(Figure S3.1-A). To avoid large vessels, regions of interest (ROI) were drawn in the 
posterior compartment of the leg. Muscle perfusion f was calculated from the 
normalized difference between consecutive images according to the equation 
(Raynaud et al., 2001): 
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where r1 is the longitudinal relaxation rate for muscle (r1=T1
-1
, T1 measured by 
saturation-recovery acquisition for each mouse at the end of 30 minutes hyperaemic 
period), M
+
 and M
-
 are the signals of positive and negative labelled perfusion images 
and λ is the blood-tissue partition coefficient (λ=0.9). 
 
31
P-NMR Spectroscopy analysis.  
 Successive 
31
P Free Induction Decays were acquired throughout rest, ischemia 
and hyperaemia. 
31
P-spectroscopy gives access to principal metabolites implicated in 
energetic metabolism such as phosphocreatine (PCr), the three α, β, γ ATP and 
inorganic phosphate (Pi). Signal intensity of these resonances is directly proportional 
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to their concentrations, which allows the quantitative following of these metabolite 
variations (Figure S3.1-B). 
 At ischemia and recovery, PCr recovery was fitted by a mono-exponential 
function with a least mean squares algorithm and pH was calculated from the 
chemical shift δPi between PCr and Pi according to the formula (Taylor et al., 1983):  
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Figure S3.1. Nuclear Magnetic Resonance analysis. Multiparametric and functional 
NMR allows measurement of muscle perfusion with imagery combined to ASL and 
energetic metabolism through 
31
P-spectroscopy. A combination of these measures in 
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one experiment gives access to relations between muscle blood supply and 
bioenergetics during a stress. (A) Perfusion is obtained by acquisition of images after 
positive and negative labelling; the perfusion map is obtained by the difference 
between consecutive images. (B) 
31
P-spectroscopy gives access to principal 
metabolites implicated in energetic metabolism such as phosphomonoesters (PME), 
inorganic phosphate (Pi), phosphodiesters (PDE), phosphocreatine (PCr) and the three 
α, β, γ ATP. pH is calculated from the chemical shift δPi between PCr and Pi. 
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Chapter 4. Non-invasive NMR study of the mouse model 
for centronuclear myopathy with mutation in the 
dynamin-2 gene 
 
Introduction 
 
Congenital myopathies are a group of genetic muscle diseases with non-
dystrophic characteristics, clinical presentation at birth and slow progression. The 
structural forms are characterized by the presence of morphological alterations within 
the muscle fiber, such as the presence of regions with protein accumulation (rods), 
regions with altered organelles distribution (cores), or with altered positioning of the 
nucleus. The kind of morphological alterations defines the three major categories of 
structural congenital myopathies: nemaline myopathy, core myopathies and 
centronuclear myopathies. 
In the group of centronucleated myopathies, muscle fibres present internalized 
or centralized nuclei, in opposition to the peripheral positioning observed in normal 
muscle fibers. Histopathological characteristics can include abnormal NADH-TR 
staining, but do not involve extensive muscle degeneration and regeneration. 
Clinically, centronuclear myopathies are highly variably regarding the age of onset 
and pattern of weakness, ranging from severe congenital forms to adult-onset forms 
with slow progression and mild phenotype (Nance et al., 2012).  The variability in the 
phenotype is related to the mutations in the involved genes. The more severe X-linked 
form of centronuclear myopathy is caused by mutations in MTM1 gene, coding for the 
protein myotubularin. Mutations in the gene coding for amphiphisin 2 (BIN1) lead to 
juvenile autosomal recessive centronuclear myopathy; and mutations in the gene 
coding for dynamin-2 (DNM2), with autosomal dominant heritage, are related to a 
generally more benign adult phenotype of centronuclear myopathy. Additional cases 
with mutations in RYR1, hJUMPY and MTMR14 genes have been also described 
(Bitoun et al., 2005, 2007; Jungbluth et al., 2008; Nance et al., 2012; Wilmshurst et 
al., 2010). Mutation in the PTPLA gene is related to centronuclear myopathy in 
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labrador dogs, but until now, there is no report of mutations in this gene causing 
centronuclear myopathy in humans (Pelé et al., 2005).  
Animal models of congenital myopathies have been developed, helping in the 
elucidation of the disease pathomechanisms and in the search for therapeutic 
strategies. Among the murine models of structural myopathies, there are several 
models for nemalinic myopathy that mimic the phenotype observed in human disease, 
in the same way as the Ryr1 knock-in models for core myopathy (Boncompagni et al., 
2009; Zvaritch et al., 2009). On the other hand, some murine strains with the same 
molecular defect as human patients do not present weakness and histopathological 
features as observed in humans, such as the Sepn1 knockout mouse, which aimed to 
model core myopathy (Rederstorff et al., 2011). 
 Among the centronuclear myopathies murine models, Mtm1 knock-out (Buj-
Bello et al., 2002) and the Mtm1 p.R69C knock-in mice (Pierson et al., 2012), models 
for myotubular myopathy, have similar severe clinical and histological features as 
observed in patients. For the DNM2 gene, a mouse model was developed carrying the 
most frequent mutation detected in patients with DNM2-related centronuclear 
myopathy: the knock-in KI-Dnm2
R465W
 mouse. In opposition to what is observed in 
humans, heterozygous mice have a small proportion of centronucleated fibers and a 
mild phenotype, with muscle atrophy and force reduction that start after 2 months of 
age (Durieux et al., 2010).  
 There is no cure or treatment for the congenital myopathies, which drives the 
study of therapies based on new methods, such as cellular and genetic approaches. 
Non-invasive methods to follow the possible benefits of these new therapeutic 
strategies in clinical trials are highly desirable. In this context, nuclear magnetic 
resonance (NMR) studies in patients and animal models for congenital myopathies 
have been developed, in a first moment to better describe muscle involvement in these 
disorders, but with potential use as outcome measures in clinical trials.   
Muscle nuclear magnetic resonance imaging (NMRI) from congenital 
myopathy patients allowed identifying the pattern of muscle involvement in these 
diseases, with strong correlation with the genotype. This pattern varies among 
congenital myopathies but also between other muscle pathologies, such as muscular 
dystrophies and inflammatory myopathies. The identification of the pattern of muscle 
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involvement can orientate the molecular study and help in the differential diagnosis in 
humans (Mercuri et al., 2007; Quijano-Roy et al., 2011, 2012).  
 There are still very few NMR studies with animal models for congenital 
myopathy. Gineste and collaborators have developed a series of NMR studies in 
murine models for nemaline myopathy, where increased energetic cost for muscle 
contraction and higher muscle T2 could be observed (Gineste et al., 2013a, 2013b, 
2013c). In this context, the aim of this study is to enrich the panel of murine models 
non-invasively characterized with NMR. KI-Dnm2
R465W
 mice model to autosomal 
dominant centronuclear myopathy were evaluated at different ages. NMR results were 
compared to histological findings, aiming to find parameters of muscle alteration 
detectable even when a mild phenotype is present. 
 
 
Materials and Methods 
 
Animals 
 In total, 29 mice were evaluated by NMR: 9 heterozygous KI-Dnm2
R465W
 
(Dnm2) mice and 5 normal littermates (wild-type) of 3 months of age; 7 Dnm2 and 8 
wild-type of 6 months of age. Additionally, 4 Dnm2 and 2 wild-type mice (4 month-
old) were included for histological analysis. Mice were kindly supplied by Dr. Marc 
Bitoun, Institut de Myologie. Mice were kept under the French rules for good animal 
care.  
 
Nuclear Magnetic Resonance (NMR) 
 For NMR measurements, mice were anesthetized with 4% isoflurane (Forene, 
Abbott, Rungis, France) delivered in 1.5 L/min air, and anesthesia was maintained 
with 1.75% isoflurane. Breathing was monitored all along the experiments, and mice 
were kept at 37 
o
C using a heating water pad.  
In vivo NMR experiments were done in a 4T magnet (Magnex, Abington, UK) 
equipped with a 20 cm diameter 200 mT.m-1 gradient insert (Bruker BioSpin MRI 
GmbH, Ettlingen, Germany) and interfaced with a Biospec Avance console using 
ParaVision 3.0.2 software (Bruker BioSpin MRI GmbH). 1H coil designed for mouse 
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experiments and built in the NMR Laboratory was used. All NMR experiments were 
done in the NMR Laboratory, Institut de Myologie, Paris, France. 
 Tridimensional T1 weighted images of the posterior limbs, from the feet to the 
lumbar region, were acquired for the anatomical evaluation (RARE - Rapid 
Acquisition with Relaxation Enhancement - sequence: TE=9.82 ms, TR=800 ms, 
NEX=1, RARE- factor = 4, FOV: 4.5 x 2.56 x 5.0 cm, matrix size: 256 x 192 x 64). 
T1 and T2 measurements were acquired in two selected slices, one in the thigh 
and one in the lower leg. The lower leg slice was positioned at 1/4 of the tibia length 
(evaluated from the 3D scan) from the knee, a position close to the maximum cross 
section area (CSA). The thigh slice was positioned symmetrically to the lower leg 
slice from the knee. For T1 measures, a saturation recovery sequence was used, with 
13 different TR (0.002, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 1.6, 2.4, 3.2, 4.0 and 6.5 s),  
TE=10 ms and NEX=2. For T2 measurements, a Multi-Slice Multi-Echo (MSME) 
sequence was used, with 32 TEs ranging from 5.03 ms to 160.96 ms (5.03 ms * n; 
n=1,..., 32), TR=2158.4 ms and NEX=4. Sequences for T1 and T2 measurement were 
acquired using the same geometry: slice thickness=2.0 mm, FOV=4.0 x 4.0 cm, 
matrix size 128x128.  
 
Data analysis  
 For 3D-T1w images, any possible fat infiltration in muscles was evaluated 
qualitatively in the tridimensional reconstruction. Tibia length was measured in a 
coronal cut (Figure 4.1-a), while  total cross section area (CSA) and cross section area 
excluding subcutaneous fat (CSAm) were measured in a transversal projection, 
positioned at 1/4 of the tibia length from the knee (Figure 4.1-b). Muscle atrophy was 
evaluated comparing the ratios CSA over tibia length (CSA/Ltibia) and CSAm over 
tibia length (CSAm/Ltibia).  
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Figure 4.1: Anatomical measures: tibia length and cross section area with and 
without subcutaneous fat. T1-weighted images showing the posterior limbs of two 
wild-type mice, illustrating the measurement of: (A) tibia length in a coronal section, 
and (B) cross section area including (CSA) and excluding subcutaneous fat (CSAm).  
 
 For T1 and T2 measurements, six regions of interest were drawn, four in the 
lower leg slice and two in the thigh slice. In the lower leg slice, ROIs encompassed 
the following muscles: gastrocnemius/soleus lateral (GL), gastrocnemius/soleus 
medial (GM), tibialis anterior/extensor digitorium longus/peroneus (TA/EDL/Pe), and 
tibialis posterior/flexor digitorium longus (TP/FDL), as exemplified in Figure 4.2-A. 
In the thigh level, two ROIs were drawn to comprise all muscles in medial (TM) or 
lateral compartments (TM) (Figure 4.2-B). One additional ROI was drawn in both 
slices including only noise, for use in T2 estimation. The NMRI signal was used for 
fitting monoexponential curves to T1 and T2 values. 
 
 
Figure 4.2: ROIs for T1 and T2 measurements. Transversal images at (A) lower 
leg and (B) thigh levels from a wild-type mouse, showing ROIs designed for T1 and 
T2 measurements. (A) At the lower leg level, 4 ROIs were selected in each leg: 
gastrocnemius lateralis (GL: 0,3), gastrocnemius medialis (GM: 1,4), TA/EDL/Pe 
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(2,5), and TP/FDL (7,8). (B) At the thigh level, two ROIs were designed for each leg: 
lateral (TL: 0,2) and medial (TM: 1,3) compartments.  
 
Histological analysis 
Four KI-Dnm2
R465W
 and 2 wild-type mice (4 month-old), which were not 
evaluated by NMR, were euthanized by cervical dislocation under anesthesia. The 
gastrocnemius muscle was collected, immediately frozen in liquid N2 cooled 
isopentane and kept at -70
o
C until use. The muscles were cut in 8 µm slices and 
stained with hematoxilin-eosin (H&E) for general histological evaluation, and with 
NADH-TR and SDH staining for the evaluation mitochondrial distribution in muscle 
fibres.  
 
Statistical analysis 
 Data were analyzed with one-way analysis of variance (ANOVA) or repeated-
measures ANOVA, followed by Bonferroni multiple comparison of means when 
appropriate (NCSS, Kaysville, UT, USA). One-way ANOVA with two factors (mouse 
strain: KI-Dnm2
R465W
 or wild-type; age: 3 or 6 months) was used to compare mice 
weight, CSA/Ltibia and CSAm/Ltibia ratios. Repeated measures ANOVA with two 
factors between groups (mouse strain: KI-Dnm2
R465W
 or wild-type; age: 3 or 6 
months) and one factor within groups (muscle group) was used to compare muscle T1 
and T2 values (mean value from left and right leg for each mouse). The differences 
were considered significant when p<0.05 (after Geisser-Greenhouse correction for the 
repeated measures ANOVA). NMR data are reported as mean ± standard deviation 
(SD).  
 
 
Results 
 
Morphometrical evaluation 
 
 Visually, T1 weighted images did not show evidences of fat infiltration or 
altered signal in muscles from KI-Dnm2
R465W
. Body weight, cross section area 
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normalized to tibia length (CSA/Ltibia) and cross section area excluding the 
subcutaneous fat normalized to tibia length (CSAm/Ltibia) were compared to evaluate 
if NMR could detect muscle atrophy in the KI-Dnm2
R465W
 mice. The values are 
described in Table 4.1.    
 
Table 4.1: Atrophy evaluation in the KI-Dnm2
R465W
 mice (Dnm2) 
 
 Weight (g) CSA(mm
2
)/Ltibia(mm)  CSAm(mm
2
)/Ltibia(mm) 
Dnm2 - 3m (n=9) 28.66 ± 2.88 2.61 ± 0.29  * 2.19 ± 0.26  * 
WT - 3m (n=5) 30.26 ± 2.22 3.16 ± 0.15 2.74 ± 0.25  # 
          
Dnm2 - 6m (n=7) 32.87 ± 4.88  2.79 ± 0.18 2.26 ± 0.15 
WT - 6m (n=8) 32.36 ± 2.17 2.92 ± 0.17 2.36 ± 0.15 
 CSA: cross section area; Ltibia: tibia length; CSA/Ltibia: atrophy index. CSAm: CSA 
excluding the subcutaneous fat; CSAm/Ltibia: lean mass atrophy index.  
*: different from wild-type (WT) at the same age, p<0.05; #: different from the 
younger mice from the same lineage, p<0.05. 
 
 
 When comparing weight, no differences were observed between KI-
Dnm2
R465W
 and wild-type mice, at both ages (Table 4.1). The only difference observed 
was between 6 and 3 months-old mice: when grouping both mouse strain the older 
mice had higher weight than the younger mice, as expected (3 months-old mice: 
29.23±2.69 g, 6 months-old mice: 32.60±3.56 g, p<0.05). The mouse strain did not 
show a major effect in weight (KI-Dnm2
R465W
: 30.50±4.31 g; wild-type: 31.55±2.35 g; 
p=0.66) and there was no combined effect of age and lineage (p=0.40).  
 KI-Dnm2
R465W
 mice presented lower CSA/Ltibia ratio than wild-type mice (KI-
Dnm2
R465W
: 2.69±0.26, wild-type: 3.01±0.20, p<0.001), indicating atrophy. The age 
did not show a major effect (3 month-old mice: 2.81±0.36; 6 month-old mice: 
2.86±0.18; p=0.71), but lineage and age presented significant interaction (p<0.05). In 
the Bonferroni multiple comparison test, 3 month-old KI-Dnm2
R465W
 mice had 
significantly reduced CSA/Ltibia ratio when compared to wild-type mice at the same 
age (Table 4.1, p<0.05)  
 110 
 
 The ratio CSAm/Ltibia was calculated in order to verify if the reduced CSA/ 
Ltibia ratio observed in KI-Dnm2
R465W
 mice was related to loss of lean tissue. 
Similarly, KI-Dnm2
R465W
 mice presented lower CSAm/Ltibia ratio than wild-type (KI-
Dnm2
R465W
: 2.22±0.21; wild-type: 2.51±0.26; p<0.001). Age did not present major 
effect over CSAm/Ltibia (3 months-old mice: 2.38±0.37; 6 months-old mice: 
2.32±0.15; p=0.07). Again, there was a significant interaction between mouse strain 
and age (p<0.01). In the Bonferroni multiple comparison test, CSAm/Ltibia was 
reduced in 3 months old KI-Dnm2
R465W
 when compared to age-matched wild-type 
mice (p<0.05). This difference disappeared when comparing 6 months-old mice, as 
observed in the comparison of CSA/Ltibia ratio. Wild-type mice showed reduction of 
CSAm/Ltibia ratio with aging (p<0.05), but this reduction was not observed in KI-
Dnm2
R465W
 mice (Table 4.1).  
 
 
T1 measurements 
 
 The T1 values in seconds (s) for the six ROIs evaluated are shown in Figure 
4.3. Mouse strain did not show a major effect on T1 values (T1 KI-Dnm2
R465W
: 
1.37±0.06 s; wild-type: 1.37±0.05 s; p=0.72). Age had an influence on muscle T1 
values: 3 months-old mice had higher muscle T1 than 6 months-old mice (3 month-
old mice: T1=1.39±0.06 s; 6 month-old mice: T1=1.35±0.06 s, p<0.05), but this 
difference was observed only when grouping both mouse strains. There was no 
interaction between mouse strain and age (p=0.93). 
  Muscle groups presented a major effect on muscle T1 values (p<0.0001), but 
there were no correlations between muscle group and mouse strain (p=0.52), between 
muscle group and age (p=0.12) or between muscle group, mouse strain and age 
(p=0.36). This indicates that T1 varies due to intrinsic differences between muscles 
groups, that are probably not related neither to age nor to the mouse strain. Bonferroni 
multiple comparison of means showed that T1 values from lateral and medial thigh 
muscles were higher than the values observed in all the ROIs corresponding to lower 
leg muscles (p<0.05). Medial thigh muscles had higher T1 value than lateral thigh 
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muscles (p<0.05). The ROI corresponding to TA/EDL/Pe had muscle T1 lower than 
all other muscles from the lower leg and thigh (p<0.05, Figure 4.3).  
 
 
 
Figure 4.3: Muscle T1 for KI-Dnm2
R465W
 (Dnm2) and wild-type (WT) mice. 
Muscle T1 (seconds) varies between muscle groups, but no differences were observed 
between KI-Dnm2
R465W
 (Dnm2) and wild-type (WT) mice at both ages. 
 
 
T2 measurements 
 
 The T2 values in millisecond (ms) for KI-Dnm2
R465W
 and wild-type mice are 
presented in Figure 4.4. Mouse strain showed a major effect on T2 values: muscle T2 
was increased in KI-Dnm2
R465W
 mice when compared to wild-type mice (KI-
Dnm2
R465W
: 31.64±1.24 ms, wild-type: 30.29±1.45 ms, p<0.0001). There was no 
effect of age on T2 values (3 month-old mice: 31.23±1.59 ms, 6 month-old mice: 
30.85±1.39 ms, p=0.66), and there was no correlation between mouse strain and age 
on the T2 values (p=0.46).  
 Bonferroni multiple comparison of means showed that both 3 and 6 month-old 
KI-Dnm2
R465W
 mice had higher muscle T2 than age-matched wild-type (T2 KI-
Dnm2
R465W
-3m: 31.79±1.36 ms, wild-type-3m: 30.23±1.51 ms, p<0.05; KI-
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Dnm2
R465W
-6m: 31.45±1.06 ms, wild-type-6m: 30.32±1.43, p<0.05). When evaluating 
the muscle groups separately, the KI-Dnm2
R465W
 mice showed higher muscle T2 than 
wild-type for all muscle groups (p<0.05, Figure 4.4).  
 
 
 Muscle group presented also a major effect on muscle T2 values (p<0.0001), 
but there were no correlations between muscle group and mouse strain (p=0.47), 
between muscle group and age (p=0.30) or between muscle group, mouse strain and 
age on muscle T2 values (p=0.58). Bonferroni multiple comparison of means showed 
that the ROIs corresponding to GL, GM and TA/EDL/Pe had lower T2 values than 
the ROIs corresponding to the thigh muscles and to TP/FDL. The T2 value of the 
medial thigh (TM) muscles was higher than the T2 value for all other ROIs. GL 
muscle showed a lower T2 value than GM (Table 2, p<0.05). In KI-Dnm2
R465W
 mice, 
the difference between muscle groups was similar to the observed in wild-type mice, 
but the T2 value for all muscle groups summed was increased (p<0.05). In general, 
each muscle group from KI-Dnm2
R465W
 mice presented a mean increase of 1.34±0.33 
ms in the T2 value, 4% of the mean T2 value from wild-type mice (Figure 4.4). 
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Figure 4.4: Muscle T2 for KI-Dnm2
R465W
 (Dnm2) and wild-type (WT) mice. 
Muscle T2 (miliseconds) is increased in KI-Dnm2
R465W
 (Dnm2) mice as compared to 
wild-type (WT), for all muscle groups, in (A) 3 month-old and (B) 6 month-old mice 
(p<0.05). Muscle groups had different T2 values in both strains. 
 
Histological analysis 
 
 Muscle from KI-Dnm2
R465W
 mice had a histological aspect similar to that of 
wild-type mice in H&E staining, with polygonal shaped fibers, thin layers of 
connective  tissue, no inflammation nor necrosis (Figure 4.6 - A, D). Few 
B 
A 
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centronucleated fibers were observed in KI-Dnm2
R465W
 mice (Figure 4.6 - A, arrow). 
NADH-TR and SDH staining revealed higher amount of mitochondrial enzimes in the 
center of some fibers in KI-Dnm2
R465W
 mice (Figure 4.6 - B, C, arrowheads). This 
observation indicated for altered distribution of mitochondria: despite the normal 
localization of nuclei in the periphery of muscle fibers, mitochondria are concentrated 
in the center of muscle fibers in this mouse model. 
 
 
Figure 4.6: Histological analysis of KI-Dnm2
R465W
 and wild-type mice (4 month-
old). H&E staining (A, D) showed very few fibers with centrally placed nuclei 
(arrow) in KI-Dnm2
R465W
 mice (A), but muscle is generally similar to wild-type mice 
(D). NADH (B, E) and SDH(C, F) staining revealed altered mitochondria distribution 
in the sarcoplasm of KI-Dnm2
R465W
 mice (arrowheads). A, B, C: KI-Dnm2
R465W
; D, E, 
F: wild-type. Scale bars = 100 µm. 
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Discussion 
 
 In this study, the heterozygous knock-in mouse with the most frequent 
mutation in patients with dynamin-2 related centronuclear myopathy, the KI-
Dnm2
R465W
 mouse, was non-invasively evaluated with NMR. Morphometric 
measures, T1 and T2 relaxometry were compared with histological analysis, the 
standard method to evaluate muscles in genetic diseases. Even if only mild alterations 
can be detected with clinical evaluation and histological analyses in this mouse 
model, this non-invasive NMR study could identify muscle atrophy and increased 
muscle T2 in the heterozygous KI-Dnm2
R465W
 mice. 
 Despite of the similar body weight, reduced ratios CSA/Ltibia and CSAm/Ltibia 
indicated muscle atrophy in the KI-Dnm2
R465W
 mice. The atrophy was particularly 
evident in 3 month-old mice, and the difference became less evident when comparing 
6 months-old mice. Durieux and collaborators compared the weight of isolated 
muscles of heterozygous KI-Dnm2
R465W
 and wild-type mice at 3 weeks, 2 months and 
8 months of age. KI-Dnm2
R465W
 mice presented progressive atrophy of 
gastrocnemius/plantaris, tibialis anterior and quadriceps muscles, while there was a 
transient weight increase for the soleus muscle at 2 months of age, and no changes for 
the extensor digitorium longus (Durieux et al., 2010). Our MRI comparison 
considered all the lower leg muscles, including gastronemius, plantaris, soleus, tibialis 
anterior and EDL, but also the other smaller muscles such as tibialis posterior and 
flexor digitorium longus. The combination of muscle atrophy, hypertrophy and 
sparing of all lower leg muscles, could be the cause of the atrophy observed with MRI 
in the KI-Dnm2
R465W
 mice only at 3 months of age.  
 In addition, only wild-type mice showed lean mass reduction with aging. This 
indicates a very slow progression, or even rescue of the myopathic phenotype in 
heterozygous KI-Dnm2
R465W
 mice. This hypothesis is corroborated by the observation 
of myofibers disorganization in 2 month-old heterozygous KI-Dnm2
R465W
 mice, with 
partial reversion of this alteration in 8 month-old KI-Dnm2
R465W
 mice (Durieux et al., 
2010). 
 Human patients with DNM2-related centronuclear myopathy show increased 
muscle signal in T1 weighted MRI, which is related to fat infiltration in the muscles. 
 116 
 
Lower leg muscles are usually compromised before thigh muscles in these patients. 
Soleus is the primarily and most affected muscle, followed by tibialis anterior, 
gastrocnemius and peroneus. In the thigh level, the posterior muscles are affected 
before anterior muscles (Catteruccia et al., 2013). In opposition to what is described 
for patients, KI-Dnm2
R465W
 mice did not show any alterations in muscle T1, for all 
muscle groups and ages studied. A decrease in  muscle T1 would be expected in the 
presence of fat infiltration, and increased T1 values could be related to edema or 
inflammation. The KI-Dnm2
R465W
 mice did not present these alterations in our 
histological analysis and on the already described model description (Durieux et al., 
2010). The absence of fat infiltration in muscles is also in agreement with other NMR 
and histological data from murine models for different muscle disease, where even if 
severe phenotype and histological aspect are observed, fat infiltration is rarely 
observed (McIntosh et al., 1998b; Pratt et al., 2013; Walter et al., 2005). 
 Despite of similar muscle T1 in KI-Dnm2
R465W
 and wild-type mice, a decrease 
in muscle T1 was observed with aging for both lineages, especially for thigh muscles. 
It is known that aging causes an increase in the intra muscular adipose tissue in 
humans (Goodpaster et al., 2001; Schwenzer et al., 2009). A similar increase in the fat 
content could be related to the decrease in T1 values observed in older mice from 
both strain, without any influence of the mutation.  
 Muscle T2 was increased in KI-Dnm2
R465W
 mice at both ages and for all 
muscle groups. An increase in muscle T2 was already observed in a mouse model to 
nemaline congenital myopathy, the transgenic mouse carrying the human Asp286Gly 
mutation in the ACTA1 gene. In this mouse model, the increase in muscle T2 
correlated negatively with maximum muscle force, and was considered related to the 
degeneration/regeneration process, indicated in the histological analysis by the 
presence of contronucleated fibers (Gineste et al., 2013b). This mouse model do not 
present the usual pathological processes related to increased muscle T2, such as 
inflammation, edema and necrosis, which are observed in dystrophic muscles. 
Histological analysis shows the presence of intracellular alterations such as nemaline 
bodies, tubular aggregates, ringbinden fibers and centronucleated fibers, in addition to 
reduced fiber diameter (Ravenscroft et al., 2011). Similarly, in our study the 
consistently increased muscle T2 in the KI-Dnm2
R465W
 could not be related to tissue 
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alterations such as edema, inflammation or necrosis. Instead of it, the increased 
muscle T2 can be possibly related to intracellular disorganization, as observed by the 
altered mitochondrial positioning (Durieux et al., 2010). Indeed, muscle water T2 
reflects the mobility of water molecules in the tissue, being possibly affected when 
muscle structure is altered (Kim et al., 2010). 
 Alterations in muscle T2 have also been observed in centronuclear myopathy 
patients with mutation in DNM2. Nevertheless, in human patients these alterations are 
usually related to fat infiltration in muscles (Quijano-Roy et al., 2012; Schessl et al., 
2007; Susman et al., 2010). Since in mouse models for genetic muscle diseases  fat 
infiltration is extremely rare, we could not correlate the increased T2 observed in KI-
Dnm2
R465W
 mice to the MRI observations in centronuclear myopathy patients. 
 Muscle groups did not show different involvement due to the disease in KI-
Dnm2
R465W
 mice at both ages. Nevertheless, it was possible to identify variations in 
both T1 and T2 values for the 6 muscle groups studied, for both mouse strains. In 
general, thigh muscles showed higher T1 and T2 values than lower leg muscles, and 
the ROI corresponding to the TP/FDL muscles showed higher T2 values than the 
other muscles. For thigh muscles, the associated increase of both muscle T1 and T2 
does not indicate for an increase in the fat content in those regions. For the TP/FDL 
muscles, the increase in muscle T2 without changes in muscle T1 is possibly related 
to the presence of a high amount of non-muscle structures in this anatomical region, 
such as vessels, nerves and connective tissue. Since both lineages show the same 
pattern of changes in T1 and T2 values for the anatomical regions evaluated, we 
hypothesized that these differences are possibly related to intrinsic characteristics of 
each muscle group, which would not be altered by the mutation in Dnm2 gene in 
mice. 
 In conclusion, this non-invasive study was able to identify muscle atrophy and 
altered muscle T2 in KI-Dnm2
R465W
 mice, even when only small differences are 
observed clinically or histologically. These results indicate that NMR, especially T2 
relaxometry, is sensitive enough to identify alterations in a pre-clinical stage in the 
centronuclear myopathy model, the heterozygous KI-Dnm2
R465W
 mouse. 
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Chapter 5. Pilot functional and metabolic evaluation of 
the KI-Dnm2R465W mice 
 
 
Introduction 
 
 In addition to the phenotypical characterization of KI-Dnm2
R465W
 mice with 
MR images, we aimed to investigate non-invasively T1 and T2 relaxometry, function 
and metabolism of this mouse model. In genetic muscle diseases, muscle blood 
perfusion, oxygen consumption and energetic metabolism may be slightly changed or 
be unaffected at rest, but defective regulations alterations might be revealed by 
stressing the muscles. Considering that the KI-Dnm2
R465W
 mouse has a mild 
phenotype, we have conducted a pilot study to evaluate possible major functional and 
metabolic alterations in this mouse model, at rest and after muscle stress. KI-
Dnm2
R465W
 mice were evaluated with multiparametric functional NMR (mpfNMR), 
which combines the dynamic acquisition of ASL images for the evaluation of tissue 
perfusion, BOLD (Blood Oxygen Level Dependent contrast) signal for the estimation 
of tissue oxygen balance, and 31P spectroscopy for the evaluation of energetic 
metabolism. Two different paradigms of muscle stress were applied: stimulation of 
concentric contractions to simulate moderate exercise, and induction of prolonged 
muscle ischemia to evaluate the energetic metabolism and muscle function under 
hypoxia and in the hyperemic response after the end of ischemic stress. 
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Pilot study 1. Exercise as the paradigm of muscle stress in KI-
Dnm2R465W mice 
 
Materials and methods 
 
Animals 
 Six mice were successfully evaluated with functional NMR after exercise as 
muscle stress. Three heterozygous KI-Dnm2
R465W
 (Dnm2) and 2 normal littermates 
(wild-type) were evaluated with 3 months of age. One KI-Dnm2
R465W
 mouse could be 
re-evaluated at 6 months of age. One WT mice was evaluated at 6 months of age for 
comparison. The mice were kindly supplied by Dr. Marc Bitoun, Institut de Myologie, 
and were kept under the French rules for good animal care. 
 
Electrical stimulation for the simulation of moderate exercise 
 The mice were laid in supine position and two surface electrodes were placed 
in the ankle and at the popliteal region with electro-conductive gel. A moderate 
exercise was simulated with pulsed electro stimulation during two minutes (pulse 
duration: 120 ms, interval between pulses: 2.5 s, pulse frequency: 50 Hz, pulse 
intensity: 2 mA). The muscle force was assessed by measuring the pressure the mouse 
foot exerted over a custom built non-magnetic ergometer dedicated to mice, allowing 
the measure of the mouse force in mili Newton - mN (Baligand et al., 2011). The 2 
minutes of electrical stimulation were followed by 10 minutes of recovery, when the 
mpf-NMR scans were acquired. Twelve bouts of exercise-recovery were repeated and 
summed to allow a higher signal to noise ratio (SNR) for the NMR measurements. 
 
Multiparametric functional NMR (mpf-NMR)  
 The setup used for the mpfNMR was the same as described in Chapter 3 - 
"Structural and functional alterations of skeletal muscle microvascular network in 
dystrophin-deficient mdx mice". Mice were laid supine with the left leg immobilized 
in extension. The calf was placed over a 2 cm diameter surface 1H coil, used for 
reception of 1H NMR signal. A 31P saddle shaped coil (length 10 mm, inner diameter 
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10 mm) was wrapping the leg. Then, the mouse was placed in a volume transmitter 
1H coil (6 cm inner diameter and 12 cm length) for the whole-body tagging of blood. 
A stack of spin echo images of the mouse leg was acquired initially, and the slice of 
interest was chosen at the calf's largest cross-section. 
 Muscle function was assessed with simultaneous measures of muscle 
perfusion and capillary oxygenation via ASL tagging and Blood Oxygen Level 
Dependent (BOLD) signals, respectively. They were interleaved with the evaluation 
of mitochondrial activity via dynamic 31P MRS. Tissue perfusion and  BOLD signal 
were acquired with an Arterial Spin Labeling (ASL) SATuration-Inversion Recovery 
(SATIR) pulse sequence. ASL is based on NMR labeling of the water spins from 
arterial blood. The labeled spins act as endogenous markers, allowing the non-
invasive evaluation of blood perfusion. After alternated positive (M+) or negative (M-) 
labeling, rapid spin-echo images were acquired (inter-echo time: 2.9 s, RARE factor: 
32, matrix size: 128 x 32, FOV: 5 x 2 cm, slice thickness: 2 mm, TR: 10 sec). The 
delay between the tag module and the image acquisition (evolution time - Tev) was 1 
second. The muscle perfusion (f) was then calculated according to Equation 5.1, 
where λ is the blood-tissue partition coefficient for the magnetization, and assuming 
λ=0.9 (Raynaud et al., 2001). The BOLD contrast can be extracted from the ASL 
spin-echo images, averaging consecutive pairs of images as described in Equation 5.2 
(Duteil et al., 2006).  
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 Muscle energy metabolism was evaluated by 31P nuclear magnetic resonance 
spectroscopy (31P NMRS). 31P FIDs were collected serially from the total volume of 
the left leg (hard-pulse: 100 µs, spectral width: 12 kHz, number of complex data 
points: 4000, TR: 2.5 sec). ASL and 31P NMRS signals were interleaved using a 
dedicated Bruker MultiScanControl tool developed on ParaVision 3.0.2 (Bruker 
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BioSpin GmbH, Ettlingen, Germany). During the recovery period of the 1H NMR 
ASL sequence, 4 successive FIDs at the 31P frequency were acquired. The interleaved 
acquisitions generated a set of perfusion-weighted images with 10 s of time resolution 
and a set of 31P spectra with time resolution 2.5 s (Baligand et al., 2009). One bout of 
MSC was acquired without electrical stimulation (rest), followed by 12 bouts with 
electrical stimulation to simulate exercise. 
 After the mpf-NMR measures, a sequence for T1 measurement was applied 
over the same geometry as the ASL scans (TR: 0.002, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 
1.6, 2.4, 3.2, 4.0 and 6.5 seconds, TE: 10 ms). The muscle T1 value for each mouse 
was used in the calculation of its blood perfusion (Equation 5.1).   
 
 
Data Analyses  
 For the perfusion images, two ROIs were drawn in the posterior compartment 
of the leg, over the muscle tissue, avoiding large vessels, fat, skin, and bone tissue. 
The ROIs covered the lateral and medial gastrocnemius and part of the soleus muscle. 
The muscle perfusion and BOLD contrast were calculated from Equations 5.1 and 
5.2, respectively. 
 Phosphorus spectra were processed with the standard Paravision 3.0.2 and 
XWIN-NMR softwares. All spectra acquired with mpfNMR were summed to 
generate a reference spectrum with higher SNR. The reference spectrum was treated: 
zero-filling (8 kHz), 8 Hz line broadening exponential multiplication, Fourier 
transform, manual zero- and first-order phase correction and manual baseline 
correction were performed. The phase and baseline correction parameters were saved 
and applied to all the individual spectra from mpf-NMR, after zero-filling, 
exponential filtering and Fourier transforming. 
 The areas under the peaks corresponding to phosphomonoesters (PME), 
inorganic phosphate (Pi), phosphodiesters (PDE), phosphocreatine (PCr) and the three 
phosphates from ATP (α, β, γ) were integrated (PME: 8.0 to 5.6 ppm; Pi: 5.6 to 3.6 
ppm; PDE: 3.5 to 1.5 ppm; PCr: 1.5 to -1.5 ppm; γ-ATP: -1.5 to -3.5; α-ATP: -6.2 to -
9.2; β-ATP: -14.5 to -17.1 ppm). pH was calculated from the chemical shift δPi 
between PCr and Pi according to Equation 5.3 (Taylor et al., 1983). 
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 PCr recovery after exercise was fitted by a mono-exponential function with a 
least mean squares algorithm, to estimate the PCr recovery time (τPCr). For the 
exercise protocol, 288 31P spectra were collected. The pH at the end of the exercise 
period was calculated based on the summation of 31P spectra over the last 25 s of 
exercise.  
 Force measurements typically varied over the 12 exercise bouts: the first 2 
bouts were related to higher but decreasing force, while the 10 consecutive exercise 
bouts were related to a similar force curve. The 10 last exercise bouts were then 
considered identical, allowing the inter-exercise summation of perfusion data and 31P 
spectra collected for each animal, which allowed improving SNR.  
 
 
Results 
 
 The completely non-invasive set-up used was adapted from the minimally 
invasive set up developed previously in the NMR laboratory (Baligand et al., 2009). 
Briefly, subcutaneous electrodes were replaced by surface electrodes for the electrical 
stimulation. The non-invasive set up was not as effective as the minimally invasive 
one: over 29 exams (including repeated acquisition trials in the same mouse, with at 
least 1 week of interval, and discarded acquisitions), only 6 could be analyzed. 
Among the 23 discarded exams, 8 of them were from KI-Dnm2
R456W
 mice and 15 
from wild-type mice. The exams were discarded due to problems in the acquisition or 
due to alterations in the mouse vital signs: in 14 exams the force measured was too 
low, indicating wrong positioning of the mouse, problems in the setup or low current 
for electrical stimulation; 1 exam was interrupted due to breakdown of the 31P coil; 1 
exam was excluded due to inefficient mouse heating during the acquisition. 3 exams 
from wild-type mice and 1 from KI-Dnm2
R456W
 were stopped due to alterations in the 
mouse's vital signs. One exam could be completed but not evaluated: this KI-
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Dnm2
R456W
 mouse had low perfusion and low PCr depletion, indicating that the 
exercise was not correctly performed, despite the normal force measurements. 2 KI-
Dnm2
R456W
 mice, one at each age, died during the acquisition, possibly due to the 
isoflurane anesthesia. 
 Two wild-type and 2 KI-Dnm2
R456W
 mice at 3 months of age and 1 wild-type 
and 1 KI-Dnm2
R456W
 mice at 6 months of age could be successfully evaluated under 
the exercise protocol. The KI-Dnm2
R456W
 mouse evaluated at 6 months of age was 
evaluated also when it was 3 month-old. Due to the small samples, no statistic 
analysis was run to compare the data. 
 The force curve showed the expected pattern for all mice:  force was higher in 
the first exercise bout, decreasing until the 3rd exercise bout. From 3rd to 12th 
exercise bouts, force was approximately constant for all mice. In general, it was not 
possible to identify any difference in force between KI-Dnm2
R456W
 and wild-type mice 
at 3 and 6 months of age (Figure 5.1). 
 
  
 
Figure 5.1. Force curve for KI-Dnm2
R456W
 (DNM2) and wild-type (WT) mice at 3 
and 6 months of age (3m, 6m, respectively). The four groups have a similar 
reduction in the force exerted until the third exercise bout. Between 3rd and 12th 
exercise bouts, force measured is approximately constant, which allows inter-exercise 
summation.  
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 During 2 minutes of electrical stimulation to simulate exercise, muscle 
perfusion increased and BOLD signal decreased in all mice (Figures 5.2 and 5.3, 
respectively). After the end of exercise, muscle perfusion decreased until it returned to 
the basal level. Perfusion curves were similar for 3 month-old KI-Dnm2
R456W
 and 
wild-type mice (Figure 5.2-a). Nevertheless, when comparing 6 month-old mice, the 
perfusion pattern tended to be different between mouse lineages: the KI-Dnm2
R456W
 
mouse tended to reach a higher and earlier perfusion peak after exercise than the age-
matched wild-type (Figure 5.2-b). Even though, when muscle perfusion was 
integrated over the total exercise and recovery time, KI-Dnm2
R465W
 mice tended to 
present lower total perfusion than wild-type mice at both ages (Table 5.1). More mice 
should be evaluated to confirm these results. 
 
Table 5.1. Maximum perfusion (ml.min
-1
.100g
-1
), time to maximum perfusion 
(seconds) and total perfusion (integral over time - 12 minutes) for KI-Dnm2
R456W
 
(Dnm2) and wild-type (WT) mice at 3 and 6 months of age.  
 3 month-old 6 month-old 
 Dnm2 (n=2) WT (n=2) Dnm2 (n=1) WT (n=1) 
Max Perf 103.05 ± 0.14 107.91 ± 3.02 154.94 115.21 
Time to max (s) 135.00 ± 42.43 155.00 ± 14.14 85.00 175.00 
Total Perfusion 343.77 ± 80.17 397.76 ± 77.03 408.49 423.73 
 
  
 Both KI-Dnm2
R456W
 and wild-type mice, at 3 and 6 months of age, showed the 
same pattern of BOLD curves. BOLD signal showed a short and transient increase in 
a first moment, during exercise, which evolved to an accentuated decrease. After 
reaching its minimum, BOLD signal started to recover and reached the initial values 
in the end of the recovery time (Figure 5.3). Results indicate that KI-Dnm2
R456W
 mice 
may reach the minimum BOLD signal earlier than WT mice, indicating that possibly 
the oxygen supply was exhausted earlier in the myopathic mice. Differences in the 
minimum BOLD value could not be detected between ages or strains (Table 5.2). 
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Figure 5.2: Perfusion profile for (A) 3 months-old mice and (B) 6 months-old 
mice. Dashed lines at 120 s indicate end of exercise and start of the recovery period. 
The perfusion profile for each mouse is presented isolated. (A) Visually, there is no 
major difference in the profile for 3 months-old KI-Dnm2
R456W
 (Dnm2) and wild-type 
(WT) mice. (B) 6 months-old KI-Dnm2
R456W
 mouse might have a higher and earlier 
perfusion peak after exercise. 
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Figure 5.3: BOLD signal evolution with time for (A) 3 month-old and (B) 6 
months-old KI-Dnm2
R456W
 (Dnm2) and wild-type (WT) mice. The BOLD profile 
for each mouse is shown in separated curves. Dashed lines at 120 s indicate the end of 
exercise and start of the recovery period.  
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Table 5.2. Minimum BOLD signal (arbitrary units) and time to reach minimum 
(seconds) for 3 and 6 months-old KI-Dnm2
R456W
 (Dnm2) and wild-type (WT) mice. 
 3 month-old 6 month-old 
 Dnm2 (n=2) WT (n=2) Dnm2 
(n=1) 
WT (n=1) 
MIN BOLD (a.u.) 0.976 ± 0.007 0.980 ± 0.012 0.974 0.982 
Time to minimum (s) 220.0 ± 7.1 270.0 ± 35.4 190.00 225.00 
 
 
 Finally, when comparing 31P MRS during exercise and recovery, there was a 
possible tendency of higher Pi/PCr ratio in 3 month-old KI-Dnm2
R465W
 mice, that was 
inverted in 6 month-old mice. Additionally, a higher acidification after exercise might 
be present in 6 month-old KI-Dnm2
R465W
 mice (Table 5.3).  
 
 
Table 5.3. 31P MRS acquired at rest, during exercise and recovery in KI-Dnm2
R456W
 
(Dnm2) and wild-type (WT) mice at 3 and 6 months of age.  
 3 month-old 6 month-old 
 Dnm2 (n=2) WT (n=2) Dmm2 (n=1) WT (n=1) 
τPCr 53.20 ± 28.02 71.91 ± 9.82 73.01 73.01 
Δ PCr 0.63 ± 0.13 0.63 ± 0.01 0.72 0.72 
pH-rest 7.18 ± 0.07 7.17 ± 0.01 7.27 7.24 
pH-end 7.07 ± 0.01 7.04 ± 0.00 6.98 7.06 
Pi/PCr - rest 0.09 ± 0.04 0.13 ± 0.00 0.11 0.08 
Pi/PCr - end  2.50 ± 1.22 2.16 ± 0.04 2.22 2.70 
PCr/ATP - rest 2.13 ± 0.45 2.23 ± 0.10 2.15 3.02 
PCr/ATP - end 0.73 ± 0.15 0.75 ± 0.03 0.93 0.86 
τPCr: time to recover PCr to the basal level; ΔPCr: percentage of PCr depletion after 
exercise; end refers to the end of exercise; Pi/PCr: proportional to ADP production; 
PCr/ATP: proportional to the metabolically functional muscle tissue.  
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Discussion 
 
 The very few KI-Dnm2
R456W
 and wild-type littermates evaluated functionally 
under this protocol showed a possible tendency of altered muscle perfusion and 
BOLD signal after moderate exercise. Force measures did not indicate for major 
differences between KI-Dnm2
R456W
 and WT mice. The young KI-Dnm2
R456W
 mice 
tended to have higher Pi/PCr ratio in the end of the exercise when compared to age-
matched wild-type, while old KI-Dnm2
R465W
 mice tended to have a more accentuated 
acidification of muscle after exercise. The reduced total perfusion and Pi/PCr ratio 
associated to altered BOLD signal could indicate for impaired muscle function in KI-
Dnm2
R465W
 mice. More mice should be evaluated to confirm the results, but it could 
not be done due to the experimental difficulties to run the exercise protocol. It is 
possible though that adjustments should be done in the set-up to allow the 
measurements (Wary et al., 2011). 
 The electrical stimulation protocol presented repeated problems, and several 
mice did not perform all the 12 bouts of exercise-recovery or presented very low force 
measures, indicating an ineffective electrical stimulation. Over 29 exams, only 6 were 
successful and could be analyzed. To allow a more adequate functional evaluation of 
the KI-Dnm2
R465W
 mice a different protocol was proposed, with perturbation of the 
muscle physiology with a prolonged ischemia. 
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Pilot study 2. Prolonged ischemia as the paradigm of muscle stress 
 
 
 Considering the methodological difficulties to continue with functional and 
metabolic evaluation of KI-Dnm2
R456W
 mice under the exercise protocol, a different 
paradigm was proposed. An ischemic condition was temporarily applied to the 
mouse’s leg using a cuff in the thigh. After 30 minutes, the cuff was quickly removed, 
causing a fast hyperemic response, when arteries and arterioles are dilated, 
minimizing its resistance. The ischemia-hyperemia paradigm allows the evaluation of 
the impact of capillaries regulation and structure in muscle blood perfusion after 
ischemic stress, allowing also the study of energetic metabolism under hypoxia and 
during the recovery period. 
  
 
Materials and Methods 
 
Animals 
 4 KI-Dnm2
R456W
 and 3 wild-type mice at 6 months of age and 3 KI-Dnm2
R456W
  
mice at 3 months of age were evaluated functionally under the ischemia protocol. 
Mice were kindly supplied by Dr. Marc Bitoun, Institut de Myologie, and were kept 
under French rules for good animal care. 
 
31P spectroscopy at rest 
 
 Phosphorus spectroscopy (31P MRS) at rest was collected before any 
perturbation in the muscle, with the same set-up used for the mpfNMR described in 
the previous pilot study. Three successive 31P acquisitions were collected (hard-
pulse: 100µs, spectral width: 12 kHz, number of complex data points: 4000, TR: 2.5 
sec, NR: 350). Localized shimming of water signal from the lower leg muscle volume 
(9x9x9 mm in general) allowed the acquisition of good quality 31P spectra (PCr line 
width of 10-25 Hz in the unfiltered 31P spectra).  
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Ischemia protocol 
 The methodology was similar to what was described in Chapter 3. After the 
acquisition of 31P MRS at rest, the mpfNMR acquisition was launched for recording 
baseline muscle perfusion. After the measurements of muscle perfusion and 31P MRS 
at rest, mice were submitted to ischemia of the left leg. Two surgical threads had been 
positioned subcutaneously around the thigh, and blood flow was interrupted by 
pulling tight the threads with the use of a 0.5 kg weight, leading to the occlusion of 
femoral artery (Bertoldi et al., 2008)(Bertoldi et al, 2008). After 30 minutes of 
ischemia, the blood flow was restored by the quick removal of the weight and 
loosening of the threads, causing a hyperemic response in the leg. The muscle 
perfusion and metabolism were monitored during the whole protocol, and the data 
were collected and analyzed as described for the previous pilot study and in Chapter 
3.  
 
 
Results 
 
 The ischemia protocol was successfully executed in 9 over 16 experiments: 3 
3-month-old KI-Dnm2
R456W
 mice, 3 6-month-old KI-Dnm2
R456W
 mice, and 3 6-month-
old wild-type mice. 2 KI-Dnm2
R456W
 mice died during the protocol. The ischemia was 
not effective in 3 mice, due to problems in the positioning of the threads. One exam 
was acquired with proper ischemia, but low hyperemia and no PCr depletion, so the 
exam was discarded. One acquisition was interrupted due to methodological problem. 
No statistical comparisons were done due to the small samples size. 
 
31P spectroscopy at rest 
 No major differences were observed in the 31P spectroscopy at rest between 6 
month-old Dnm2 and wild-type mice, neither between 3 and 6 month-old KI-
Dnm2
R456W
 mice (Table 5.4).
 132 
 
Table 5.4: 31P NMR spectroscopy at rest for the ischemia protocol.  
 
KI-Dnm2
R456W
 WT 
 
3 month-old (n=3) 6 month-old (n=3) 6 month-old (n=3) 
PME/PCr 0.16 ± 0.08 0.19 ± 0.03 0.18 ± 0.11 
PDE/PCr 0.04 ± 0.07 0.11 ± 0.06 0.06 ± 0.03 
pH 7.11 ± 0.12 7.03 ± 0.15 7.04 ± 0.11 
Pi/PCr 0.12 ± 0.08 0.20 ± 0.06 0.19 ± 0.06 
PCr/ATP-γ 2.57 ± 0.39 2.69 ± 0.15 2.68 ± 0.25 
PME: phosphomonoesters; PDE: phosphodiesters; Pi/PCr: proportional to ADP 
production rate; PCr/ATP-γ: proportional to the metabolically functional muscle 
tissue. 
 
 
mpfNMR  
 For all mouse groups, muscle perfusion at rest was similar (Table 5.5). After 
prolonged ischemia, the perfusion profile in hyperemic response was similar for all 
mouse groups. Blood perfusion increased quickly after tourniquet release, and 
returned to basal levels in the recovery phase (Figure 5.4). Nevertheless, KI-
Dnm2
R465W
 mice tended to achieve lower maximal and total perfusion than wild-type 
mice. Additionally, the maximal perfusion was observed later in the myopathic mice 
(Table 5.5).  
 In the comparison between KI-Dnm2
R456W
 mice at different ages, maximum 
perfusion in 3 month-old mice tended to be lower than in 6 month-old mice (Figure 
5.4-B).  
 
Table 5.5: Perfusion data for KI-Dnm2
R456W
 (Dnm2) and wild-type (WT) mice. 
 Dnm2 WT 
  3 month-old (n=3) 6 month-old (n=3) 6 month-old (n=3) 
Perf at rest 5.16 ± 1.94 7.61 ± 6.62 6.22 ± 1.50 
MAX perf 44.23 ± 4.80 70.95 ± 43.66 85.02 ± 38.92 
Time to peak (s) 284.67 ± 81.68 272.00 ± 93.66 215.00 ± 3.46 
Total Perf 365.95 ± 202.10 340.91 ± 131.19 393.32 ± 194.96 
Perfusion at rest (ml.min
-1
.100g
-1
), maximum perfusion after the cuff release (ml.min
-
1
.100g
-1
), time to peak (seconds) and total perfusion (integral over time - 65 minutes) 
for 3- and 6-month-old KI-Dnm2
R456W
  mice and 6-month-old wild-type mice.  
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Figure 5.4: Perfusion profile after the cuff release for KI-Dnm2
R456W
 (Dnm2) and 
wild-type (WT) mice at 3 and 6 months of age. (A) Comparison between mouse 
strains, 6 month-old mice. (B) Comparison between 3 and 6 month-old  KI-
Dnm2
R456W
 mice. 
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Dynamic 31P spectroscopy   
 Even if 9 mice could complete the mpfNMR ischemia protocol, only 4 mice 
depleted more than 50% of muscle PCr: the three 6-month-old wild-type mice and 
one 3-month-old KI-Dnm2
R456W
 mouse. All 6 month-old KI-Dnm2
R456W
 mice and two 
3-month-old KI-Dnm2
R456W
 mice depleted a smaller amount of PCr (19-39%). No 
comparison could be done between KI-Dnm2
R456W
 and wild-type mice or between KI-
Dnm2
R456W
 mice at different ages, since only one KI-Dnm2
R456W
 mouse achieved the 
minimal PCr depletion and there were no measurements from age-matched wild-type. 
It is possible, though, that the reduced PCr depletion observed in KI-Dnm2
R456W
 mice 
could be related to altered energetic metabolism under hypoxia in this mouse model, 
but more mice should be scanned to verify this hypothesis.  
 
 
Discusssion 
 
 When submitting KI-Dnm2
R456W
 mice to prolonged ischemia, a possible trend 
of reduced perfusion and impaired energetic metabolism in the affected mice was 
observed. This trend is consistent with the results from the previous pilot study, when 
muscle perfusion was measured after simulated exercise. To confirm if these possible 
functional or metabolic alterations are indeed present in the KI-Dnm2
R465W
 mice more 
animals should be analyzed. 
 Even if results were speculative, these pilot studies revealed methodological 
barriers to functional evaluation with exercise as muscle perturbation. In opposite, 
functional evaluation was feasible in the mouse model to centronuclear myopathy 
with mutation in dynamin-2 when ischemia was applied as muscle stress. Considering 
this, a third pilot study was proposed: the functional and metabolic evaluation of the 
muscle from KI-Dnm2
R456W
 mice after an acute lesion, using the ischemia-hyperemia 
paradigm. 
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Pilot study 3. Regeneration in the DNM2 mice: T1, T2 and functional 
analysis after injury  
 
 Even with the very small sample sizes, either when exercise or when ischemia 
were applied as perturbation to the muscle physiology, a tendency of reduced muscle 
perfusion possibly combined to impaired energetic metabolism might be present in 
the heterozygous KI-Dnm2
R456W
 mouse. There are indications that myotubular 
myopathy patients, with mutation in MTM1, have reduced population of satellite cells, 
which would lead to impaired muscle regeneration (Shichiji et al., 2013). A similar 
reduction in the number of satellite cells is observed in the Mtm1-null mouse (Lawlor 
et al., 2012). If the reduced number of satellite cells is a common feature in 
centronucelar myopathies, this population would be altered also in KI-Dnm2
R456W
 
mice, impacting on the muscle regeneration after injury.  
 To access muscle function and metabolism in KI-Dnm2
R456W
 mice under 
muscle regeneration, the functional evaluation following ischemic stress was repeated 
in KI-Dnm2
R456W
 and wild-type after an acute electrically induced muscle injury. Our 
hypothesis was that if there were any impairment in muscle regeneration, it would be 
reflected by poorer metabolic and functional measurements. The purpose was to study 
the myopathic muscle under extreme conditions, when possible differences in muscle 
function and metabolism would be more evident. 
 
 
Materials and Methods 
 
Animals 
Four KI-Dnm2
R456W
 mice and 5 wild-type littermates, females, 3 month-old, were 
evaluated. Mice were supplied by Dr. Marc Bitoun, and were kept under controlled 
environment, with 12/12 hours illumination cycle, with food and water at libidum, 
following the French rules for animal care. 
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Muscle Injury 
 Mice were anesthetized with isoflurane (5% for induction, 1.75% for 
maintenance, 1.5 l/min airflow) and the left gastrocnemius was shaved. The 
electrically induced damage was done by positioning two circular electrodes (7 mm 
diameter, 4 mm of distance between electrodes) covered with ultrasound transmission 
gel perpendicularly to muscle fibers, over the gastrocnemius muscle. Animals were 
submitted to 8 electrical pulses (voltage: 100V), with duration of 20 milliseconds and 
an interval of 0.5 second between pulses, in order to induce muscle damage.  
 
NMR 
 The NMR evaluation consisted of T2 measurements of both limbs, followed 
by mpfNMR under and after ischemic stress and T1 measurements of the injured limb 
as described previously. Imediately after the NMR session, mice were euthanized by 
cervical dislocation under isoflurane anesthesia. 
 Three time points after muscle lesion were selected for this pilot study: 3, 5 
and 10 days after injury. One KI-Dnm2
R456W
 and two wild-type mice were evaluated at 
3 and at 5 days after injury; 2 KI-Dnm2
R456W
 and 2 wild-type mice were evaluated 10 
days after injury. The interruption of the blood flow to the calf was not effective in 
both wild-type mice evaluated 3 days after muscle lesion. One of these mice was 
euthanized for the histological evaluation, and the second one was evaluated again at 
10 days after injury. 
 
 
Results 
 
Muscle Perfusion 
 Perfusion at rest, maximal perfusion and total blood perfusion values after the 
tourniquet release are shown in Table 5.6. Perfusion at rest tended to be increased 
both in KI-Dnm2
R456W
 and wild-type mice up to the 5
th
 day after muscle injury. Both 
lineages showed a decrease in the perfusion at rest from the 5
th
 to the 10
th
 day after 
muscle lesion, reaching values closer to the normal ones for each strain (Table 5.5). 
This apparently increased blood perfusion at rest may be related to the inflammatory 
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process observed in the acute response to the injury, which includes accentuated 
edema.  
 After tourniquet release, all mice showed increased perfusion, characterizing 
the hyperemic response. Nevertheless, KI-Dnm2
R456W
 mice tended to have a more 
accentuated increase in blood perfusion than wild-type mice, both at 5 and 10 days 
after injury (maximal perfusion in KI-Dnm2
R456W
 mice was 3 to 4 times higher than 
wild-type at the same time after injury). At 3 days after injury, there were no wild-
type mice for the comparison (Figure 5.5).  
 At 5 days after injury, in addition to the increased maximal perfusion, KI-
Dnm2
R456W
 presented higher total perfusion than wild-type. This was not maintained 
at 10 days after injury, when despite of the higher maximal perfusion in Dnm2 mice, 
no differences were evident in the total perfusion (Table 5.6). 
 
 
Table 5.6. Perfusion at rest (PerfREST), maximal perfusion (PerfMAX) and total 
perfusion (PerfTOTAL) after tourniquet release (ml.min
-1
.100g
-1
), 3-, 5- and 10-days 
after injury, for KI-Dnm2
R456W
 and wild-type mice. 
  
PerfREST PerfMAX PerfTOTAL 
3 d 
Dnm2 (n=1) 15.9 ± 9.1 202.5 1292.5 
WT (n=2) 30.1 ± 1.3 -- -- 
5 d 
Dnm2 (n=1) 35.7 ± 11.7 233.9 2062.7 
WT (n=2) 31.0 ± 28.6 75.7 ± 38.1 662.6 ± 198.5 
10 d 
Dnm2 (n=2) 12.0 ± 3.2 229.3 ± 99.9 686.7 ± 133.5 
WT (n=2) 4.6 ± 0.7 51.0 ± 20.1 669.7 ± 179.5 
 
 
 When the perfusion profiles were evaluated, a marked difference could be 
observed between KI-Dnm2
R456W
 and wild-type mice. Regardless of the moment after 
muscle injury, KI-Dnm2
R456W
 mice presented a high perfusion peak just after the 
tourniquet release, 3 to 4 times higher than the maximal perfusion achieved by wild-
type mice. This initial peak was followed by a rapid decrease in blood perfusion, 
reaching values near to those observed in wild-type mice. The KI-Dnm2
R456W
 mice 
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evaluated 3 and 5 days after muscle injury apparently presented this first peak during 
a longer period than the KI-Dnm2
R456W
 mice evaluated 10 days after muscle injury 
(Figure 5.5).  
 
 
 
 
Figure 5.5. Blood perfusion profile for KI-Dnm2
R456W
 (Dnm2) and wild-type 
(WT) mice, 3-, 6- and 10-days after muscle injury. In all time points, KI-
Dnm2
R456W
 mice presented a high initial perfusion peak, not observed in wild-type 
mice. 
 
Muscle T2 evaluation after muscle injury 
 Muscle T2 reflected inflammatory and degenerative processes observed after 
acute lesion. Both KI-Dnm2
R456W
 and wild-type mice showed increased muscle T2 
after muscle lesion. Increased T2 was confined to the posterior compartment of the 
leg: while muscle T2 was increased in gastrocnemius, no changes were observed in 
tibialis anterior muscle for both strains. The increase in muscle T2 was more 
accentuated up to 5 days after injury. Both KI-Dnm2
R456W
 and wild-type mice showed 
a tendency of returning to normal muscle T2 values with time. Nevertheless, until the 
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last time point evaluated (10 days after injury), the injured leg still showed increased 
T2 values in both mouse strains, indicating that the regeneration process was not 
completed even in the wild-type mice (Table 5.7).  
 
Table 5.7. Muscle T2 (ms) for Gastrocnemius and Tibialis Anterior muscles at 
different time points after injury. 
  
Gastrocnemius Tibialis Anterior 
  
Injured Contralateral Injured Contralateral 
3 d Dnm2 (n=1) 79.5 ±  0.9 32.9 ± 1.5 30.4 29.8 
  WT (n=2) 91.0 ±  2.4 28.4 ± 0.6 27.5 ± 0.1 27.6 ± 0.5 
5 d Dnm2 (n=1) 112.5 ±  13.0 30.0 ± 0.6 30.3 29.7 
  WT (n=2) 88.2 ±  23.0 28.9 ± 0.5 28.4 ± 0.1 28.1 ± 0.3 
10 d Dnm2 (n=2) 45.6 ±  1.8 30.8 ± 1.2 29.9 ± 0.3 29.3 ± 0.7 
  WT (n=2) 40.6 ±  1.1 28.5 ± 0.5 27.9 ± 0.5 28.1 ± 0.0 
Gastrocnemius: mean value for medial and lateral gastrocnemius.3d, 5d, 10d: 3-, 5-, 
and 10-days after muscle injury in the posterior compartment of the leg.  
 
Muscle T1 after acute muscle injury 
 Muscle T1 was measured only in the injured leg, due to the setup used for the 
images acquisition. A possibly reduced muscle T1 was observed in the first days after 
injury, showing a tendency to return to normal values with time. The same pattern 
was observed in KI-Dnm2
R456W
 and wild-type mice (Table 5.8). 
 
Table 5.8. Muscle T1 (s), 3-, 5- and 10-days after muscle injury. 
  
Muscle T1 (s) 
3 d Dnm2 (n=1) 1.18 
  WT (n=0) -- 
5 d Dnm2 (n=1) 1.27 
  WT (n=2) 1.34 ± 0.09 
10 d Dnm2 (n=2) 1.43 ± 0.11 
  WT (n=2) 1.41 ± 0.17 
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Discussion 
 
 Despite the small number of mice evaluated, this pilot study indicates for 
possible major differences between KI-Dnm2
R456W
 and wild-type mice during the 
regeneration process. These differences were particularly evidenced when regarding 
maximum perfusion after ischemia. All KI-Dnm2
R456W
 mice showed 3 to 4 times 
higher maximum perfusion than WT mice, at all time points studied. Such a high 
perfusion might indicate altered regulation of vascular control after ischemic stress. 
Interestingly, KI-Dnm2
R465W
 mice tended to present reduced total perfusion in the 
previous pilot studies, without muscle injury. A deeper evaluation of muscle 
regeneration and vascularization in KI-Dnm2
R465W
 mice would be interesting to better 
understand the disease mechanisms in this murine model. 
 In addition to the perfusion results, T2 measurements showed increased T2 in 
the injured muscle, with T2 approaching the normal values with time after injury for 
both strains. This was already expected, once muscle T2 is related to edema, necrosis 
and inflammation, which tend to be normalized approximately 15 days after injury 
(Baligand et al., 2012). Nevertheless, the evaluation of the time to return to normal T2 
values could be an interesting non-invasive indicative of possibly altered regeneration 
in KI-Dnm2
R465W
 mice. 
 Even if this was a pilot study, with very few mice evaluated, the results 
indicate for major differences in muscle function during regeneration in KI-
Dnm2
R465W
 mice. More mice should be evaluated to confirm these hypotheses. 
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Chapter 6 
 
Evaluation of the potential use of micro-
Computed Tomography in the study of 
muscles from murine models for muscle 
dystrophies 
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Chapter 6. Evaluation of the potential use of micro-
Computed Tomography in the study of muscles from 
murine models for muscle dystrophies 
 
Introduction 
 
 Muscle imaging techniques such as computed tomography (CT) and nuclear 
magnetic resonance imaging (NMRI) have the capacity to assess the severity and 
identify patterns of muscle fatty infiltrative involvement in chronic muscle disorders. 
While NMR offers a wealth of other biomarkers (fibrosis, perfusion, energy 
metabolism) to characterize the skeletal muscle, CT scans offers the advantage of a 
lower cost of installation and maintenance. CT produces images with usually higher 
resolution but with less contrast for soft tissues than NMRI.  
 In human patients, CT images have been used in the evaluation of muscle 
disorders since the early 80s. Atrophy, fat infiltration and altered X-ray opacity was 
observed in affected muscles (Bulcke et al., 1981; Grindrod et al., 1983; Jiddane et 
al., 1983; Schwartz et al., 1988; Stern et al., 1984; Termote et al., 1980; De Visser 
and Verbeeten, 1985). In addition to the evaluation of muscle radiodensity, CT 
images can be used to estimate muscle volume and mass, variables that often correlate 
negatively with the disease progression (Nakayama et al., 2013a).  
 The development of high-resolution tomography (micro-CT) has permitted the 
acquisition of images from small animals. Mouse models for muscle dystrophies have 
already been studied with micro-CT, but the investigation were focused on the 
evaluation of bones, lung and airway alterations (Lopez et al., 2008; Novotny et al., 
2011, 2014). To our knowledge, the description of muscle alterations in mice with 
micro-CT was restricted to the identification of atrophy (Manske et al., 2010; Weber 
et al., 2012).  
 In this context, our purpose was to evaluate how informative muscle micro-CT 
analysis could be in the study of mouse models for muscle dystrophy. Two severely 
affected mouse strains were scanned: Large
myd
 and the double mutant mdx/Large
myd
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mice, in addition to wild-type mice. Large
myd
 mice have a mutation in the 
glycosyltransferase Large gene, which leads to poor glycosylation of the protein 
alpha-dystroglycan (α-DG) and altered link of the sarcolemma with the extracellular 
matrix (Grewal et al., 2001). The double mutant mdx/Large
myd
 mouse harbors 
mutations in the Large and in the dystrophin genes, resulting in total absence of the 
protein dystrophin, deficient glycosylation of  α-DG and a very severe dystrophic 
phenotype (Martins et al., 2013). These two dystrophic strains present fibrosis, 
inflammation and necrosis in the muscle, in addition to regenerating fibers. 
Nevertheless, at variance with human patients, no fat infiltration is observed in 
muscles.  
 In this study, cross sectional area, muscle X-ray opacity and muscle signal 
heterogeneity in the micro-CT images were evaluated in the two dystrophic strains 
Large
myd
 and mdx/Large
myd
, and compared to wild-type mice. In addition, we tested 
the efficacy of micro-CT images in the detection of the degeneration/regeneration 
process in a model of muscle damage induced by electroporation. Our micro-CT 
results confirmed that, even with increased resolution, micro-CT images are not 
sensitive enough to detect alterations observed in dystrophic and injured muscle other 
than changes in muscle volume, such as those related to inflammation, necrosis and 
fibrosis.  
 
 
Materials and Methods 
 
Animals  
 
 34 mice were scanned: 4 mdx/Large
myd
; 12 Large
myd
 and 18 C57Black/6 mice 
(wild-type), aged between 2 and 6 months. 13 wild-type mice were scanned for the 
phenotype characterization, and 5 wild-type mice were scanned after muscle injury (3 
mice scanned 3 days after injury, 2 mice scanned 15 days after injury). Mice were 
supplied by the Human Genome Research Center animal house, Bioscience Institute 
(Sao Paulo), and kept in controlled environment, with water and food at libidum, 12 
hours light/12 hours dark.  
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Muscle injury with electroporation 
 
 To better understand the effect of muscle lesions on the X-ray opacity, 
muscles of 5 wild-type mice (2 month-old) were injured by electroporation. Three 
mice were scanned 3 days after injury, when  muscles are under an accentuated 
inflammatory process with edema, necrosis and inflammation, which would increase 
the muscle water content. Two mice were scanned 15 days after injury, when muscle 
was regenerating, with altered cytoarchitecture, characterized by smaller fibers with 
centrally placed nuclei. These time points were chosen based on previous results from 
the group (Vainzof et al., 2014), where marked differences could be detected in the 
histological analysis of normal murine muscle after electrically induced injury (Figure 
6.1). 
 
 
Figure 6.1. Normal murine muscle (A) in comparison to injured muscle in the acute 
phase after lesion (B - 3 days after injury) and when regeneration has overcome 
degeneration (C - 15 days after injury). H&E, zoom 200X. Adapted from (Vainzof et 
al., 2014). 
 
 Mice were anesthetized by intraperitoneal injection of 40 µl of 2:1 ketamine 
10% : xylazine 2% mixture. The left hindlimb was shaved and two circular electrodes 
with 0.7 mm diameter were positioned facing the posterior compartment of the lower 
leg, over the gastrocnemius muscles, with a 4 mm distance between them, and 
covered with electroconductive gel. Eight unipolar pulses of 100V, with 20 ms 
duration and 500 ms interval, were applied to induce muscle injury 
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Micro-CT  
 
 Mice were anesthetized with 4% isoflurane, and anesthesia was maintained 
with 1.75% isoflurane mixed with oxygen, in a 1 L/min gas flow. Then, mice were 
prone positioned with the posterior limbs symmetrically extended for the micro-CT 
scans. During all the scan time, the mice breathing rate was monitored by video. After 
images acquisition, all mice were euthanized in CO2 chamber, and muscles were 
collected for further posterior histological, protein or molecular analyses. 
 Micro-CT scans were performed in a micro-tomography system (SkyScan 
1176 in vivo micro-CT, SkyScan, Kontich, Belgium). Scanning parameters were: 50 
kV, 500 mA; Filter Al 0.5 mm; voxel volume 18 mm
3
. The acquisition time was 13 
minutes, and experiment time never exceeded 30 minutes, including mouse 
positioning.  
 Projection images were reconstructed with the NRecon Reconstruction 
Software, provided by the manufacturer (SkyScan). Reconstructed images were 
smoothed (smooth factor=3, Gaussian function); ring and beam hardening artifacts 
were corrected (ring reduction factor: 10%; beam hardening correction factor: 19%). 
All images were reconstructed over the same dynamic range, resulting in identical 
gray scales. 
 
 
Data Analysis 
 
 The images were analyzed with the CT-Analyser Software (SkyScan). Tibia 
length (Ltibia) was measured and one transversal slice was selected at approximately ¼ 
of the tibia length from the knee to the feet, where no fat from the popliteal region 
was visible. On that slice, the cross-section area (CSA) was measured, and the ratio 
CSA/Ltibia was compared as an index of atrophy. In the same image, one ROI was 
drawn comprising the muscles from the posterior compartment of the lower leg 
(gastrocnemius and soleus), excluding any fat, skin and bone tissue. A second ROI 
was drawn in the empty space to estimate the noise. The histogram of grayscale 
values inside muscle ROI was evaluated. While mean intensity identifies changes in 
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radiodensity in the whole tissue, the ratio SDsignal/SDnoise (SD: standard deviation) 
inside the muscle ROI was used as a measurement of the muscle signal heterogeneity.  
 
 
Statistical Analysis 
 
 The analyses were done with one-way ANOVA, with Bonferroni comparison 
of means when necessary (NCSS 2001, Kaysville, Utah, USA). Differences were 
considered siginificant if p< 0.05. Muscle radiodensity and signal heterogeneity data 
are reported as mean ± SD. 
 
 
Results 
 
Phenotypical characterization of the dystrophic muscle with micro-CT 
 
  No differences in the radiodensity were detected in the comparison between 
male and female mice or between mice with different age from the same strain, both 
for wild-type and Large
myd
 mice. Considering this, all mice from each strain were 
grouped for further analysis.  
 In the comparison between mouse strains, a marked difference related to 
atrophy was observed (Figure 6.2). CSA/Ltibia was different between the three mouse 
lineages (p<0.01), being reduced in the more affected mdx/Large
myd
 mice when 
compared to wild-type, while Large
myd
 mice showed intermediary values (Table 6.1). 
Nevertheless, when comparing intensity and heterogeneity of muscle signal, the 
differences observed between the groups were not considered significant: among 256 
tones in the grayscale, the differences were of the order of one tone (Table 6.1).  
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Figure 6.2. Transversal reconstructed micro-CT images from (A) mdx/Large
myd
, 
(B) Large
myd
 and (C) wild-type mice. Apart from atrophy, no difference was 
identified in the muscle signal for the three strains. The arrowheads show the 
subcutaneous fat, with reduced signal in comparison to muscle and skin. 
 
 
Table 6.1. Micro-CT results for mdx/Large
myd
, Large
myd
 and wild-type mice.   
 X-ray opacity 
(GS) 
Heterogeneity 
(SDsignal/SDnoise - GS) 
CSA/Ltibia ** 
(mm) 
mdxLarge
myd
 (n=4) 27.6 ± 0.2 2.4 ± 0.3 96.3 ± 13.9 
Large
myd
 (n=12) 27.6 ± 0.2 2.1 ± 0.2 121.7 ± 22.8 
Wild-type (n=13) 27.8 ± 0.2 2.0 ± 0.1 143.4 ± 22.6 
CSA: cross section area; Ltibia: tibia length; GS: grayscale; SD: standard deviation; px: 
pixels.  
 
 
Evaluation of injured muscle with micro-CT 
 
 This pilot study was conducted to evaluate if an acute and severe muscle 
lesion would create alterations that could be detected with micro-CT images. While 
murine dystrophic muscle presents mainly necrosis, infiltrates of inflammatory cells 
and fibrosis, normal murine muscle presents accentuated inflammation and necrosis 
in the acute phase after injury, with important edema observed 3 days after lesion 
(Figure 6.1-B). After 15 days, injured muscle shows predominance of smaller 
regenerating fibers, identifiable by the centrally placed nuclei (Figure 6.1-C). Three 
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mice were scanned 3 days after injury, and 2 mice were scanned 15 days after injury. 
Injured leg was compared to the contralateral leg from the same mouse. Due to the 
small number of mice studied, no statistical analysis was done. 
 In both time points, injured leg tended to show increased CSA/Ltibia, 
compatible with the edema induced by muscle lesion. A slightly reduced X-ray 
opacity was observed in the injured leg in the acute phase after lesion. This can be 
caused by the higher amount of water present in the tissue due to edema, which would 
reduce its global radiodensity. In the second time point (15 days after injury), no 
differences were observed in X-ray opacity or signal heterogeneity between injured 
and control legs, even if muscle cytoarchitecture is changed in the histological 
analysis (Table 6.2). 
 
Table 6.2. Effect of muscle injury after 3 and 15 days in the micro-CT results.  
 Muscle X-ray opacity 
(GS) 
Heterogeneity 
(SDsignal/SDnoise - GS) 
CSA/Ltibia  
(mm) 
3 days 
after injury 
(n=3) 
Injured 27.4 ± 0.3 2.1 ± 0.3 163.7 ± 6.2 
Control 28.4 ± 0.0 2.0 ± 0.0 139.9 ± 10.1 
15 days  
after injury 
(n=2) 
Injured 28.1 ± 0.2 2.0 ± 0.0 132.5 ± 0.8 
Control 28.4 ± 0.1 2.0 ± 0.0 115.5 ± 6.6 
CSA: cross section area; Ltibia: tibia length; GS: grayscale; SD: standard deviation; px: 
pixels. 
 
 
Discussion  
 
 In this study, we have shown that micro-CT images can identify muscle 
atrophy, but not major alterations in the muscle content in mice. Two severely 
affected mouse strains were scanned, Large
myd
 and the double mutant mdx/Large
myd
 
mice. Both strains present severe muscle dystrophy, with necrosis, inflammatory 
infiltration and fibrosis in the histological analysis. These dystrophic mice showed 
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atrophy in micro-CT images, as already described in morphological studies (Lane et 
al., 1975; Martins et al., 2013). Nevertheless, the dystrophic alterations in the muscles 
were not reflected by muscle X-ray opacity or muscle signal heterogeneity. In the 
evaluation of injured muscle from normal mice, the presence of edema, necrosis and 
inflammation tended to be reflected by reduced muscle X-ray opacity in the acute 
phase after lesion. 
 In humans, the quantitative evaluation of muscle radiodensity shows reduced 
muscle signal usually related to the fat replacement observed in muscle dystrophies, 
polymyositis and neurogenic disorders (Bilgen et al., 2001; Swash et al., 1995; Vlak 
et al., 2000). Duchenne and Becker muscular dystrophies patients present alterations 
in muscle radiodensity in CT images even in early stages of the disease, and the CT 
numbers (X-ray opacity) decrease with the advance of the disease (Arai et al., 1995). 
Not only the absolute CT values, but the histogram of the muscle radiodensity also 
changed with disease progression in patients with Duchenne muscular dystrophy, 
evidencing the increase in the fat content in the muscles (Nakayama et al., 2013b). In 
opposite, patients with Pompe disease showed high density  in liver and skeletal 
muscles in CT scans, compatible with the glycogen accumulation in these tissues, that 
tend to get closer to normal values after treatment (Ishigaki et al., 2012). This 
indicated that fat replacement is not the only factor influencing changes in the muscle 
radiodensity in CT images. 
 Micro-CT studies of dystrophic mice have so far focused on the evaluation of 
bone structure and architecture, extracting information such as trabecular bone 
morphometry, cortical bone geometry and volumetric bone density (Novotny et al., 
2011, 2014). The low-coefficient of X-ray attenuation of soft tissues, such as muscle, 
limits the visualization of internal details in CT or micro-CT images. The use of 
micro-CT in the study of soft tissue has been developed recently, but with techniques 
that include decalcification, dehydration and/or the use of contrast agents in ex-vivo 
specimens. When the soft-tissue had been previously treated, ex-vivo contrast 
enhanced micro-CT allowed the visualization of muscle structures, achieving 
resolution down to the level of skeletal muscle fibers, close to the histological 
resolution (Aoyagi et al., 2013; Baverstock et al., 2013; Jeffery et al., 2011; Metscher, 
2009).  
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 The in vivo evaluation of mouse muscle with micro-CT was still limited to a 
few studies. Contrast-enhanced micro-CT allowed the cardiac evaluation of living 
mice (Badea et al., 2006). Muscle loss after botulin toxin injection and in sarcopenia 
condition in mice was described by measuring the muscle cross section area from 
micro-CT images (Manske et al., 2010; Weber et al., 2012). Micro-CT images of the 
Tnt
mdm
 mouse, model for muscle dystrophy with myositis, showed skeletal anomalies 
in the spine and thoracic rib cage in addition to reduction of lung volume. In addition 
to morphological, histological and molecular data, these micro-CT results supported 
the hypothesis of early mechanical diaphragm dysfunction in this murine model 
(Lopez et al., 2008).  
 In general, mouse models to muscle dystrophies do not present fat infiltration 
in the muscles as human patients do (Carnwath and Shotton, 1987; McIntosh et al., 
1998b). This is the case for the two dystrophic mouse strains evaluated in this study, 
including the very severely affected mdx/Large
myd
 mouse, in which the major 
dystrophic alterations observed in histological analysis are necrosis, inflammation and 
fibrosis (Martins et al., 2013). They remained undetected by micro-CT imaging. Our 
results support the hypothesis that muscle alterations might possibly be evidenced in 
micro-CT images only in very extreme conditions, such as the acute phase after 
extensive electrically induced muscle damage.  
 In conclusion, these preliminary results showed that micro-CT images can 
identify muscle atrophy in mouse model for muscular dystrophy. However, even if CT 
images identified alterations in muscle composition in dystrophic human patients, it 
was not possible to reach the same in murine models with micro-CT images. It is 
possible though that with the use of proper contrast agents new avenues could be 
opened in the evaluation of murine soft tissue with micro-CT. 
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General Conclusions and Perspectives 
  
 
 In this thesis, different mouse models for genetic muscle diseases were non-
invasively characterized, with innovative techniques for data acquisition and analyses. 
The combined use of magnetic resonance imaging and texture analysis allowed the 
identification of subtle differences in three dystrophic mouse models with variable 
degree of muscle involvement: the mdx mouse, with absence of the protein 
dystrophin, functionally and histologically mildly altered model for Duchenne 
muscular dystrophy; the Large
myd
 mouse, with defective glycosylation of the protein 
α-DG and severe phenotype, model for congenital muscular dystrophy 1D; and the 
double mutant mdx/Large
myd
, with both mutations and a very severe phenotype. 
Different patterns of distribution of muscle alterations according to the mutation 
could be detected in these murine models. Even if the images were acquired in a 2T 
magnet, this somewhat extends to murine models for muscle dystrophies what is 
observed in human patients, where the pattern of muscle involvement varies 
according to the primary genetic mutation. 
 In addition to the ability to identify different muscle phenotypes, these results 
reveal that NMR can be sensitive enough to identify pre-clinical alterations in mouse 
models for genetic muscle disorders even when no major phenotypical or histological 
changes can be detected. With functional multiparametric NMR, it was possible to 
detect age-related alterations in muscle blood perfusion in the widely studied mdx 
dystrophic mouse. These alterations could be observed even in young-adult mice, 
when no vascular alterations were visible in the histological analysis. The NMR data 
unraveled changes in the muscle function, raising questions about the impact of 
pericytes and vascular alterations in the dystrophy disease mechanisms.  
 Despite technical difficulties, NMR morphologic evaluation and relaxometry 
identified alterations in the KI-Dnm2
R465W
 mouse, model for autosomal dominant 
centronuclear myopathy, which presents only mild phenotypical and histological 
alterations. The continuation of the functional and metabolic evaluation of this mouse 
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model could put light on the disease mechanisms and the phenotypical differences in 
the mouse model when compared to human patients. 
 All the four evaluated murine models for genetic muscle disorders presented 
two common features: increased muscle T2 and absence of fat infiltration. This was 
observed even in early stages of muscle involvement, and in the presence of mild 
phenotypes such as the KI-Dnm2
R465W
 mouse. An increase in muscle T2 is also 
observed in dystrophic and in some myopathic patients, being related to necrosis and 
inflammation in early stages of muscle involvement, and to fat infiltration in late 
stages of the disease, when the degenerated muscle has been replaced by adipose 
tissue.  
 While the three studied dystrophic mice presented necrosis and an important 
inflammatory process, the mouse model to centronuclear myopathy displayed only 
altered distribution of organelles in the sarcoplasm, namely mitochondria and nuclei 
of a few percentage of muscle fibers. These observations support the hypothesis that 
even if no fat infiltration, necrosis or inflammation were observed in genetic muscle 
disorders, alterations in muscle structure and physiology could result in increased 
muscle T2. Despite the fact that increased muscle T2 could not be related to specific 
histopathological changes, it allowed the evaluation of muscle involvement at the 
tissue level, different from standard histological analyses that usually evaluate small 
muscle specimens.  
 Additionally, high resolution computed tomography was used in the search for 
alterations in the muscle of murine models for muscle dystrophies. Muscle atrophy 
could be detected in the dystrophic Large
myd
 and mdx/Large
myd
 mice. However, even 
if alterations in muscle X-ray opacity in human patients were already described, no 
differences could be observed in the intensity or heterogeneity of muscle signal in the 
dystrophic strains. In the acute phase after muscle injury in control mice, a tendency 
of reduced X-ray opacity may be present. These results support the hypothesis that 
major alterations, such as accentuated inflammation and edema, must be present to 
allow the identification of changes in muscle X-ray opacity in mice. In addition to the 
reduced dimensions, the absence of fat infiltration in the murine dystrophic muscle 
disabled the identification of differences in micro-CT signal intensity and 
heterogeneity. 
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 In summary, this thesis contributed to the expansion of the basic phenotypical 
characterization of mouse models for muscle genetic disorders with non-invasive 
techniques. This is an essential step prior to the use of non-invasive techniques as 
outcome measures in pre-clinical studies for therapeutic protocols. Because of its non-
traumatic and non-invasive character, these methods have great potential as outcome 
measure in pre-clinical studies in mouse models for genetic muscle disorders. In 
special, NMR gives reproducible, sensitive and objective results from morphological, 
functional and metabolic approaches, allowing early identification of subtle muscle 
alterations in longitudinal studies. This is highly valuable in clinical and pre-clinical 
therapeutic protocols, making it a good predictor of muscle functional improvement. 
 The translation of the non-invasive methods used in this thesis to human 
patients is almost direct. Non-invasive outcome measures are essential in clinical 
trials and in the follow-up of dystrophic and myopathic patients. Reducing invasive 
and painful proceedings such as biopsies can improve the quality of life for these 
patients, who can be already under severe disease conditions. In parallel to the 
development of new therapeutic approaches, there is an increasing interest in non-
invasive and non-traumatic tools to access any benefice in patients. 
 Finally, this thesis comprised an important transfer of knowledge in the field 
of non-invasive evaluation of murine models for genetic diseases. For the first time, 
the muscle of mouse models for different forms of genetic muscle diseases was 
evaluated non-invasively in Brazil with NMR and micro-CT, thanks to the close 
collaboration developed between the Brazilian and French research groups. 
 
 
 
 
 
 
 
 
 
 
 155 
 
Bibliography 
 
Ahmad, N., Welch, I., Grange, R., Hadway, J., Dhanvantari, S., Hill, D., Lee, T.-Y., 
and Hoffman, L.M. (2011). Use of imaging biomarkers to assess perfusion and 
glucose metabolism in the skeletal muscle of dystrophic mice. BMC Musculoskelet. 
Disord. 12, 127. 
Aleman, M., Riehl, J., Aldridge, B. M., Lecouteur, L. A., Stott, J. L. & Pessah, I. N. 
(2004) Association of a mutation in the ryanodine receptor 1 gene with equine 
malignant hyperthermia. Muscle & nerve. 30, 356–365. 
Allamand, V., and Campbell, K.P. (2000). Animal models for muscular dystrophy: 
valuable tools for the development of therapies. Hum. Mol. Genet. 9, 2459–2467. 
Amthor, H., Egelhof, T., McKinnell, I., Ladd, M.E., Janssen, I., Weber, J., Sinn, H., 
Schrenk, H.-H., Forsting, M., Voit, T., et al. (2004). Albumin targeting of damaged 
muscle fibres in the< i> mdx</i> mouse can be monitored by MRI. Neuromuscul. 
Disord. 14, 791–796. 
Ando, J., and Kamiya, A. (1992). Blood flow and vascular endothelial cell function. 
Front. Med. Biol. Eng. Int. J. Jpn. Soc. Med. Electron. Biol. Eng. 5, 245–264. 
Aoyagi, H., Iwasaki, S., and Nakamura, K. (2013). Three-dimensional observation of 
mouse tongue muscles using micro-computed tomography. Odontology 1–8. 
Arai, Y., Osawa, M., and Fukuyama, Y. (1995). Muscle CT scans in preclinical cases 
of Duchenne and Becker muscular dystrophy. Brain Dev. 17, 95–103. 
Araishi, K., Sasaoka, T., Imamura, M., Noguchi, S., Hama, H., Wakabayashi, E., 
Yoshida, M., Hori, T., and Ozawa, E. (1999). Loss of the sarcoglycan complex and 
sarcospan leads to muscular dystrophy in β-sarcoglycan-deficient mice. Hum. Mol. 
Genet. 8, 1589–1598. 
Araujo, E.C., Fromes, Y., and Carlier, P.G. (2014). New Insights on Human Skeletal 
Muscle Tissue Compartments Revealed by In Vivo T2 NMR Relaxometry. Biophys. 
J. 106, 2267–2274. 
Arpan, I., Forbes, S.C., Lott, D.J., Senesac, C.R., Daniels, M.J., Triplett, W.T., Deol, 
J.K., Sweeney, H.L., Walter, G.A., and Vandenborne, K. (2013). T2 mapping 
provides multiple approaches for the characterization of muscle involvement in 
neuromuscular diseases: a cross-sectional study of lower leg muscles in 5–15-year-old 
boys with Duchenne muscular dystrophy. NMR Biomed. 26, 320–328. 
Arsic, N., Zacchigna, S., Zentilin, L., Ramirez-Correa, G., Pattarini, L., Salvi, A., 
Sinagra, G., and Giacca, M. (2004). Vascular endothelial growth factor stimulates 
skeletal muscle regeneration in vivo. Mol. Ther. 10, 844–854. 
 156 
 
Asai, A., Sahani, N., Kaneki, M., Ouchi, Y., Martyn, J.J., and Yasuhara, S.E. (2007). 
Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, 
and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2, 
e806. 
Bachmann, G., Damian, M.S., Koch, M., Schilling, G., Fach, B., and Stöppler, S. 
(1996). The clinical and genetic correlates of MRI findings in myotonic dystrophy. 
Neuroradiology 38, 629–635. 
Badea, C.T., Bucholz, E., Hedlund, L.W., Rockman, H.A., and Johnson, G.A. (2006). 
Imaging methods for morphological and functional phenotyping of the rodent heart. 
Toxicol. Pathol. 34, 111–117. 
Bagher, P., Duan, D., and Segal, S.S. (2011). Evidence for impaired neurovascular 
transmission in a murine model of Duchenne muscular dystrophy. J. Appl. Physiol. 
110, 601–609. 
Baligand, C., Gilson, H., Menard, J.C., Schakman, O., Wary, C., Thissen, J.-P., and 
Carlier, P.G. (2009). Functional assessment of skeletal muscle in intact mice lacking 
myostatin by concurrent NMR imaging and spectroscopy. Gene Ther. 17, 328–337. 
Baligand, C., Wary, C., Menard, J.C., Giacomini, E., Hogrel, J.-Y., and Carlier, P.G. 
(2011). Measuring perfusion and bioenergetics simultaneously in mouse skeletal 
muscle: a multiparametric functional-NMR approach. NMR Biomed. 24, 281–290. 
Baligand, C., Jouvion, G., Schakman, O., Gilson, H., Wary, C., Thissen, J.-P., and 
Carlier, P.G. (2012). Multiparametric functional nuclear magnetic resonance imaging 
shows alterations associated with plasmid electrotransfer in mouse skeletal muscle. J. 
Gene Med. 14, 598–608. 
Barresi, R., and Campbell, K.P. (2006). Dystroglycan: from biosynthesis to 
pathogenesis of human disease. J. Cell Sci. 119, 199–207. 
Baverstock, H., Jeffery, N.S., and Cobb, S.N. (2013). The morphology of the mouse 
masticatory musculature. J. Anat. 223, 46–60. 
Beggs, A.H., Böhm, J., Snead, E., Kozlowski, M., Maurer, M., Minor, K., Childers, 
M.K., Taylor, S.M., Hitte, C., Mickelson, J.R., et al. (2010). MTM1 mutation 
associated with X-linked myotubular myopathy in Labrador Retrievers. Proc. Natl. 
Acad. Sci. 107, 14697–14702. 
Buj-Bello, A., Laugel, V., Messaddeq, N., Zahreddine, H., Laporte, J., Pellissier, J.-F., 
and Mandel, J.-L. (2002). The lipid phosphatase myotubularin is essential for skeletal 
muscle maintenance but not for myogenesis in mice. Proc. Natl. Acad. Sci. 99, 
15060–15065. 
Bertoldi, D., Loureiro de Sousa, P., Fromes, Y., Wary, C., and Carlier, P.G. (2008). 
Quantitative, dynamic and noninvasive determination of skeletal muscle perfusion in 
 157 
 
mouse leg by NMR arterial spin-labeled imaging. Magn. Reson. Imaging 26, 1259–
1265. 
Bilgen, C., Bilgen, I.G., and Sener, R.N. (2001). Oculopharyngeal muscular 
dystrophy: clinical and CT findings. Comput. Med. Imaging Graph. 25, 527–529. 
Bitoun, M., Maugenre, S., Jeannet, P.-Y., Lacène, E., Ferrer, X., Laforêt, P., Martin, 
J.-J., Laporte, J., Lochmüller, H., Beggs, A.H., et al. (2005). Mutations in dynamin 2 
cause dominant centronuclear myopathy. Nat. Genet. 37, 1207–1209. 
Bitoun, M., Bevilacqua, J.A., Prudhon, B., Maugenre, S., Taratuto, A.L., Monges, S., 
Lubieniecki, F., Cances, C., Uro-Coste, E., Mayer, M., et al. (2007). Dynamin 2 
mutations cause sporadic centronuclear myopathy with neonatal onset. Ann. Neurol. 
62, 666–670. 
Böhm, J., Vasli, N., Maurer, M., Cowling, B., Shelton, G.D., Kress, W., Toussaint, 
A., Prokic, I., Schara, U., Anderson, T.J., et al. (2013). Altered Splicing of the BIN1 
Muscle-Specific Exon in Humans and Dogs with Highly. PLoS Genet. 9, e003430. 
Boncompagni, S., Rossi, A.E., Micaroni, M., Hamilton, S.L., Dirksen, R.T., Franzini-
Armstrong, C., and Protasi, F. (2009). Characterization and temporal development of 
cores in a mouse model of malignant hyperthermia. Proc. Natl. Acad. Sci. 106, 
21996–22001. 
Borrelli, O., Salvia, G., Mancini, V., Santoro, L., Tagliente, F., Romeo, E.F., and 
Cucchiara, S. (2005). Evolution of gastric electrical features and gastric emptying in 
children with Duchenne and Becker muscular dystrophy. Am. J. Gastroenterol. 100, 
695–702. 
Bradley, W.G., O’Brien, M.D., Walder, D.N., Murchison, D., Johnson, M., and 
Newell, D.J. (1975). Failure to confirm a vascular cause of muscular dystrophy. Arch. 
Neurol. 32, 466. 
Brenman, J.E., Chao, D.S., Xia, H., Aldape, K., and Bredt, D.S. (1995). Nitric oxide 
synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in 
Duchenne muscular dystrophy. Cell 82, 743–752. 
Bresolin, N., Castelli, E., Comi, G.P., Felisari, G., Bardoni, A., Perani, D., Grassi, F., 
Turconi, A., Mazzucchelli, F., Gallotti, D., et al. (1994). Cognitive impairment in 
Duchenne muscular dystrophy. Neuromuscul. Disord. 4, 359–369. 
Brunelli, S., Sciorati, C., D’Antona, G., Innocenzi, A., Covarello, D., Galvez, B.G., 
Perrotta, C., Monopoli, A., Sanvito, F., Bottinelli, R., et al. (2007). Nitric oxide 
release combined with nonsteroidal antiinflammatory activity prevents muscular 
dystrophy pathology and enhances stem cell therapy. Proc. Natl. Acad. Sci. 104, 264–
269. 
Buckland, K.F., and Gaspar, B.H. (2014). Gene and cell therapy for children—New 
medicines, new challenges? Adv. Drug Deliv. Rev. 73, 162–169. 
 158 
 
Bulcke, J.A., Crolla, D., Termote, J.-L., Baert, A., Palmers, Y., and van den Bergh, R. 
(1981). Computed tomography of muscle. Muscle Nerve 4, 67–72. 
Bulfield, G., Siller, W.G., Wight, P.A., and Moore, K.J. (1984). X chromosome-
linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. 81, 1189–1192. 
Burch, T.G., Prewitt, R.L., and Law, P.K. (1981). In vivo morphometric analysis of 
muscle microcirculation in dystrophic mice. Muscle Nerve 4, 420–424. 
Carnwath, J.W., and Shotton, D.M. (1987). Muscular dystrophy in the< i> mdx</i> 
mouse: Histopathology of the soleus and extensor digitorum longus muscles. J. 
Neurol. Sci. 80, 39–54. 
Catteruccia, M., Fattori, F., Codemo, V., Ruggiero, L., Maggi, L., Tasca, G., Fiorillo, 
C., Pane, M., Berardinelli, A., Verardo, M., et al. (2013). Centronuclear myopathy 
related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic 
features of an Italian cohort. Neuromuscul. Disord. 23, 229–238. 
Childers, M.K., Joubert, R., Poulard, K., Moal, C., Grange, R.W., Doering, J.A., 
Lawlor, M.W., Rider, B.E., Jamet, T., Danièle, N., et al. (2014). Gene therapy 
prolongs survival and restores function in murine and canine models of myotubular 
myopathy. Sci. Transl. Med. 6, 220ra10. 
Christov, C., Chrétien, F., Abou-Khalil, R., Bassez, G., Vallet, G., Authier, F.-J., 
Bassaglia, Y., Shinin, V., Tajbakhsh, S., Chazaud, B., et al. (2007). Muscle satellite 
cells and endothelial cells: close neighbors and privileged partners. Mol. Biol. Cell 
18, 1397–1409. 
Claire, W., Naulet, T., Thibaud, J.-L., Monnet, A., Blot, S., and Carlier, P.G. (2012). 
Splitting of Pi and other 31P NMR anomalies of skeletal muscle metabolites in canine 
muscular dystrophy. NMR Biomed. 25, 1160–1169. 
Clifford, P.S., and Hellsten, Y. (2004). Vasodilatory mechanisms in contracting 
skeletal muscle. J. Appl. Physiol. 97, 393–403. 
Cole, M.A., Rafael, J.A., Taylor, D.J., Lodi, R., Davies, K.E., and Styles, P. (2002). A 
quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. 
Neuromuscul. Disord. 12, 247–257. 
Crosbie, R.H., Barresi, R., and Campbell, K.P. (2002). Loss of sarcolemma nNOS in 
sarcoglycan-deficient muscle. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 16, 
1786–1791. 
Dalkilic, I., and Kunkel, L.M. (2003). Muscular dystrophies: genes to pathogenesis. 
Curr. Opin. Genet. Dev. 13, 231–238. 
Dangain, J., and Vrbova, G. (1984). Muscle development in mdx mutant mice. 
Muscle Nerve 7, 700–704. 
 159 
 
Davies, K.E., and Nowak, K.J. (2006). Molecular mechanisms of muscular 
dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 7, 762–773. 
Deasy, B.M., Feduska, J.M., Payne, T.R., Li, Y., Ambrosio, F., and Huard, J. (2009). 
Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic 
skeletal muscle. Mol. Ther. 17, 1788–1798. 
Deconinck, N., and Dan, B. (2007). Pathophysiology of duchenne muscular 
dystrophy: current hypotheses. Pediatr. Neurol. 36, 1–7. 
Deconinck, A.E., Rafael, J.A., Skinner, J.A., Brown, S.C., Potter, A.C., Metzinger, 
L., Watt, D.J., Dickson, J.G., Tinsley, J.M., and Davies, K.E. (1997). Utrophin-
dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717–
727. 
Desguerre, I., Mayer, M., Leturcq, F., Barbet, J.-P., Gherardi, R.K., and Christov, C. 
(2009). Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor 
outcome associated with macrophage alternative activation. J. Neuropathol. Exp. 
Neurol. 68, 762–773. 
Detombe, S.A., Dunmore-Buyze, J., and Drangova, M. (2012). Evaluation of eXIA 
160XL cardiac-related enhancement in C57BL/6 and BALB/c mice using micro-CT. 
Contrast Media Mol. Imaging 7, 240–246. 
Dubowitz, V. (2004). Therapeutic efforts in Duchenne muscular dystrophy; the need 
for a common language between basic scientists and clinicians. Neuromuscul. Disord. 
14, 451–455. 
Dubowitz, V., Sewry, C.A., and Oldfors, A. (2013). Muscle Biopsy: A Practical 
Approach (Elsevier Health Sciences). 
Duclos, F., Straub, V., Moore, S.A., Venzke, D.P., Hrstka, R.F., Crosbie, R.H., 
Durbeej, M., Lebakken, C.S., Ettinger, A.J., Van Der Meulen, J., et al. (1998). 
Progressive muscular dystrophy in α-sarcoglycan–deficient mice. J. Cell Biol. 142, 
1461–1471. 
Dunn, J.F., and Zaim-Wadghiri, Y. (1999). Quantitative magnetic resonance imaging 
of the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve 22, 1367–
1371. 
Dunn, J.F., Frostick, S., Brown, G., and Radda, G.K. (1991). Energy status of cells 
lacking dystrophin: an in vivo/in vitro study of< i> mdx</i> mouse skeletal muscle. 
Biochim. Biophys. Acta BBA-Mol. Basis Dis. 1096, 115–120. 
Dunn, J.F., Tracey, I., and Radda, G.K. (1993). Exercise Metabolism in Duchenne 
Muscular Dystrophy: A Biochemical and 31P-nuclear Magnetic Resonance Study of 
mdx Mice. Proc. R. Soc. Lond. B Biol. Sci. 251, 201–206. 
 160 
 
Durieux, A.-C., Vignaud, A., Prudhon, B., Viou, M.T., Beuvin, M., Vassilopoulos, S., 
Fraysse, B., Ferry, A., Lainé, J., Romero, N.B., et al. (2010). A centronuclear 
myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. 
Hum. Mol. Genet. 19, 4820–4836. 
Duteil, S., Wary, C., Raynaud, J.S., Lebon, V., Lesage, D., Leroy-Willig, A., and 
Carlier, P.G. (2006). Influence of vascular filling and perfusion on BOLD contrast 
during reactive hyperemia in human skeletal muscle. Magn. Reson. Med. 55, 450–
454. 
Emery, A.E. (2002). The muscular dystrophies. The Lancet 359, 687–695. 
Engel, W.K. (1967). Muscle biopsies in neuromuscular diseases. Pediatr. Clin. North 
Am. 14, 963. 
Engel, W.K., and Hawley, R.J. (1977). Focal lesions of muscle in peripheral vascular 
disease. J. Neurol. 215, 161–168. 
Ennen, J.P., Verma, M., and Asakura, A. (2013). Vascular-targeted therapies for 
Duchenne muscular dystrophy. Skelet Muscle 3, 9. 
Ervasti, J.M., and Campbell, K.P. (1991). Membrane organization of the dystrophin-
glycoprotein complex. Cell 66, 1121–1131. 
Ervasti, J.M., and Campbell, K.P. (1993). A role for the dystrophin-glycoprotein 
complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809–
823. 
Fan, Z., Wang, J., Ahn, M., Shiloh-Malawsky, Y., Chahin, N., Elmore, S., Bagnell Jr, 
C.R., Wilber, K., An, H., Lin, W., et al. (2014). Characteristics of magnetic resonance 
imaging biomarkers in a natural history study of golden retriever muscular dystrophy. 
Neuromuscul. Disord. 24, 178–191. 
Fidziańska, A., Glinka, Z., and Walski, M. (1986). An ultrastructural study of the 
vascular and muscular basement membrane in Duchenne-type dystrophy. Clin. 
Neuropathol. 6, 257–261. 
Finanger, E.L., Russman, B., Forbes, S.C., Rooney, W.D., Walter, G.A., and 
Vandenborne, K. (2012). Use of skeletal muscle MRI in diagnosis and monitoring 
disease progression in Duchenne muscular dystrophy. Phys. Med. Rehabil. Clin. N. 
Am. 23, 1–10. 
Fischmann, A., Hafner, P., Fasler, S., Gloor, M., Bieri, O., Studler, U., and Fischer, 
D. (2012). Quantitative MRI can detect subclinical disease progression in muscular 
dystrophy. J. Neurol. 259, 1648–1654. 
Fischmann, A., Hafner, P., Gloor, M., Schmid, M., Klein, A., Pohlman, U., Waltz, T., 
Gonzalez, R., Haas, T., Bieri, O., et al. (2013). Quantitative MRI and loss of free 
ambulation in Duchenne muscular dystrophy. J. Neurol. 260, 969–974. 
 161 
 
Fugier, C., Klein, A.F., Hammer, C., Vassilopoulos, S., Ivarsson, Y., Toussaint, A., 
Tosch, V., Vignaud, A., Ferry, A., Messaddeq, N., et al. (2011). Misregulated 
alternative splicing of BIN1 is associated with T tubule alterations and muscle 
weakness in myotonic dystrophy. Nat. Med. 17, 720–725. 
Fujii, J., Otsu, K., Zorzato, F., de Leon, S., Khanna, V.K., Weiler, J.E., O’Brien, P.J., 
and Maclennan, D.H. (1991). Identification of a mutation in porcine ryanodine 
receptor associated with malignant hyperthermia. Science 253, 448–451. 
Gaeta, M., Messina, S., Mileto, A., Vita, G.L., Ascenti, G., Vinci, S., Bottari, A., 
Vita, G., Settineri, N., Bruschetta, D., et al. (2012). Muscle fat-fraction and mapping 
in Duchenne muscular dystrophy: evaluation of disease distribution and correlation 
with clinical assessments. Skeletal Radiol. 41, 955–961. 
Gatehouse, P.D., and Bydder, G.M. (2003). Magnetic Resonance Imaging of Short T< 
sub> 2</sub> Components in Tissue. Clin. Radiol. 58, 1–19. 
Gineste, C., Le Fur, Y., Vilmen, C., Le Troter, A., Pecchi, E., Cozzone, P.J., 
Hardeman, E.C., Bendahan, D., and Gondin, J. (2013a). Combined MRI and 31P-
MRS investigations of the ACTA1 (H40Y) mouse model of nemaline myopathy show 
impaired muscle function and altered energy metabolism. PloS One 8, e61517. 
Gineste, C., Duhamel, G., Le Fur, Y., Vilmen, C., Cozzone, P.J., Nowak, K.J., 
Bendahan, D., and Gondin, J. (2013b). Multimodal MRI and 31P-MRS Investigations 
of the ACTA1 (Asp286Gly) Mouse Model of Nemaline Myopathy Provide Evidence 
of Impaired In Vivo Muscle Function, Altered Muscle Structure and Disturbed 
Energy Metabolism. PloS One 8, e72294. 
Gineste, C., De Winter, J.M., Kohl, C., Witt, C.C., Giannesini, B., Brohm, K., Le Fur, 
Y., Gretz, N., Vilmen, C., Pecchi, E., et al. (2013c). < i> In vivo</i> and< i> in 
vitro</i> investigations of heterozygous nebulin knock-out mice disclose a mild 
skeletal muscle phenotype. Neuromuscul. Disord. 23, 357–369. 
Goodpaster, B.H., Carlson, C.L., Visser, M., Kelley, D.E., Scherzinger, A., Harris, 
T.B., Stamm, E., and Newman, A.B. (2001). Attenuation of skeletal muscle and 
strength in the elderly: The Health ABC Study. J. Appl. Physiol. 90, 2157–2165. 
Grady, R.M., Teng, H., Nichol, M.C., Cunningham, J.C., Wilkinson, R.S., and Sanes, 
J.R. (1997). Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: 
a model for Duchenne muscular dystrophy. Cell 90, 729–738. 
Gray, S.K., McGee-Lawrence, M.E., Sanders, J.L., Condon, K.W., Tsai, C.-J., and 
Donahue, S.W. (2012). Black bear parathyroid hormone has greater anabolic effects 
on trabecular bone in dystrophin-deficient mice than in wild type mice. Bone 51, 578–
585. 
Grewal, P.K., and Hewitt, J.E. (2002). Mutation of< i> Large</i>, which encodes a 
putative glycosyltransferase, in an animal model of muscular dystrophy. Biochim. 
Biophys. Acta BBA-Gen. Subj. 1573, 216–224. 
 162 
 
Grewal, P.K., Holzfeind, P.J., Bittner, R.E., and Hewitt, J.E. (2001). Mutant 
glycosyltransferase and altered glycosylation of α-dystroglycan in the myodystrophy 
mouse. Nat. Genet. 28, 151–154. 
Griffin, J.L., Williams, H.J., Sang, E., Clarke, K., Rae, C., and Nicholson, J.K. 
(2001). Metabolic Profiling of Genetic Disorders: A Multitissue< sup> 1</sup> H 
Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into 
Dystrophic Tissue. Anal. Biochem. 293, 16–21. 
Grindrod, S., Tofts, P., and Edwards, R. (1983). Investigation of human skeletal 
muscle structure and composition by X-ray computerised tomography. Eur. J. Clin. 
Invest. 13, 465–468. 
Grounds, M.D., Radley, H.G., Lynch, G.S., Nagaraju, K., and De Luca, A. (2008). 
Towards developing standard operating procedures for pre-clinical testing in the mdx 
mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 31, 1–19. 
Gudrun, B., Andrew, G.E., Boysen, G., and Engel, A.G. (1975). Effects of 
microembolization on the skeletal muscle blood flow. A critique of the microvascular 
occlusion model of Duchenne dystrophy. Acta Neurol. Scand. 52, 71–80. 
Gumerson, J.D., and Michele, D.E. (2011). The dystrophin-glycoprotein complex in 
the prevention of muscle damage. BioMed Res. Int. 2011, 210797. 
Gurniak, C.B., Chevessier, F., Jokwitz, M., Jönsson, F., Perlas, E., Richter, H., 
Matern, G., Boyl, P.P., Chaponnier, C., Fürst, D., et al. (2014). Severe protein 
aggregate myopathy in a knockout mouse model points to an essential role of cofilin2 
in sarcomeric actin exchange and muscle maintenance. Eur. J. Cell Biol. 93, 252–266. 
Hack, A.A., Ly, C.T., Jiang, F., Clendenin, C.J., Sigrist, K.S., Wollmann, R.L., and 
McNally, E.M. (1998). γ-Sarcoglycan deficiency leads to muscle membrane defects 
and apoptosis independent of dystrophin. J. Cell Biol. 142, 1279–1287. 
Hathaway, P.W., Engel, W.K., and Zellweger, H. (1970). Experimental myopathy 
after microarterial embolization: comparison with childhood X-linked 
pseudohypertrophic muscular dystrophy. Arch. Neurol. 22, 365–378. 
Heerschap, A., Bergman, A.H., Van Vaals, J.J., Wirtz, P., Loermans, H.M., and 
Veerkamp, J.H. (1988). Alterations in relative phosphocreatine concentrations in 
preclinical mouse muscular dystrophy revealed by in vivo NMR. NMR Biomed. 1, 
27–31. 
Heier, C.R., Guerron, A.D., Korotcov, A., Lin, S., Gordish-Dressman, H., Fricke, S., 
Sze, R.W., Hoffman, E.P., Wang, P., and Nagaraju, K. (2014). Non-Invasive MRI and 
Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging 
and in Energy Deficits. PloS One 9, e112477. 
Hepple, R.T. (1997). A new measurement of tissue capillarity: the capillary-to-fibre 
perimeter exchange index. Can. J. Appl. Physiol. 22, 11–22. 
 163 
 
Hoffman, E.P., Brown Jr, R.H., and Kunkel, L.M. (1987). Dystrophin: the protein 
product of the Duchenne muscular dystrophy locus. Cell 51, 919–928. 
Hsieh, T.-J., Jaw, T.-S., Chuang, H.-Y., Jong, Y.-J., Liu, G.-C., and Li, C.-W. (2009). 
Muscle metabolism in Duchenne muscular dystrophy assessed by in vivo proton 
magnetic resonance spectroscopy. J. Comput. Assist. Tomogr. 33, 150–154. 
Huang, Y., Majumdar, S., Genant, H.K., Chan, W.P., Sharma, K.R., Yu, P., Mynhier, 
M., and Miller, R.G. (1994). Quantitative MR relaxometry study of muscle 
composition and function in Duchenne muscular dystrophy. J. Magn. Reson. Imaging 
4, 59–64. 
Ichioka, S., Shibata, M., Kosaki, K., Sato, Y., Harii, K., and Kamiya MD, A. (1997). 
Effects of shear stress on wound-healing angiogenesis in the rabbit ear chamber. J. 
Surg. Res. 72, 29–35. 
Ishigaki, K., Yoshikawa, Y., Kuwatsuru, R., Oda, E., Murakami, T., Sato, T., Saito, 
T., Umezu, R., and Osawa, M. (2012). High-density CT of muscle and liver may 
allow early diagnosis of childhood-onset Pompe disease. Brain Dev. 34, 103–106. 
Jeffery, N.S., Stephenson, R.S., Gallagher, J.A., Jarvis, J.C., and Cox, P.G. (2011). 
Micro-computed tomography with iodine staining resolves the arrangement of muscle 
fibres. J. Biomech. 44, 189–192. 
Jiddane, M., Gastaut, J.L., Pellissier, J.F., Pouget, J., Serratrice, G., and Salamon, G. 
(1983). CT of primary muscle diseases. Am. J. Neuroradiol. 4, 773–776. 
Jungbluth, H., Wallgren-Pettersson, C., and Laporte, J. (2008). Centronuclear 
(myotubular) myopathy. Orphanet J Rare Dis 3, 26. 
Kabaeva, Z., Meekhof, K.E., and Michele, D.E. (2011). Sarcolemma instability 
during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan 
extracellular matrix receptor function. Hum. Mol. Genet. 20, 3346–3355. 
Kemp, G.J., Taylor, D.J., Dunn, J.F., Frostick, S.P., and Radda, G.K. (1993). Cellular 
energetics of dystrophic muscle. J. Neurol. Sci. 116, 201–206. 
Kim, H.K., Laor, T., Horn, P.S., Racadio, J.M., Wong, B., and Dardzinski, B.J. 
(2010). T2 Mapping in Duchenne Muscular Dystrophy: Distribution of Disease 
Activity and Correlation with Clinical Assessments 1. Radiology 255, 899–908. 
Kinali, M., Arechavala-Gomeza, V., Cirak, S., Glover, A., Guglieri, M., Feng, L., 
Hollingsworth, K.G., Hunt, D., Jungbluth, H., Roper, H.P., et al. (2011). Muscle 
histology vs MRI in Duchenne muscular dystrophy. Neurology 76, 346–353. 
Kobzik, L., Reid, M.B., Bredt, D.S., and Stamler, J.S. (1994). Nitric oxide in skeletal 
muscle. Nature 372, 546–548. 
Koehler, J. (1977). Blood vessel structure in Duchenne muscular dystrophy. I. Light 
and electron microscopic observations in resting muscle. Neurology 27, 861–861. 
 164 
 
Kuang, W., Xu, H., Vachon, P.H., Liu, L., Loechel, F., Wewer, U.M., and Engvall, E. 
(1998). Merosin-deficient congenital muscular dystrophy. Partial genetic correction in 
two mouse models. J. Clin. Invest. 102, 844–852. 
Lamminen, A.E. (1990). Magnetic resonance imaging of primary skeletal muscle 
diseases: patterns of distribution and severity of involvement. Br. J. Radiol. 63, 946–
950. 
Landisch, R.M., Kosir, A.M., Nelson, S.A., Baltgalvis, K.A., and Lowe, D.A. (2008). 
Adaptive and nonadaptive responses to voluntary wheel running by mdx mice. 
Muscle Nerve 38, 1290–1293. 
Lane, P.W., Beamer, T.C., and Myers, D.D. (1975). Myodystrophy, a new myopathy 
on chromosome 8 of the mouse. J. Hered. 67, 135–138. 
Lawlor, M.W., Alexander, M.S., Viola, M.G., Meng, H., Joubert, R., Gupta, V., 
Motohashi, N., Manfready, R.A., Hsu, C.P., Huang, P., et al. (2012). Myotubularin-
deficient myoblasts display increased apoptosis, delayed proliferation, and poor cell 
engraftment. Am. J. Pathol. 181, 961–968. 
Lederlin, M., Ozier, A., Dournes, G., Ousova, O., Girodet, P.-O., Begueret, H., 
Marthan, R., Montaudon, M., Laurent, F., and Berger, P. (2012). In vivo micro-CT 
assessment of airway remodeling in a flexible OVA-sensitized murine model of 
asthma. PloS One 7, e48493. 
Lee, K.H., Baek, M.Y., Moon, K.Y., Song, W.K., Chung, C.H., Ha, D.B., and Kang, 
M.-S. (1994). Nitric oxide as a messenger molecule for myoblast fusion. J. Biol. 
Chem. 269, 14371–14374. 
Leinonen, H., Juntunen, J., Somer, H., and Rapola, J. (1979). Capillary circulation 
and morphology in Duchenne muscular dystrophy. Eur. Neurol. 18, 249–255. 
Leroy-Willig, A., Willig, T.N., Henry-Feugeas, M.C., Frouin, V., Marinier, E., 
Boulier, A., Barzic, F., Schouman-Claeys, E., and Syrota, A. (1997). Body 
composition determined with MR in patients with Duchenne muscular dystrophy, 
spinal muscular atrophy, and normal subjects. Magn. Reson. Imaging 15, 737–744. 
Liu, G.C., Jong, Y.J., Chiang, C.H., and Jaw, T.-S. (1993). Duchenne muscular 
dystrophy: MR grading system with functional correlation. Radiology 186, 475–480. 
Lodi, R., Muntoni, F., Taylor, J., Kumar, S., Sewry, C.A., Blamire, A., Styles, P., and 
Taylor, D.J. (1997). Correlative MR imaging and< sup> 31</sup> P-MR 
spectroscopy study in sarcoglycan deficient limb girdle muscular dystrophy. 
Neuromuscul. Disord. 7, 505–511. 
Lodi, R., Kemp, G.J., Muntoni, F., Thompson, C.H., Rae, C., Taylor, J., Styles, P., 
and Taylor, D.J. (1999). Reduced cytosolic acidification during exercise suggests 
defective glycolytic activity in skeletal muscle of patients with Becker muscular 
 165 
 
dystrophy An in vivo 31P magnetic resonance spectroscopy study. Brain 122, 121–
130. 
Lopez, M.A., Pardo, P.S., Cox, G.A., and Boriek, A.M. (2008). Early mechanical 
dysfunction of the diaphragm in the muscular dystrophy with myositis (Ttnmdm) 
model. Am. J. Physiol.-Cell Physiol. 295, C1092–C1102. 
Loufrani, L., Matrougui, K., Gorny, D., Duriez, M., Blanc, I., Lévy, B.I., and Henrion, 
D. (2001). Flow (shear stress)–induced endothelium-dependent dilation is altered in 
mice lacking the gene encoding for dystrophin. Circulation 103, 864–870. 
Loufrani, L., Dubroca, C., You, D., Li, Z., Levy, B., Paulin, D., and Henrion, D. 
(2004). Absence of dystrophin in mice reduces NO-dependent vascular function and 
vascular density: total recovery after a treatment with the aminoglycoside gentamicin. 
Arterioscler. Thromb. Vasc. Biol. 24, 671–676. 
Love, D.R., Byth, B.C., Tinsley, J.M., Blake, D.J., and Davies, K.E. (1993). 
Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. 
Neuromuscul. Disord. 3, 5–21. 
Mahmoud-Ghoneim, D., Cherel, Y., Lemaire, L., de Certaines, J.D., and Maniere, A. 
(2006). Texture analysis of magnetic resonance images of rat muscles during atrophy 
and regeneration. Magn. Reson. Imaging 24, 167–171. 
Manske, S.L., Boyd, S.K., and Zernicke, R.F. (2010). Muscle and bone follow similar 
temporal patterns of recovery from muscle-induced disuse due to botulinum toxin 
injection. Bone 46, 24–31. 
Manske, S.L., Good, C.A., Zernicke, R.F., and Boyd, S.K. (2012). High-frequency, 
low-magnitude vibration does not prevent bone loss resulting from muscle disuse in 
mice following botulinum toxin injection. PloS One 7, e36486. 
Marden, F.A., Connolly, A.M., Siegel, M.J., and Rubin, D.A. (2005). Compositional 
analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. 
Skeletal Radiol. 34, 140–148. 
Martins, P.C., Ayub-Guerrieri, D., Martins-Bach, A.B., Onofre-Oliveira, P., 
Malheiros, J.M., Tannus, A., de Sousa, P.L., Carlier, P.G., and Vainzof, M. (2013). 
Dmdmdx/Largemyd: a new mouse model of neuromuscular diseases useful for 
studying physiopathological mechanisms and testing therapies. Dis. Model. Mech. 6, 
1167–1174. 
Mathur, S., Vohra, R.S., Germain, S.A., Forbes, S., Bryant, N.D., Vandenborne, K., 
and Walter, G.A. (2011). Changes in muscle T2 and tissue damage after downhill 
running in mdx mice. Muscle Nerve 43, 878–886. 
Matsakas, A., Yadav, V., Lorca, S., and Narkar, V. (2013). Muscle ERRγ mitigates 
Duchenne muscular dystrophy via metabolic and angiogenic reprogramming. FASEB 
J. 27, 4004–4016. 
 166 
 
Mavrogeni, S., Papavasiliou, A., Douskou, M., Kolovou, G., Papadopoulou, E., and 
Cokkinos, D.V. (2009). Effect of deflazacort on cardiac and sternocleidomastoid 
muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study. Eur. 
J. Paediatr. Neurol. 13, 34–40. 
McIntosh, L., Granberg, K.-E., Brière, K.M., and Anderson, J.E. (1998a). Nuclear 
magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and 
glucocorticoid treatments: correlation with repair. NMR Biomed. 11, 1–10. 
McIntosh, L.M., Baker, R.E., and Anderson, J.E. (1998b). Magnetic resonance 
imaging of regenerating and dystrophic mouse muscle. Biochem. Cell Biol. 76, 532–
541. 
Mendell, J.R., Engel, W.K., and Derrer, E.C. (1971). Duchenne muscular dystrophy: 
functional ischemia reproduces its characteristic lesions. Science 172, 1143–1145. 
Mercuri, E., and Muntoni, F. (2012). The ever-expanding spectrum of congenital 
muscular dystrophies. Ann. Neurol. 72, 9–17. 
Mercuri, E., Pichiecchio, A., Allsop, J., Messina, S., Pane, M., and Muntoni, F. 
(2007). Muscle MRI in inherited neuromuscular disorders: past, present, and future. J. 
Magn. Reson. Imaging 25, 433–440. 
Messina, S., Mazzeo, A., Bitto, A., Aguennouz, M., Migliorato, A., De Pasquale, 
M.G., Minutoli, L., Altavilla, D., Zentilin, L., Giacca, M., et al. (2007). VEGF 
overexpression via adeno-associated virus gene transfer promotes skeletal muscle 
regeneration and enhances muscle function in mdx mice. FASEB J. 21, 3737–3746. 
Metscher, B.D. (2009). MicroCT for comparative morphology: simple staining 
methods allow high-contrast 3D imaging of diverse non-mineralized animal tissues. 
BMC Physiol. 9, 11. 
Miike, T. (1983). Maturational defect of regenerating muscle fibers in cases with 
Duchenne and congenital muscular dystrophies. Muscle Nerve 6, 545–552. 
Miike, T., Sugino, S., Ohtani, Y., Taku, K., and Yoshioka, K. (1987). Vascular 
endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the 
preclinical stage. J. Neurol. Sci. 82, 67–80. 
Mirabella, M., Servidei, S., Manfredi, G., Ricci, E., Frustaci, A., Bertini, E., Rana, 
M., and Tonali, P. (1993). Cardiomyopathy may be the only clinical manifestation in 
female carriers of Duchenne muscular dystrophy. Neurology 43, 2342–2342. 
Mitsuhashi, S., and Kang, P.B. (2012). Update on the genetics of limb girdle muscular 
dystrophy. Semin. Pediatr. Neurol. 19, 211–218. 
Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., 
Nabeshima, Y., and Takeda, S. (1997). Laminin α2 chain-null mutant mice by 
 167 
 
targeted disruption of the< i> Lama2</i> gene: a new model of merosin (laminin 2)-
deficient congenital muscular dystrophy. FEBS Lett. 415, 33–39. 
Miyatake, M., Miike, T., Zhao, J., Yoshioka, K., Uchino, M., and Usuku, G. (1989). 
Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin 
in Duchenne muscular dystrophy. J. Neurol. Sci. 93, 11–17. 
Moore, C.J., and Winder, S.J. (2012). The inside and out of dystroglycan post-
translational modification. Neuromuscul. Disord. 22, 959–965. 
Muller, J., Vayssiere, N., Royuela, M., Leger, M.E., Muller, A., Bacou, F., Pons, F., 
Hugon, G., and Mornet, D. (2001). Comparative evolution of muscular dystrophy in 
diaphragm, gastrocnemius and masseter muscles from old male mdx mice. J. Muscle 
Res. Cell Motil. 22, 133–139. 
Muntoni, F., Mateddu, A., Marchei, F., Clerk, A., and Serra, G. (1993). Muscular 
weakness in the< i> mdx</i> mouse. J. Neurol. Sci. 120, 71–77. 
Muntoni, F., Torelli, S., and Brockington, M. (2008). Muscular dystrophies due to 
glycosylation defects. Neurotherapeutics 5, 627–632. 
Nakayama, T., Kuru, S., Okura, M., Motoyoshi, Y., and Kawai, M. (2013a). 
Estimation of net muscle volume in patients with muscular dystrophy using muscle 
CT for prospective muscle volume analysis: an observational study. BMJ Open 3, 
e003603. 
Nakayama, T., Kuru, S., and Kawai, M. (2013b). Analysis using histograms of muscle 
CT images in patients with Duchenne muscular dystrophy. BMJ Case Rep. 2013, 
bcr2013009301. 
Nance, J.R., Dowling, J.J., Gibbs, E.M., and Bönnemann, C.G. (2012). Congenital 
myopathies: an update. Curr. Neurol. Neurosci. Rep. 12, 165–174. 
Newman, R.J., Bore, P.J., Chan, L., Gadian, D.G., Styles, P., Taylor, D., and Radda, 
G.K. (1982). Nuclear magnetic resonance studies of forearm muscle in Duchenne 
dystrophy. Br. Med. J. (Clin. Res. Ed.) 284, 1072–1074. 
Nguyen, F., Guigand, L., Goubault-Leroux, I., Wyers, M., and Cherel, Y. (2005). 
Microvessel density in muscles of dogs with golden retriever muscular dystrophy. 
Neuromuscul. Disord. 15, 154–163. 
Nigro, G., Comi, L.I., Politano, L., and Bain, R.J.I. (1990). The incidence and 
evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 
271–277. 
Nketiah, G., Savio, S., Dastidar, P., Nikander, R., Eskola, H., and Sievänen, H. 
(2014). Detection of exercise load-associated differences in hip muscles by texture 
analysis. Scand. J. Med. Sci. Sports. Epub ahead of print. 
 168 
 
Novotny, S.A., Warren, G.L., Lin, A.S., Guldberg, R.E., Baltgalvis, K.A., and Lowe, 
D.A. (2011). Bone is functionally impaired in dystrophic mice but less so than 
skeletal muscle. Neuromuscul. Disord. 21, 183–193. 
Novotny, S.A., Warren, G.L., Lin, A.S., Guldberg, R.E., Baltgalvis, K.A., and Lowe, 
D.A. (2012). Prednisolone treatment and restricted physical activity further 
compromise bone of mdx mice. J. Musculoskelet. Neuronal Interact. 12, 16–23. 
Novotny, S.A., Mader, T.L., Greising, A.G., Lin, A.S., Guldberg, R.E., Warren, G.L., 
and Lowe, D.A. (2014). Low intensity, high frequency vibration training to improve 
musculoskeletal function in a mouse model of duchenne muscular dystrophy. PloS 
One 9, e104339. 
Odintsov, B., Chun, J.L., and Berry, S.E. (2013). Whole body MRI and fluorescent 
microscopy for detection of stem cells labeled with superparamagnetic iron oxide 
(SPIO) nanoparticles and DiI following intramuscular and systemic delivery. In 
Imaging and Tracking Stem Cells, (Springer), pp. 177–193. 
Ohlendieck, K., and Campbell, K.P. (1991). Dystrophin-associated proteins are 
greatly reduced in skeletal muscle from mdx mice. J. Cell Biol. 115, 1685–1694. 
Ottenheijm, C.A., Buck, D., de Winter, J.M., Ferrara, C., Piroddi, N., Tesi, C., Jasper, 
J.R., Malik, F.I., Meng, H., Stienen, G.J., et al. (2013). Deleting exon 55 from the 
nebulin gene induces severe muscle weakness in a mouse model for nemaline 
myopathy. Brain 136, 1718–1731. 
Pacak, C.A., Walter, G.A., Gaidosh, G., Bryant, N., Lewis, M.A., Germain, S., Mah, 
C.S., Campbell, K.P., and Byrne, B.J. (2007). Long-term skeletal muscle protection 
after gene transfer in a mouse model of LGMD-2D. Mol. Ther. 15, 1775–1781. 
De Paepe, B., and De Bleecker, J.L. (2013). Cytokines and chemokines as regulators 
of skeletal muscle inflammation: presenting the case of Duchenne muscular 
dystrophy. Mediators Inflamm. 2013, 540370. 
Paik, S.-H., Kim, W.-K., Park, J.-S., Park, C.-S., and Jin, G.-Y. (2014). A 
Quantitative Study of Airway Changes on Micro-CT in a Mouse Asthma Model: 
Comparison With Histopathological Findings. Allergy Asthma Immunol. Res. 6, 75–
82. 
Palladino, M., Gatto, I., Neri, V., Straino, S., Smith, R.C., Silver, M., Gaetani, E., 
Marcantoni, M., Giarretta, I., Stigliano, E., et al. (2013). Angiogenic Impairment of 
the Vascular Endothelium A Novel Mechanism and Potential Therapeutic Target in 
Muscular Dystrophy. Arterioscler. Thromb. Vasc. Biol. 33, 2867–2876. 
Papoti, D. (2006). Transdutores de RF para experimentos de imagens de pequenos 
animais. Universidade de São Paulo. 
Paradas, C., Llauger, J., Diaz-Manera, J., Rojas-Garcia, R., De Luna, N., Iturriaga, C., 
Márquez, C., Usón, M., Hankiewicz, K., Gallardo, E., et al. (2010). Redefining 
 169 
 
dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. 
Neurology 75, 316–323. 
Pastoret, C., and Sebille, A. (1995). < i> mdx</i> mice show progressive weakness 
and muscle deterioration with age. J. Neurol. Sci. 129, 97–105. 
Pelé, M., Tiret, L., Kessler, J.-L., Blot, S., and Panthier, J.-J. (2005). SINE exonic 
insertion in the PTPLA gene leads to multiple splicing defects and segregates with the 
autosomal recessive centronuclear myopathy in dogs. Hum. Mol. Genet. 14, 1417–
1427. 
Percival, J.M., Siegel, M.P., Knowels, G., and Marcinek, D.J. (2013). Defects in 
mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne 
muscular dystrophy are not alleviated by PDE5 inhibition. Hum. Mol. Genet. 22, 
153–167. 
Pichiecchio, A., Uggetti, C., Egitto, M., Berardinelli, A., Orcesi, S., Gorni, K., 
Zanardi, C., and Tagliabue, A. (2002). Quantitative MR evaluation of body 
composition in patients with Duchenne muscular dystrophy. Eur. Radiol. 12, 2704–
2709. 
Pierson, C.R., Dulin-Smith, A.N., Durban, A.N., Marshall, M.L., Marshall, J.T., 
Snyder, A.D., Naiyer, N., Gladman, J.T., Chandler, D.S., Lawlor, M.W., et al. (2012). 
Modeling the human MTM1 p. R69C mutation in murine Mtm1 results in exon 4 
skipping and a less severe myotubular myopathy phenotype. Hum. Mol. Genet. 21, 
811–825. 
Poliachik, S.L., Friedman, S.D., Carter, G.T., Parnell, S.E., and Shaw, D.W. (2012). 
Skeletal muscle edema in muscular dystrophy: clinical and diagnostic implications. 
Phys. Med. Rehabil. Clin. N. Am. 23, 107–122. 
Pratt, S.J., Xu, S., Mullins, R.J., and Lovering, R.M. (2013). Temporal changes in 
magnetic resonance imaging in the mdx mouse. BMC Res. Notes 6, 262. 
Quijano-Roy, S., Carlier, R.Y., and Fischer, D. (2011). Muscle imaging in congenital 
myopathies. Semin. Pediatr. Neurol. 18, 221–229. 
Quijano-Roy, S., Avila-Smirnow, D., and Carlier, R.Y. (2012). Whole body muscle 
MRI protocol: pattern recognition in early onset NM disorders. Neuromuscul. Disord. 
22, S68–S84. 
Rae, C., Scott, R.B., Thompson, C.H., Dixon, R.M., Dumughn, I., J Kemp, G., Male, 
A., Pike, M., Styles, P., and Radda, G.K. (1998). Brain biochemistry in Duchenne 
muscular dystrophy: A< sup> 1</sup> H magnetic resonance and neuropsychological 
study. J. Neurol. Sci. 160, 148–157. 
Rando, T.A. (2001a). The dystrophin–glycoprotein complex, cellular signaling, and 
the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24, 1575–
1594. 
 170 
 
Rando, T.A. (2001b). Role of nitric oxide in the pathogenesis of muscular 
dystrophies: a ―two hit‖ hypothesis of the cause of muscle necrosis. Microsc. Res. 
Tech. 55, 223–235. 
Ravenscroft, G., Jackaman, C., Bringans, S., Papadimitriou, J.M., Griffiths, L.M., 
McNamara, E., Bakker, A.J., Davies, K.E., Laing, N.G., and Nowak, K.J. (2011). 
Mouse models of dominant ACTA1 disease recapitulate human disease and provide 
insight into therapies. Brain 134, 1101–1115. 
Raynaud, J.S., Duteil, S., Vaughan, J.T., Hennel, F., Wary, C., Leroy-Willig, A., and 
Carlier, P.G. (2001). Determination of skeletal muscle perfusion using arterial spin 
labeling NMRI: validation by comparison with venous occlusion plethysmography. 
Magn. Reson. Med. 46, 305–311. 
Razek, A.A., Kandell, A.Y., Elsorogy, L.G., Elmongy, A., and Basett, A.A. (2009). 
Disorders of cortical formation: MR imaging features. Am. J. Neuroradiol. 30, 4–11. 
Rederstorff, M., Castets, P., Arbogast, S., Lainé, J., Vassilopoulos, S., Beuvin, M., 
Dubourg, O., Vignaud, A., Ferry, A., Krol, A., et al. (2011). Increased muscle stress-
sensitivity induced by selenoprotein N inactivation in mouse: a mammalian model for 
SEPN1-related myopathy. PloS One 6, e23094. 
Rickards, D., Isherwood, I., Hutchinson, R., Gibbs, A., and Cumming, W.J.K. (1982). 
Computed tomography in dystrophia myotonica. Neuroradiology 24, 27–31. 
Rittweger, J., Möller, K., Bareille, M.-P., Felsenberg, D., and Zange, J. (2013). 
Muscle X-ray attenuation is not decreased during experimental bed rest. Muscle 
Nerve 47, 722–730. 
Roberts, C.K., Barnard, R.J., Scheck, S.H., and Balon, T.W. (1997). Exercise-
stimulated glucose transport in skeletal muscle is nitric oxide dependent. Am. J. 
Physiol.-Endocrinol. Metab. 36, E220–E225. 
Roberts, M.C., Mickelson, J.R., Patterson, E.E., Nelson, T.E., Armstrong, P.J., 
Brunson, D.B., and Hogan, K. (2001). Autosomal dominant canine malignant 
hyperthermia is caused by a mutation in the gene encoding the skeletal muscle 
calcium release channel (RYR1). Anesthesiology 95, 716–725. 
Romero, N.B., and Clarke, N.F. (2012). Congenital myopathies. Handb. Clin. Neurol. 
113, 1321–1336. 
Rudroff, T., Weissman, J.A., Bucci, M., Seppänen, M., Kaskinoro, K., Heinonen, I., 
and Kalliokoski, K.K. (2014). Positron emission tomography detects greater blood 
flow and less blood flow heterogeneity in the exercising skeletal muscles of old 
compared with young men during fatiguing contractions. J. Physiol. 592, 337–349. 
Saab, G., Thompson, R.T., and Marsh, G.D. (1999). Multicomponent T2 relaxation of 
in vivo skeletal muscle. Magn. Reson. Med. 42, 150–157. 
 171 
 
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., 
Delp, S., Pomerantz, J.H., Artandi, S.E., et al. (2010). Short telomeres and stem cell 
exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059–
1071. 
Salimena, M.C., Lagrota-Candido, J., and Quírico-Santos, T. (2000). Gender 
dimorphism influences extracellular matrix expression and regeneration of muscular 
tissue in mdx dystrophic mice. Histochem. Cell Biol. 122, 435–444. 
Sander, M., Chavoshan, B., Harris, S.A., Iannaccone, S.T., Stull, J.T., Thomas, G.D., 
and Victor, R.G. (2000). Functional muscle ischemia in neuronal nitric oxide 
synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. 
Proc. Natl. Acad. Sci. 97, 13818–13823. 
Schatzberg, S.J., Olby, N.J., Breen, M., Anderson, L.V., Langford, C.F., Dickens, 
H.F., Wilton, S.D., Zeiss, C.J., Binns, M.M., Kornegay, J.N., et al. (1999). Molecular 
analysis of a spontaneous dystrophinknockout’dog. Neuromuscul. Disord. 9, 289–
295. 
Schessl, J., Medne, L., Hu, Y., Zou, Y., Brown, M.J., Huse, J.T., Torigian, D.A., 
Jungbluth, H., Goebel, H.-H., and Bönnemann, C.G. (2007). MRI in< i> DNM2</i>-
related centronuclear myopathy: Evidence for highly selective muscle involvement. 
Neuromuscul. Disord. 17, 28–32. 
Schmidt, S., Vieweger, A., Obst, M., Mueller, S., Gross, V., Gutberlet, M., 
Steinbrink, J., Taubert, S., Misselwitz, B., Luedemann, L., et al. (2009). Dysferlin-
deficient Muscular Dystrophy: Gadofluorine M Suitability at MR Imaging in a Mouse 
Model 1. Radiology 250, 87–94. 
Schwartz, M.S., Swash, M., Ingram, D.A., Davis, G.R., Thompson, A.J., Thakkar, C., 
and Hart, G. (1988). Patterns of selective involvement of thigh muscles in 
neuromuscular disease. Muscle Nerve 11, 1240–1245. 
Schwenzer, N.F., Martirosian, P., Machann, J., Schraml, C., Steidle, G., Claussen, 
C.D., and Schick, F. (2009). Aging effects on human calf muscle properties assessed 
by MRI at 3 Tesla. J. Magn. Reson. Imaging 29, 1346–1354. 
Sewry, C.A., Jimenez-Mallebrera, C., and Muntoni, F. (2008). Congenital 
myopathies. Curr. Opin. Neurol. 21, 569–575. 
Shelton, G.D., and Engvall, E. (2005). Canine and feline models of human inherited 
muscle diseases. Neuromuscul. Disord. 15, 127–138. 
Shichiji, M., Biancalana, V., Fardeau, M., Hogrel, J.-Y., Osawa, M., Laporte, J., and 
Romero, N.B. (2013). Extensive morphological and immunohistochemical 
characterization in myotubular myopathy. Brain Behav. 3, 476–486. 
Shieh, P.B. (2013). Muscular dystrophies and other genetic myopathies. Neurol. Clin. 
31, 1009–1029. 
 172 
 
Shimatsu, Y., Katagiri, K., Furuta, T., Nakura, M., Tanioka, Y., Yuasa, K., Tomohiro, 
M., Kornegay, J.N., Nonaka, I., and Takeda, S. (2003). Canine X-linked muscular 
dystrophy in Japan (CXMDJ). Exp. Anim. 52, 93–97. 
Shimizu-Motohashi, Y., and Asakura, A. (2014). Angiogenesis as a novel therapeutic 
strategy for Duchenne muscular dystrophy through decreased ischemia and increased 
satellite cells. Front. Physiol. 5, 50. 
Sicinski, P., Geng, Y., Ryder-Cook, Al.S., Barnard, E.A., Darlison, M.G., and 
Barnard, P.J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a 
point mutation. Science 244, 1578–1580. 
Škoch, A., Jirák, D., Vyhnanovská, P., Dezortová, M., Fendrych, P., Rolencová, E., 
and Hájek, M. (2004). Classification of calf muscle MR images by texture analysis. 
Magn. Reson. Mater. Phys. Biol. Med. 16, 259–267. 
Stedman, H.H., Sweeney, H.L., Shrager, J.B., Maguire, H.C., Panettieri, R.A., Petrof, 
B., Narusawa, M., Leferovich, J.M., Sladky, J.T., and Kelly, A.M. (1991). The mdx 
mouse diaphragm reproduces the degenerative changes of Duchenne muscular 
dystrophy. Nature 352, 536–539. 
Stern, L.M., Caudrey, D.J., Perrett, L.V., and Boldt, D.W. (1984). Progression of 
muscular dystrophy assessed by computed tomography. Dev. Med. Child Neurol. 26, 
569–573. 
Straino, S., Germani, A., Di Carlo, A., Porcelli, D., De Mori, R., Mangoni, A., 
Napolitano, M., Martelli, F., Biglioli, P., and Capogrossi, M.C. (2004). Enhanced 
arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 110, 
3341–3348. 
Straub, V., and Campbell, K.P. (1997). Muscular dystrophies and the dystrophin-
glycoprotein complex. Curr. Opin. Neurol. 10, 168–175. 
Straub, V., Rafael, J.A., Chamberlain, J.S., and Campbell, K.P. (1997). Animal 
models for muscular dystrophy show different patterns of sarcolemmal disruption. J. 
Cell Biol. 139, 375–385. 
Straub, V., Duclos, F., Venzke, D.P., Lee, J.C., Cutshall, S., Leveille, C.J., and 
Campbell, K.P. (1998). Molecular pathogenesis of muscle degeneration in the δ-
sarcoglycan-deficient hamster. Am. J. Pathol. 153, 1623–1630. 
Straub, V., Donahue, K.M., Allamand, V., Davisson, R.L., Kim, Y.R., and Campbell, 
K.P. (2000). Contrast agent-enhanced magnetic resonance imaging of skeletal muscle 
damage in animal models of muscular dystrophy. Magn. Reson. Med. 44, 655–659. 
Strzelecki, M., Szczypinski, P., Materka, A., and Klepaczko, A. (2013). A software 
tool for automatic classification and segmentation of 2D/3D medical images. Nucl. 
Instrum. Methods Phys. Res. Sect. Accel. Spectrometers Detect. Assoc. Equip. 702, 
137–140. 
 173 
 
Susman, R.D., Quijano-Roy, S., Yang, N., Webster, R., Clarke, N.F., Dowling, J., 
Kennerson, M., Nicholson, G., Biancalana, V., Ilkovski, B., et al. (2010). Expanding 
the clinical, pathological and MRI phenotype of< i> DNM2</i>-related centronuclear 
myopathy. Neuromuscul. Disord. 20, 229–237. 
Swash, M., Brown, M.M., and Thakkar, C. (1995). CT muscle imaging and the 
clinical assessment of neuromuscular disease. Muscle Nerve 18, 708–714. 
Szczypinski, P.M., Strzelecki, M., and Materka, A. (2007). Mazda-a software for 
texture analysis. In 2007 International Simposium of Information Technology 
Convergence, (IEEE), pp. 245–249. 
Szczypiński, P.M., Strzelecki, M., Materka, A., and Klepaczko, A. (2009). MaZda—
A software package for image texture analysis. Comput. Methods Programs Biomed. 
94, 66–76. 
Tanabe, Y., Esaki, K., and Nomura, T. (1986). Skeletal muscle pathology in X 
chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol. (Berl.) 69, 
91–95. 
Tardif-de Géry, S., Vilquin, J.-T., Carlier, P., Raynaud, J.-S., Wary, C., Schwartz, K., 
and Leroy-Willig, A. (2000). Muscular transverse relaxation time measurement by 
magnetic resonance imaging at 4 Tesla in normal and dystrophic< i> dy</i>/< i> 
dy</i> and< i> dy2j</i>/< i> dy2j</i> mice. Neuromuscul. Disord. 10, 507–513. 
Tasca, G., Monforte, M., Iannaccone, E., Laschena, F., Ottaviani, P., Silvestri, G., 
Masciullo, M., Mirabella, M., Servidei, S., and Ricci, E. (2012a). Muscle MRI in 
female carriers of dystrophinopathy. Eur. J. Neurol. 19, 1256–1260. 
Tasca, G., Iannaccone, E., Monforte, M., Masciullo, M., Bianco, F., Laschena, F., 
Ottaviani, P., Pelliccioni, M., Pane, M., Mercuri, E., et al. (2012b). Muscle MRI in 
Becker muscular dystrophy. Neuromuscul. Disord. 22, S100–S106. 
Taylor, D.J., Bore, P.J., Styles, P., Gadian, D.G., and Radda, G.K. (1983). 
Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study. Mol. 
Biol. Med. 1, 77–94. 
Termote, J.-L., Baert, A., Crolla, D., Palmers, Y., and Bulcke, J.A. (1980). Computed 
tomography of the normal and pathologic muscular system. Radiology 137, 439–444. 
Thibaud, J.-L., Monnet, A., Bertoldi, D., Barthelemy, I., Blot, S., and Carlier, P.G. 
(2007). Characterization of dystrophic muscle in golden retriever muscular dystrophy 
dogs by nuclear magnetic resonance imaging. Neuromuscul. Disord. 17, 575–584. 
Thibaud, J.-L., Azzabou, N., Barthelemy, I., Fleury, S., Cabrol, L., Blot, S., and 
Carlier, P.G. (2012). Comprehensive longitudinal characterization of canine muscular 
dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul. Disord. 22, S85–
S99. 
 174 
 
Thomas, G.D. (2013). Functional muscle ischemia in Duchenne and Becker muscular 
dystrophy. Front. Physiol. 4, 381. 
Torriani, M., Townsend, E., Thomas, B.J., Bredella, M.A., Ghomi, R.H., and Tseng, 
B.S. (2012). Lower leg muscle involvement in Duchenne muscular dystrophy: an MR 
imaging and spectroscopy study. Skeletal Radiol. 41, 437–445. 
Tosch, V., Rohde, H.M., Tronchère, H., Zanoteli, E., Monroy, N., Kretz, C., 
Dondaine, N., Payrastre, B., Mandel, J.-L., and Laporte, J. (2006). A novel PtdIns3P 
and PtdIns (3, 5) P2 phosphatase with an inactivating variant in centronuclear 
myopathy. Hum. Mol. Genet. 15, 3098–3106. 
Tosetti, M., Linsalata, S., Battini, R., Volpi, L., Cini, C., Presciutti, O., Muntoni, F., 
Cioni, G., and Siciliano, G. (2011). Muscle metabolic alterations assessed by 31-
phosphorus magnetic resonance spectroscopy in mild becker muscular dystrophy. 
Muscle Nerve 44, 816–818. 
Trinity, J.D., Layec, G., and Lee, J.F. (2014). Heterogeneity of blood flow: impact of 
age on muscle specific tissue perfusion during exercise. J. Physiol. 592, 1729–1730. 
Tubridy, N., Fontaine, B., and Eymard, B. (2001). Congenital myopathies and 
congenital muscular dystrophies. Curr. Opin. Neurol. 14, 575–582. 
Vainzof, M., Ayub-Guerrieri, D., Onofre, P.C., Martins, P.C., Lopes, V.F., 
Zilberztajn, D., Maia, L.S., Sell, K., and Yamamoto, L.U. (2008). Animal models for 
genetic neuromuscular diseases. J. Mol. Neurosci. 34, 241–248. 
Vainzof, M., Almeida, C.F., Ishiba, R., Martins-Bach, A.B., Santos, A.L.F., and 
Nogueira, L. Using electroporation as a model of degeneration/regeneration to 
investigate the regenerative potential in neuromuscular disorders (NMD).(Abstract 
2871T). Presented at the 64th Annual Meeting of The American Society of Human 
Genetics, October 21, 2014 in San Diego, CA. 
Valentine, B.A., Winand, N.J., Pradhan, D., Moise, N., de Lahunta, A., Kornegay, 
J.N., and Cooper, B.J. (1992). Canine X-linked muscular dystrophy as an animal 
model of Duchenne muscular dystrophy: A review. Am. J. Med. Genet. 42, 352–356. 
Verhaert, D., Richards, K., Rafael-Fortney, J.A., and Raman, S.V. (2011). Cardiac 
Involvement in Patients With Muscular Dystrophies Magnetic Resonance Imaging 
Phenotype and Genotypic Considerations. Circ. Cardiovasc. Imaging 4, 67–76. 
Vidal, G.D., Wary, C., Giacomini, E., Emmanuel, F., and Carlier, P.G. (2002). A truly 
non-invasive set-up study of perfusion and energy metabolism in the rat calf in vivo: 
application to a model of peripheral arterial disease. MAGMA 15, 25. 
De Visser, M., and Verbeeten, B. (1985). Computed tomography of the skeletal 
musculature in Becker-type muscular dystrophy and benign infantile spinal muscular 
atrophy. Muscle Nerve 8, 435–444. 
 175 
 
Vlak, M., van der Kooi, E., and Angelini, C. (2000). Correlation of clinical function 
and muscle CT scan images in limb-girdle muscular dystrophy. Neurol. Sci. 21, 
S975–S977. 
Voisin, V., Sébrié, C., Matecki, S., Yu, H., Gillet, B., Ramonatxo, M., Israël, M., and 
De la Porte, S. (2005). l-arginine improves dystrophic phenotype in< i> mdx</i> 
mice. Neurobiol. Dis. 20, 123–130. 
Walter, G., Cordier, L., Bloy, D., and Lee Sweeney, H. (2005). Noninvasive 
monitoring of gene correction in dystrophic muscle. Magn. Reson. Med. 54, 1369–
1376. 
Wang, J., Fan, Z., Vandenborne, K., Walter, G., Shiloh-Malawsky, Y., An, H., 
Kornegay, J.N., and Styner, M.A. (2013). Statistical texture analysis based MRI 
quantification of Duchenne muscular dystrophy in a canine model. In SPIE Medical 
Imaging, (International Society for Optics and Photonics), p. 86720F – 86720F. 
Wary, C., Jouvion, G., Baligand, C., and Carlier, P.G. (2011). Improved set-up for 
fully non-invasive electrostimulation in assessment of muscle perfusion and energy 
metabolism in mice using multiparametric functional NMR (poster). Presented at 
Myology 2011, 4th International Congress of Myology, May 9-13, 2011,in Lille, 
France. 
Wattjes, M.P., Kley, R.A., and Fischer, D. (2010). Neuromuscular imaging in 
inherited muscle diseases. Eur. Radiol. 20, 2447–2460. 
Weber, H., Rauch, A., Adamski, S., Chakravarthy, K., Kulkarni, A., Dogdas, B., 
Bendtsen, C., Kath, G., Alves, S.E., Wilkinson, H.A., et al. (2012). Automated rodent 
in situ muscle contraction assay and myofiber organization analysis in sarcopenia 
animal models. J. Appl. Physiol. 112, 2087–2098. 
Weber, M.-A., Nagel, A.M., Jurkat-Rott, K., and Lehmann-Horn, F. (2011). Sodium 
(23Na) MRI detects elevated muscular sodium concentration in Duchenne muscular 
dystrophy. Neurology 77, 2017–2024. 
Wehling, M., Spencer, M.J., and Tidball, J.G. (2001). A nitric oxide synthase 
transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155, 123–131. 
Wei, B., Lu, Y., and Jin, J.-P. (2014). Deficiency of slow skeletal muscle troponin T 
causes atrophy of type I slow fibres and decreases tolerance to fatigue. J. Physiol. 592, 
1367–1380. 
Willcocks, R.J., Arpan, I.A., Forbes, S.C., Lott, D.J., Senesac, C.R., Senesac, E., 
Deol, J., Triplett, W.T., Baligand, C., Daniels, M.J., et al. (2014). Longitudinal 
measurements of MRI-T< sub> 2</sub> in boys with Duchenne muscular dystrophy: 
Effects of age and disease progression. Neuromuscul. Disord. 24, 393–401. 
 176 
 
Wilmshurst, J.M., Lillis, S., Zhou, H., Pillay, K., Henderson, H., Kress, W., Müller, 
C.R., Ndondo, A., Cloke, V., Cullup, T., et al. (2010). RYR1 mutations are a common 
cause of congenital myopathies with central nuclei. Ann. Neurol. 68, 717–726. 
Winand, N., Pradham, D., Cooper, B. (1994). Molecular characterization of severe 
Duchenne-type muscular dystrophy in a family of rottweiler dogs. In: Molecular 
mechanisms of neuromuscular disease. Tucson: Muscular Dystrophy Association; 
1994. 
Wren, T.A., Bluml, S., Tseng-Ong, L., and Gilsanz, V. (2008). Three-point technique 
of fat quantification of muscle tissue as a marker of disease progression in Duchenne 
muscular dystrophy: preliminary study. Am. J. Roentgenol. 190, W8–W12. 
Yamamoto, D.L., Vitiello, C., Zhang, J., Gokhin, D.S., Castaldi, A., Coulis, G., 
Piaser, F., Filomena, M.C., Eggenhuizen, P.J., Kunderfranco, P., et al. (2013). The 
nebulin SH3 domain is dispensable for normal skeletal muscle structure but is 
required for effective active load bearing in mouse. J. Cell Sci. 126, 5477–5489. 
Yemisci, M., Gursoy-Ozdemir, Y., Vural, A., Can, A., Topalkara, K., and Dalkara, T. 
(2009). Pericyte contraction induced by oxidative-nitrative stress impairs capillary 
reflow despite successful opening of an occluded cerebral artery. Nat. Med. 15, 1031–
1037. 
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., and 
Hoffman, E. (2009). Efficacy of systemic morpholino exon-skipping in duchenne 
dystrophy dogs. Ann. Neurol. 65, 667–676. 
Zvaritch, E., Kraeva, N., Bombardier, E., McCloy, R.A., Depreux, F., Holmyard, D., 
Kraev, A., Seidman, C.E., Seidman, J.G., Tupling, A.R., et al. (2009). Ca2+ 
dysregulation in Ryr1I4895T/wt mice causes congenital myopathy with progressive 
formation of minicores, cores, and nemaline rods. Proc. Natl. Acad. Sci. 106, 21813–
21818. 
 
